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Detection of circulating tumor DNA (ctDNA) has potential as a noninvasive, specific, broadly 
applicable biomarker for cancer. To evaluate the utility of ctDNA as a biomarker for pancreatic 
ductal adenocarcinoma (PDAC) we performed targeted analysis of tumors from 51 preoperative, 
stage II patients and examined tumor-specific mutations in the ctDNA.  We detected ctDNA in 
43% of preoperative patients, and found that detection post-resection predicted clinical relapse 
and poor outcome, with evidence of recurrence by ctDNA detected 6.5 months earlier than CT 
imaging.  To further explore early detection of cancer using ctDNA we developed an approach 
called targeted error correction sequencing (TEC-Seq) that allows ultrasensitive direct evaluation 
of sequence changes in circulating cell-free DNA (cfDNA) using massively parallel sequencing. 
We used this approach to examine 58 cancer-related genes encompassing 81 kb. Analysis of 
plasma from 44 healthy individuals identified genomic changes related to clonal hematopoiesis in 
16% of asymptomatic individuals but no alterations in driver genes related to solid cancers. 
Evaluation of 200 patients with colorectal, breast, lung, or ovarian cancer detected somatic 
mutations in the plasma of 71, 59, 59, and 68%, respectively, of patients with stage I or II disease. 
Analyses of mutations in the circulation revealed high concordance with alterations in the tumors 
of these patients. In patients with resectable colorectal cancers, higher amounts of preoperative 
circulating tumor DNA were associated with disease recurrence and decreased overall survival.  
We further applied the TEC-Seq approach to detect response to targeted tyrosine kinase inhibitors 
in lung cancer patients and found that patients with radiographic response to therapy had a drop in 
ctDNA from an average mutant allele fraction of 3.59% to 0.13% within 6-22 days, while non-
responders had limited changes in ctDNA.  Patients with ctDNA based molecular responses had 
improved progression-free survival (12.0 vs 1.5 months, P = 0.001), which was detected on 
average 38 days earlier and was more predictive than CT imaging.  These observations provide a 
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broadly applicable approach for noninvasive detection of cancer and highlight the utility of 
ctDNA as a biomarker for early detection, identification of windows of opportunity for 
therapeutic intervention, and prediction of outcome.    
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Cancer is a widespread and devastating disease of genetic origin.  Several biomarkers have been 
developed for disease monitoring, however these are often unspecific, have limited clinical use, 
and are not applicable across multiple cancer stages and types.  The development of noninvasive 
liquid biopsy methods based on the analysis of cfDNA provides the opportunity for a new 
generation of diagnostic approaches.  Although cfDNA in the circulation was first described more 
than 50 years ago (1), abnormalities in cancer patients were observed only decades later (2, 3) and 
showed that such individuals have higher amounts of cfDNA.  In patients with cancer, a fraction 
of cfDNA is tumor-derived and is termed circulating tumor DNA, or ctDNA.  In principle, 
analysis of ctDNA has the advantage of identifying alterations that are extremely specific to the 
tumor. The application of next-generation sequencing (NGS), together with advanced 
computational methods, has recently allowed ctDNA-based tumor genotyping in a variety of 
cancer types (4-13).  These approaches can be applied to monitor patients with late-stage cancers 
either through direct detection of ctDNA or through liquid biopsies guided by tumor tissue 
sequencing, and point to the possibility of noninvasive direct early-detection of cancer.   
We first assessed the utility of liquid biopsy approaches to evaluate ctDNA for noninvasive 
detection of early-stage pancreatic cancer as well as for identifying recurrent or residual disease 
(6).  Worldwide, over 250,000 patients develop PDAC every year and the vast majority die of 
their disease (14). PDAC comprises 85% of all pancreatic neoplasms, with 60–70% of cancers 
localized to the head of the pancreas, 20–25% in the body or tail and the remaining cases 
involving the entire organ (15). Currently, surgical resection of the tumor is the only potentially 
curative treatment. However, only a minority (15–20%) of patients are candidates for 
pancreatectomy at the time of diagnosis (16). This can largely be attributed to the fact that 
pancreatic cancer develops over decades as a result of the accumulation of genetic mutations and 
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other molecular abnormalities and clinical presentation often occurs very late in the history of the 
disease4. The 5-year survival rate for those diagnosed with pancreatic cancer remains <10% (14).  
To identify genetic alterations that may be related to patient outcome and other clinical 
characteristics, we performed genomic analyses of pancreatic adenocarcinomas and used droplet 
digital PCR analyses of liquid biopsies to evaluate ctDNA for non-invasive detection of early-
stage pancreatic cancer as well as for identifying recurrent or residual disease.  These analyses 
provide predictors of clinical outcome in pancreatic cancer, have implications for personalized 
therapeutic intervention in these patients, and show the potential for early detection of cancer. 
Through our analyses of liquid biopsies from pancreatic cancer patients we observed that 
detection of ctDNA is possible in patients with localized disease and we further explored the 
concept of direct detection of cancer at early stage.  More than 14 million individuals are newly 
diagnosed with cancer worldwide each year, with the majority having invasive or metastatic 
disease (17). It is well established that much of the morbidity and mortality in human cancer is 
related to the late diagnosis, where surgical and pharmacologic therapies are less effective (18).  
While early detection of stage II pancreatic cancer patients using ctDNA was promising, we 
relied on the evaluation of mutations in the tumor tissue in order to follow alterations in the 
blood.  In a true screening setting, prior knowledge of tumor-derived mutations would not be 
possible and droplet digital PCR approaches to evaluate specific mutations would not broadly 
capture the repertoire of mutations across cancer types and stages.  Further challenges to early 
detection include extremely low levels of alterations in ctDNA for patients with localized disease.  
Unfortunately, clinically proven biomarkers that can be used to broadly diagnose and guide 
patient management early in the course of disease are not available. Serum-based protein 
biomarkers such as cancer antigen 125, carcinoembryonic antigen (CEA), prostate-specific 
antigen, and cancer antigen 19-9 are commonly used for monitoring cancer patients, but because 
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these proteins are also found in the serum of individuals without cancer, they are typically not 
useful for disease diagnosis (19-23). Other approaches for early detection of cancer, such as stool-
based molecular tests or colonoscopies, are limited to individual tumor types and have challenges 
in patient compliance (24, 25). Currently, no widely applicable biomarkers have been developed 
for broad detection of human cancer.    
We have developed an ultrasensitive approach for direct analysis of sequence alterations in 
commonly altered cancer genes in cfDNA without prior knowledge of alterations in the tumor 
(26). The sensitivity and specificity of the methodology were evaluated in a clinically relevant 
cohort of healthy individuals and those with early-stage disease in four common cancers. We 
identified sequence alterations in cell proliferation genes in individuals without cancer, 
established the sensitivity of the approach for detecting tumor-specific alterations in the plasma of 
cancer patients, evaluated concordance between plasma and tumor samples from the same 
patients, and showed that the amounts of ctDNA can serve as a predictive marker of patient 
outcome.  
To extend our liquid biopsy analyses from early detection of cancer to the setting of disease 
monitoring, we used the TEC-Seq approach to assess the clinical value of a comprehensive 
analysis of ctDNA alterations to evaluate tumor burden at timepoints rapidly following targeted 
therapy in stage IV lung cancer patients.  The management of oncogene-addicted cancer has been 
improved by the development of targeted therapies that act against a variety of cancer 
dependencies (27, 28). However, therapeutic efficacy of targeted agents has been limited by 
incomplete pharmacological suppression of tumors or through the selection of resistance 
mutations in clonal populations of tumor cells.  Disease monitoring using computed tomography 
(CT) imaging is the current clinical practice for assessing response to targeted therapy, yet this 
approach does not fully represent the molecular and pathologic changes occurring in tumors 
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during therapy.  Repeat tissue biopsies of accessible cancer lesions have been used to provide 
insights into therapeutic decision-making but rarely capture the complexity of intra- and inter-
tumoral heterogeneity and are invasive procedures with potential complications.  Theoretically, 
the ability to non-invasively track specific clonal populations of tumor cells through time has the 
potential to inform therapy sequence and combinatorial strategies.  However, there are currently 
no approved or clinically recognized non-invasive molecularly defined strategies to assess early 
drug responsiveness or adaptive resistance in cancer patients before radiographic progression.  A 
variety of studies have focused on changes in ctDNA during the course of therapy, but have 
largely focused on the analysis of specific or limited number of alterations that may only 
represent specific subclones of the tumor (5, 29, 30).  More recent studies have used panels of 
commonly mutated driver genes to allow detection of multiple driver clones, typically at the time 
of diagnosis (7, 10, 26, 31).  However, no study has yet assessed the utility of direct detection of 
ctDNA at early, clinically relevant timepoints during targeted therapy. 
We hypothesized that kinetic changes in the amount of DNA released from tumor cells may occur 
within hours to days of treatment administration.  We used TEC-Seq to evaluate patients 
previously diagnosed with late-stage non-small cell lung cancer who had response or progression 
on tyrosine kinase inhibitors, including afatinib, a second generation inhibitor of the epidermal 
growth factor receptor (EGFR) and erb-b2 receptor tyrosine kinase 2 (ERBB2), and osimertinib, a 
third-generation tyrosine kinase inhibitor targeting EGFR with activating and T790M resistance 
mutations (32, 33).  These analyses investigated whether rapid changes and the overall levels in 
the amounts of ctDNA can serve as real-time and predictive biomarkers of patient outcome to a 
targeted cancer therapy.   
Overall, we examined the utility of ctDNA as a biomarker for cancer using droplet digital PCR 
approaches to detect tumor-derived alterations in the blood of stage II pancreatic cancer patients 
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as well developed a novel next-generation sequencing approach for direct detection of ctDNA 
and applied it for detection of cancer at early stage and during the course of targeted therapy.  
These analyses, taken together, highlight the feasibility of noninvasive, sensitive and specific 










CLINICAL IMPLICATIONS OF GENOMIC ALTERATIONS IN THE TUMOR  






Samples obtained for sequencing analyses 
 
Pancreatic ductal adenocarcinoma tumor specimens and matched germline specimens (from 
peripheral blood) from 51 patients were used for targeted genomic analyses (Tables 2.1 and 2.2). 
Plasma samples were obtained at the time of diagnosis from 44 of these patients as well as seven 
additional patients (Table 2.2). Informed consent for research use was obtained from all patients 
at the enrolling institution (University of Pennsylvania, Washington University in St. Louis, 
Herlev Hospital at the University of Copenhagen) before tissue banking and study approval was 
obtained. Primary tumor samples for genomic analyses were selected from patients with 
resectable stage II disease, verified to have  >10% viable tumor cell content by histopathological 
assessment and demonstrated to be wild-type for the DAXX/ATRX loci, which have been shown 
to be associated with improved outcome in patients with pancreatic neuroendocrine tumors (34). 
For a subset of cases, plasma samples were obtained at multiple time points after surgery. 
 
Sample preparation and next-generation sequencing 
 
Sample preparation, library construction, exome and targeted capture, next-generation sequencing 
and bioinformatics analyses of tumor and normal samples were performed as previously 
described (35). In brief, DNA was extracted from frozen or formalin-fixed paraffin-embedded 
tissue, along with matched blood or saliva samples using the Qiagen DNA formalin-fixed 
paraffin-embedded tissue kit or Qiagen DNA blood mini kit (Qiagen, CA). Genomic DNA from 
tumor and normal samples were fragmented and used for Illumina TruSeq library construction 
(Illumina, San Diego, CA) according to the manufacturer’s instructions or as previously described 
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(36). In brief, 50 ng–3mg of genomic DNA in 100 ml of TE was fragmented in a Covaris 
sonicator (Covaris, Woburn, MA) to a size of 150–450 bp.  To remove fragments smaller than 
150 bp, DNA was purified using Agencourt AMPure XP beads (Beckman Coulter, IN) in a ratio 
of 1.0 to 0.9 of PCR product to beads twice and washed using 70% ethanol as per the 
manufacturer’s instructions. Purified, fragmented DNA was mixed with 36 ml of H2O, 10 ml of 
End-Repair Reaction Buffer, 5 ml of End-Repair Enzyme Mix (cat# E6050, NEB, Ipswich, MA). 
The 100-ml end-repair mixture was incubated at 20 C for 30 min, and purified using Agencourt 
AMPure XP beads (Beckman Coulter, IN) in a ratio of 1.0 to 1.25 of PCR product to beads and 
washed using 70% ethanol as per the manufacturer’s instructions. To A-tail, 42 ml of end-
repaired DNA was mixed with 5 ml of 10dA Tailing Reaction Buffer and 3 ml of Klenow (cat# 
E6053, NEB, Ipswich, MA). The 50-ml mixture was incubated at 37 C for 30 min and purified 
using Agencourt AMPure XP beads (Beckman Coulter, IN) in a ratio of 1.0 to 1.0 of PCR 
product to beads and washed using 70% ethanol as per the manufacturer’s instructions. For 
adaptor ligation, 25 ml of A-tailed DNA was mixed with 6.7 ml of H2O, 3.3 ml of PE-adaptor 
(Illumina), 10 ml of 5Ligation buffer and 5 ml of Quick T4 DNA ligase (cat# E6056, NEB, 
Ipswich, MA). The ligation mixture was incubated at 20 C for 15 min and purified using 
Agencourt AMPure XP beads (Beckman Coulter, IN) in a ratio of 1.0 to 0.95 and 1.0 of PCR 
product to beads twice and washed using 70% ethanol as per the manufacturer’s instructions. To 
obtain an amplified library, twelve PCRs of 25 ml each were set up, each including 15.5 ml of 
H2O, 5 ml of 5Phusion HF buffer, 0.5 ml of a dNTP mix containing 10mM of each dNTP, 1.25 
ml of dimethylsulphoxide, 0.25 ml of Illumina PE primer #1, 0.25 ml of Illumina PE primer #2, 
0.25 ml of Hotstart Phusion polymerase and 2 ml of the DNA. The PCR program used was: 98 C 
for 2min; 12 cycles of 98 C for 15 s, 65 C for 30 s, 72 C for 30 s; and 72 C for 5min. DNA was 
purified using Agencourt AMPure XP beads (Beckman Coulter, IN) in a ratio of 1.0 to 1.0 of 
PCR product to beads and washed using 70% ethanol as per the manufacturer’s instructions. 
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Targeted regions were captured in solution using the Agilent SureSelect v.4 kit or a custom 
targeted panel for the 111 genes of interest according to the manufacturer’s instructions (Agilent, 
Santa Clara, CA). The captured library was then purified with a Qiagen MinElute column 
purification kit and eluted in 17 ml of 70C EB to obtain 15 ml of captured DNA library. The 
captured DNA library was amplified in the following way: Eight 30 ml PCR reactions each 
containing 19 ml of H2O, 6 ml of 5Phusion HF buffer, 0.6 ml of 10mM dNTP, 1.5 ml of 
dimethylsulphoxide, 0.30 ml of Illumina PE primer #1, 0.30 ml of Illumina PE primer #2, 0.30 ml 
of Hotstart Phusion polymerase and 2 ml of captured exome library were set up. The PCR 
program used was: 98 C for 30 s; 14 cycles (exome) or 16 cycles (targeted) of 98 C for 10 s, 65 C 
for 30 s, 72 C for 30 s; and 72 C for 5min. To purify PCR products, a NucleoSpin Extract II 
purification kit (Macherey-Nagel, PA) was used following the manufacturer’s instructions. 
Paired-end sequencing, resulting in 150 bases from each end of the fragment for targeted 
libraries, was performed using Illumina HiSeq 2000/2500 and Illumina MiSeq instrumentation 
(Illumina, San Diego, CA).  
 
Analysis of next-generation sequencing data 
 
Somatic mutations were identified using VariantDx (37) custom software for identifying 
mutations in matched tumor and normal samples. Before mutation calling, primary processing of 
sequence data for both tumor and normal samples were performed using Illumina CASAVA 
software (v1.8), including masking of adapter sequences. Sequence reads were aligned against the 
human reference genome (version hg18) using ELAND with additional realignment of select 
regions using the Needleman–Wunsch method25. Candidate somatic mutations, consisting of 
point mutations, insertions and deletions were then identified using VariantDx across the either 
the whole exome or regions of interest. VariantDx examines sequence alignments of tumor 
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samples against a matched normal while applying filters to exclude alignment and sequencing 
artifacts. In brief, an alignment filter was applied to exclude quality failed reads, unpaired reads 
and poorly mapped reads in the tumor. A base quality filter was applied to limit inclusion of bases 
with reported phred quality score 430 for the tumor and 420 for the normal. A mutation in the 
tumor was identified as a candidate somatic mutation only when (i) distinct paired reads 
contained the mutation in the tumor; (ii) the number of distinct paired reads containing a 
particular mutation in the tumor was at least 2% of the total distinct read pairs for targeted 
analyses and 10% of read pairs for exome and (iii) the mismatched base was not present in 41% 
of the reads in the matched normal sample as well as not present in a custom database of common 
germline variants derived from dbSNP and (iv) the position was covered in both the tumor and 
normal. Mutations arising from misplaced genome alignments, including paralogous sequences, 
were identified and excluded by searching the reference genome. Candidate somatic mutations 
were further filtered based on gene annotation to identify those occurring in protein coding 
regions. Functional consequences were predicted using snpEff and a custom database of CCDS, 
RefSeq and Ensembl annotations using the latest transcript versions available on hg18 from 
UCSC (https://genome.ucsc.edu/). Predictions were ordered to prefer transcripts with canonical 
start and stop codons and CCDS or Refseq transcripts over Ensembl when available. Finally, 
mutations were filtered to exclude intronic and silent changes, while retaining mutations resulting 
in missense mutations, nonsense mutations, frameshifts or splice-site alterations. A manual visual 
inspection step was used to further remove artefactual changes. In addition, all sequence data 
from tumors that harbored single-base substitutions in MLL, MLL2, MLL3 and ARID1A genes 






Analysis without a matched normal sample 
 
For the identification of putative somatic mutations without a matched normal, additional filters 
were applied. First, mutations present in an unmatched normal sample, sequenced to a similar 
coverage and on the same platform as the matched normal, were removed. Second, alterations 
reported in the 1000 Genomes project, present in 41% of the population or listed as Common in 
dbSNP138 were filtered.  
 
Statistical analyses of clinical and genetic data 
 
Curves for overall survival and progression-free survival (calculated as the time from diagnosis to 
disease progression) were constructed using the Kaplan–Meier method and compared between 
groups using the log-rank test. Cox proportional hazards regression analysis was used to 
determine which independent factors jointly had a significant impact on overall survival. All P 
values were based on two-sided testing and differences were considered significant at P<0.05. 
Statistical analyses of clinical and genetic features were performed with SPSS version 22 for 
windows. 
 
Digital PCR analyses 
 
KRAS, BRAF or PIK3CA somatic point mutations were identified through sequencing analysis 
of tumor tissues. In cases with matched plasma samples, point mutations were detected in the 
plasma using droplet digital PCR (ddPCR) using the BioRad QX200 Droplet Digital PCR System 
(Hercules, CA). In brief, specific ddPCR assays for each point mutation were obtained from 
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BioRad (Hercules, CA) and applied to assess the mutant allele fraction (mutant genomic 
equivalents/total genomic equivalents). Before analysis of each point mutation in the patient 
plasma sample, a panel of at least 160 normal control analyses was used to confirm the mutation 







Next-generation sequencing analyses of pancreatic cancer 
 
We used next-generation sequencing to examine targeted regions in 51 patient tumors. These 
approaches allowed us to identify sequence changes, including single base and small insertion or 
deletion mutations in 116 specific genes in the targeted analyses (Figure 2.1 and Table 2.1). The 
pancreatic cancers analyzed were stage II tumors in patients who underwent potentially curative 
resections (Table 2.2). Given the low neoplastic cellularity of pancreatic cancers5, we enriched 
for neoplastic cells by macrodissecting primary tumors, and performed high-coverage sequencing 
of these enriched samples. We obtained a per-base sequencing coverage of 754-fold for each 
tumor analyzed by targeted cancer gene sequencing (Table 2.3).  
 
Non-invasive detection of early-stage pancreatic cancer 
 
In parallel to the sequencing analyses of neoplastic tissues, we evaluated the utility of using 
somatic mutations in ctDNA to identify patients likely to recur after surgical intervention. 
Through sequencing analyses of tumor samples, we identified somatic mutations that could be 
used to detect ctDNA in 51 patients from whom plasma was available, largely focusing on 
alterations in the KRAS gene. Using digital PCR (dPCR) approaches, we were able to 
demonstrate that these alterations were detectable in the plasma of 22 patients (43%) at the time 
of diagnosis, with a specificity of 499.9% (Table 2.4). Consistent with recent reports (4, 10), 
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these results suggest that a significant fraction of early-stage pancreatic cancers could be 
diagnosed non-invasively using approaches that focus on a few specific genetic alterations.  
dPCR analyses were performed using plasma samples obtained at various time points after 
surgical resection (Table 2.5). These analyses revealed that patients with detectable ctDNA in 
their plasma were more likely to relapse than those with undetectable alterations (P<0.02, log-
rank test, Figure 2.2). Disease progression using ctDNA was detected at an average of 3.1 months 
after surgery compared with 9.6 months using standard computed tomography imaging 
(P<0.0004, paired t-test, Figure 2.3). The presence of ctDNA at the time of diagnosis also 
provided a predictor of disease recurrence (P<0.015, log-rank test, Figure 2.4). These analyses 
suggest that tests to detect sequence alterations in cell-free DNA may provide a highly specific 




Figure 2.1.  Schematic of next-generation sequencing and ctDNA analyses.  Next-generation sequencing analyses were performed for tumor 
specimens obtained from pancreatic ductal adenocarcinoma patients using either whole-exome or targeted analyses focused on 116 genes. 
Genomic alterations were evaluated for potential clinical utility or as prognostic indicators. Somatic mutations identified through genomic 
analyses were used to evaluate patient plasma for detection of ctDNA at the time of diagnosis or after surgical intervention.  
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Figure 2.2.  Detection of residual disease using ctDNA analyses.  Patients with detectable ctDNA after surgical resection (n=10) were more 
likely to relapse and die from disease compared with those with undetectable ctDNA (n=10). The median time to recurrence as determined by CT 
imaging was 9.9 months for individuals with detectable ctDNA and was not reached for those without detectable ctDNA (P=0.0199, log-rank).  




























Figure 2.3.  Detection of residual disease using CT imaging and ctDNA analyses.  Comparison between the time to detection of recurrence 
using ctDNA and standard-of-care CT imaging revealed that the average time to recurrence was 3.1 months for individuals with detectable ctDNA 


































Figure 2.4.  Prediction of Recurrence using ctDNA Detected at Baseline. The hazard ratio for tumor recurrence among individuals with 
detectable circulating tumor DNA (ctDNA) compared to those without detectable ctDNA was 2.39 (95% CI = 1.18–4.81, log rank). The median 
time to recurrence was 15.2 months for individuals without detectable ctDNA (n=29) and 7.9 months for those with detectable ctDNA (n=22).  




























 Table 2.1.  Summary of genes analyzed using targeted cancer gene sequencing. 
 
ABL1 CREBBP IDH1 MSH6 PTPN11 
AKT1 CTNNB1 IDH2 MYC RB1 
AKT2 DAXX IGF1R MYCN RET 
ALK DNMT3A IGF2R MYD88 RNF43 
APC EGFR IKZF1 NF1 ROS1 
AR ERBB2 JAK1 NF2 RUNX1 
ARID1A ERBB3 JAK2 NOTCH1 SF3B1 
ARID1B ERBB4 JAK3 NOTCH2 SMAD2 
ASXL1 EZH2 KDR NOTCH3 SMAD3 
ATM FBXW7 KIT NOTCH4 SMAD4 
ATRX FGFR1 KRAS NPM1 SMARCB1 
BAP1 FGFR2 MAML1 NRAS SMO 
BRAF FGFR3 MDM2 PALB2 STAG2 
BRCA1 FGFR4 MDM4 PAX5 STK11 
BRCA2 FLT3 MED12 PBRM1 TET2 
CBL FOXL2 MEN1 PDGFRA TGFBR2 
CCND1 GATA1 MET PDGFRB TNFAIP3 
CCNE1 GATA2 MLH1 PIK3CA TP53 
CDH1 GNA11 MLL PIK3R1 TPMT 
CDK4 GNAQ MLL2 PMS2 TSC1 
CDK6 GNAS MLL3 PRSS1 TSC2 
CDKN2A HNF1A MPL PTCH1 TSHR 
CEBPA HRAS MSH2 PTEN VHL 




Table 2.2.  Summary of Pancreatic Ductal Adenocarcinoma Cases Analyzed. 
















CGPLPA14 68 Adenocarcinoma Male Poor 3.5 IIa No Yes 6.7 1 13.1 1 
CGPLPA15 70 Adenocarcinoma Female Well 3.5 IIb No Yes 6.9 1 12.1 1 
CGPLPA16 56 Adenocarcinoma Female Moderate 3.2 IIb No Yes 5.7 1 18.5 1 
CGPLPA17 65 Adenocarcinoma Male Well 2.5 IIb No Yes 10.2 1 11.4 1 
CGPLPA19 73 Adenocarcinoma Male Poor 4.0 IIa No No 6.9 1 6.9 1 
CGPLPA20 58 Adenocarcinoma Female Poor 1.5 IIb No Yes 10.1 1 41.8 0 
CGPLPA23 58 Adenocarcinoma Female Moderate 3.4 IIb No Yes 4.2 1 5.6 1 
CGPLPA24 59 Adenocarcinoma Male Moderate Not Available IIb No Yes 12.0 1 13.5 1 
CGPLPA25 69 Adenocarcinoma Female Poor 1.0 IIb No Yes 4.5 1 5.0 1 
CGPLPA26 64 Adenocarcinoma Male Well 4.0 IIb No Yes 1.8 1 5.5 1 
CGPLPA27 59 Adenocarcinoma Male Moderate 2.0 IIb No Yes 2.5 1 2.5 1 
CGPLPA28 79 Adenocarcinoma Female Well 3.0 IIb No Yes 15.5 1 34.6 1 
CGPLPA31 37 Adenocarcinoma Male Moderate 4.0 IIb No Yes 18.4 1 37.1 0 
CGPLPA33 67 Adenocarcinoma Female Well 4.0 IIb No Yes 5.2 1 5.9 1 
CGPLPA34 73 Adenocarcinoma Male Well 8.0 IIb No Yes 5.3 1 11.6 1 
CGPLPA35 77 Adenocarcinoma Female Moderate 3.0 IIb No Yes 8.1 1 9.8 1 
CGPLPA36 65 Adenocarcinoma Male Poor 3.0 IIb No Yes 35.2 0 35.2 0 
CGPLPA37 67 Adenocarcinoma Female Not Available 3.5 IIb No Yes 4.3 1 16.7 1 
CGPLPA39 67 Adenocarcinoma Female Well 3.5 IIb No Yes 33.6 0 33.6 0 
CGPLPA40 64 Adenocarcinoma Male Well 2.5 IIb No Yes 14.1 1 15.0 1 
CGPLPA41 69 Adenocarcinoma Male Well 4.5 IIb No Yes 7.4 1 15.0 1 
CGPLPA42 73 Adenocarcinoma Male Moderate 4.5 IIb No Yes 10.7 1 20.9 1 
CGPLPA43 69 Adenocarcinoma Male Well 2.0 IIa No No 26.8 1 32.2 0 
CGPLPA45 61 Adenocarcinoma Female Well 2.5 IIb No Yes 27.2 0 27.2 0 
CGPLPA50 77 Adenocarcinoma Female Well 2.2 IIb No Yes 10.3 1 17.5 1 
CGPLPA51 49 Adenocarcinoma Female Not Available 3.0 IIb No Yes 29.2 0 29.2 0 
CGPLPA55 67 Adenocarcinoma Male Poor 3.0 IIb No Yes 7.8 1 9.7 1 
CGPLPA56 62 Adenocarcinoma Male Well 2.0 IIb No Yes 15.2 1 25.2 0 
CGPLPA57 73 Adenocarcinoma Male Well 3.0 IIb No Yes 25.2 0 25.2 0 
CGPLPA60 53 Adenocarcinoma Male Moderate 3.0 IIb No Yes 11.2 1 24.3 0 
CGPLPA63 59 Adenocarcinoma Male Moderate 3.5 IIb No Yes 13.3 1 23.7 0 
CGPLPA65 66 Adenocarcinoma Female Moderate 12.5 IIb No Yes 8.1 1 23.3 0 
CGPLPA73 66 Adenocarcinoma Male Poor 4.0 IIb No Yes 5.3 1 6.7 1 
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CGPLPA75 75 Adenocarcinoma Female Poor 7.0 IIb No Yes 5.4 1 6.7 1 
CGPLPA77 69 Adenocarcinoma Male Moderate 2.0 IIb No Yes 21.4 0 21.4 0 
CGPLPA78 70 Adenocarcinoma Male Not Available 1.5 IIb No Yes 20.8 0 20.8 0 
CGPLPA80 70 Adenocarcinoma Male Well 2.0 IIb No Yes 20.6 0 20.6 0 
CGPLPA81 62 Adenocarcinoma Male Moderate 5.0 IIb No Yes 8.2 1 8.5 1 
CGPLPA82 63 Adenocarcinoma Male Poor 2.7 IIb No Yes 4.0 1 4.1 1 
CGPLPA83 72 Adenocarcinoma Male Poor 2.0 IIb No Yes 6.3 1 6.8 1 
CGPLPA84 68 Adenocarcinoma Female Well 3.5 IIb No Yes 5.6 1 7.7 1 
CGPLPA88 69 Adenocarcinoma Female Well 3.0 IIa No Yes 16.2 0 16.2 0 
CGPLPA89 62 Adenocarcinoma Female Moderate 2.7 IIb No Yes 15.6 0 15.6 0 
CGPLPA90 68 Adenocarcinoma Male Moderate 2.4 IIb No Yes 15.2 0 15.2 0 
CGPLPA13 47 Adenocarcinoma Male Well 3.5 III No Yes 9.3 1 12.5 1 
CGPLPA29 68 Adenocarcinoma Female Not Available 2.3 Ib No Yes 37.3 0 37.3 0 
CGPLPA30 65 Adenocarcinoma Male Not Available 2 III No Yes 9.6 1 12.9 1 
CGPLPA64 74 Adenocarcinoma Female Moderate 4 III No Yes 23.5 0 23.5 0 
CGPLPA66 77 Adenocarcinoma Female Moderate 1.6 III No Yes 12.8 1 22.8 0 
CGPLPA72 72 Adenocarcinoma Male Not Available 3 IIb No Yes 22.3 0 22.3 0 










Table 2.3.  Summary of next-generation sequencing analyses performed. 
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reads 
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CGPLPA14 Tumor 150 1,422,206,700 1,233,948,600 87% 589,739,532 48% 617,026 97% 895.6 785.0 
CGPLPA14 Normal 150 1,097,615,400 973,933,050 89% 480,874,737 49% 618,000 97% 734.4 686.3 
CGPLPA15 Tumor 150 1,432,918,800 1,138,913,400 79% 633,520,028 56% 613,867 96% 961.4 686.3 
CGPLPA15 Normal 150 1,282,901,400 1,158,667,350 90% 591,188,745 51% 619,785 97% 890.3 831.6 
CGPLPA16 Tumor 150 1,325,756,700 1,137,578,550 86% 620,235,011 55% 617,943 97% 949.8 173.1 
CGPLPA16 Normal 150 1,369,431,000 1,198,075,800 87% 598,680,103 50% 618,967 97% 915.8 794.0 
CGPLPA17 Tumor 150 1,273,804,200 1,096,218,600 86% 545,386,390 50% 615,865 96% 829.6 719.8 
CGPLPA17 Normal 150 1,156,002,900 1,040,958,300 90% 548,090,254 53% 618,586 97% 830.3 773.2 
CGPLPA19 Tumor 150 1,450,699,200 1,294,802,100 89% 720,184,514 56% 620,257 97% 1091.2 213.3 
CGPLPA19 Normal 150 923,131,200 818,532,600 89% 419,071,315 51% 618,661 97% 643.2 561.2 
CGPLPA20 Tumor 150 1,388,595,600 1,273,161,750 92% 621,750,824 49% 620,316 97% 944.6 892.4 
CGPLPA20 Normal 150 1,141,947,900 1,022,130,750 90% 539,339,890 53% 617,010 97% 820.4 771.2 
CGPLPA23 Tumor 150 1,276,030,800 1,004,910,000 79% 538,518,453 54% 613,081 96% 820.5 434.5 
CGPLPA23 Normal 150 1,168,223,400 1,044,452,250 89% 527,833,659 51% 616,857 97% 805.1 748.4 
CGPLPA24 Tumor 150 1,368,000,000 1,250,000,000 91% 600,317,082 48% 620,384 97% 907.4 687.1 
CGPLPA25 Tumor 150 1,325,500,800 1,144,549,650 86% 619,895,244 54% 616,688 97% 944.2 842.4 
CGPLPA25 Normal 150 1,102,142,100 1,005,024,000 91% 514,688,345 51% 618,797 97% 786.7 723.9 
CGPLPA26 Tumor 150 763,197,900 660,287,550 87% 339,718,956 51% 612,229 96% 493.2 456.5 
CGPLPA26 Normal 150 779,267,700 697,112,550 89% 360,672,012 52% 614,646 96% 524.5 488.2 
CGPLPA27 Tumor 150 846,427,500 741,015,150 88% 375,084,381 51% 613,466 96% 549.8 512.7 
CGPLPA27 Normal 150 780,752,400 703,056,450 90% 365,704,778 52% 616,224 97% 525.9 487.0 
CGPLPA28 Tumor 150 977,580,300 878,913,000 90% 466,375,081 53% 616,159 97% 716.6 666.7 
CGPLPA28 Normal 150 963,573,000 876,802,800 91% 448,269,780 51% 617,579 97% 688.3 638.6 
CGPLPA31 Tumor 150 1,442,430,000 1,231,364,250 85% 636,015,051 52% 616,795 97% 953.0 850.1 
CGPLPA31 Normal 150 1,673,482,800 1,311,890,400 78% 710,364,927 54% 616,529 97% 1084.8 890.7 
CGPLPA33 Tumor 150 1,733,820,600 1,293,419,550 75% 755,071,067 58% 611,022 96% 1133.3 683.7 
CGPLPA33 Normal 150 1,388,404,500 1,122,970,800 81% 580,438,755 52% 618,657 97% 871.2 739.5 
CGPLPA34 Tumor 150 1,252,716,900 1,166,142,900 93% 577,954,111 50% 621,622 97% 869.8 781.0 
CGPLPA35 Tumor 150 1,448,322,600 1,209,805,800 84% 614,782,917 51% 616,478 97% 924.0 828.0 
CGPLPA35 Normal 150 1,523,119,500 1,155,712,500 76% 619,509,476 54% 614,486 96% 931.7 714.1 
CGPLPA36 Tumor 150 1,595,898,600 1,396,011,150 87% 767,902,754 55% 618,417 97% 1177.3 1013.7 
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CGPLPA36 Normal 150 1,368,051,000 1,073,128,650 78% 572,338,961 53% 614,464 96% 864.0 722.0 
CGPLPA37 Tumor 150 1,389,140,100 1,192,749,600 86% 637,329,732 53% 617,222 97% 964.5 840.8 
CGPLPA37 Normal 150 1,403,295,300 1,073,562,150 77% 586,179,382 55% 613,935 96% 884.8 727.5 
CGPLPA39 Tumor 150 1,130,873,700 1,031,655,750 91% 521,195,716 51% 619,367 97% 789.1 718.5 
CGPLPA39 Normal 150 1,353,234,300 1,103,716,200 82% 596,625,068 54% 618,965 97% 904.6 756.4 
CGPLPA40 Tumor 150 1,486,219,500 1,320,968,850 89% 713,934,786 54% 618,452 97% 1075.4 954.4 
CGPLPA40 Normal 150 1,274,490,300 981,103,350 77% 530,900,815 54% 614,055 96% 802.3 712.5 
CGPLPA41 Tumor 150 1,420,233,000 1,195,861,200 84% 687,813,722 58% 616,947 97% 1039.9 873.1 
CGPLPA41 Normal 150 1,485,501,600 1,153,747,650 78% 634,839,180 55% 615,599 96% 964.9 809.8 
CGPLPA42 Tumor 150 1,381,733,100 1,160,990,100 84% 659,950,398 57% 614,881 96% 1002.3 754.5 
CGPLPA42 Normal 150 1,455,513,000 1,065,667,950 73% 576,250,237 54% 614,823 96% 876.2 761.7 
CGPLPA43 Tumor 150 1,305,021,900 1,163,152,950 89% 612,966,256 53% 617,406 97% 930.0 844.1 
CGPLPA43 Normal 150 1,348,954,500 1,007,244,000 75% 548,707,683 54% 615,198 96% 833.2 724.1 
CGPLPA45 Tumor 150 1,207,611,000 1,065,541,950 88% 566,123,421 53% 618,594 97% 862.2 680.9 
CGPLPA45 Normal 150 1,133,718,900 1,042,314,150 92% 502,563,596 48% 622,745 98% 763.3 667.7 
CGPLPA50 Tumor 150 892,917,600 774,671,400 87% 405,099,468 52% 611,192 96% 621.8 443.2 
CGPLPA50 Normal 150 1,114,662,000 1,022,400,300 92% 516,589,764 51% 619,687 97% 785.5 698.6 
CGPLPA51 Tumor 150 1,310,000,000 1,120,000,000 86% 587,000,000 52% 617,018 97% 890.8 663.3 
CGPLPA51 Normal 150 1,460,000,000 1,330,000,000 91% 711,000,000 53% 619,485 97% 1080.8 899.4 
CGPLPA55 Tumor 150 1,258,117,500 1,090,245,750 87% 571,086,668 52% 616,173 97% 876.4 706.6 
CGPLPA55 Normal 150 1,080,838,200 963,629,250 89% 498,882,825 52% 618,398 97% 754.6 592.9 
CGPLPA56 Tumor 150 1,139,238,600 1,027,636,650 90% 546,588,989 53% 617,006 97% 832.9 681.0 
CGPLPA56 Normal 150 1,163,296,800 1,055,723,850 91% 577,632,226 55% 619,354 97% 886.8 821.1 
CGPLPA57 Tumor 150 1,421,929,500 1,279,022,100 90% 671,418,966 52% 617,267 97% 1023.7 769.9 
CGPLPA57 Normal 150 1,490,680,200 1,335,699,600 90% 686,759,055 51% 618,341 97% 1048.1 726.3 
CGPLPA60 Tumor 150 1,064,281,500 936,046,050 88% 497,472,976 53% 619,076 97% 763.5 600.7 
CGPLPA60 Normal 150 961,133,100 890,114,250 93% 467,206,901 52% 620,430 97% 716.2 637.3 
CGPLPA63 Tumor 150 1,440,349,800 1,254,282,000 87% 685,755,803 55% 616,687 97% 1037.0 526.4 
CGPLPA63 Normal 150 1,053,303,000 975,994,500 93% 511,180,718 52% 620,515 97% 783.6 733.5 
CGPLPA65 Tumor 150 998,749,200 890,638,950 89% 457,905,966 51% 615,244 96% 698.4 575.7 
CGPLPA65 Normal 150 1,444,104,900 1,270,918,950 88% 636,112,669 50% 618,303 97% 958.5 725.9 
CGPLPA73 Tumor 150 1,482,431,100 1,216,092,300 82% 724,672,761 60% 614,615 96% 1101.7 597.7 
CGPLPA73 Normal 150 1,122,234,600 1,040,857,200 93% 539,267,848 52% 621,805 97% 817.7 750.3 
CGPLPA75 Tumor 150 1,361,733,000 1,180,700,850 87% 638,268,594 54% 616,074 96% 968.0 754.7 
CGPLPA75 Normal 150 1,247,388,300 1,159,974,300 93% 655,366,609 56% 619,155 97% 995.9 903.8 
CGPLPA77 Tumor 150 1,293,679,200 1,144,525,200 88% 604,144,412 53% 617,003 97% 920.6 773.1 
CGPLPA77 Normal 150 1,135,085,100 1,068,456,000 94% 596,796,267 56% 619,086 97% 907.8 826.4 
CGPLPA78 Tumor 150 1,414,849,200 1,197,070,800 85% 654,034,434 55% 616,298 97% 995.4 683.9 
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CGPLPA78 Normal 150 1,039,368,600 973,212,750 94% 527,655,278 54% 620,350 97% 803.4 746.2 
CGPLPA80 Tumor 150 1,249,176,000 976,683,900 78% 545,997,777 56% 611,837 96% 833.0 611.8 
CGPLPA80 Normal 150 1,245,922,200 1,152,128,700 92% 584,937,511 51% 619,538 97% 891.4 789.1 
CGPLPA81 Tumor 150 1,094,793,600 983,800,800 90% 497,918,684 51% 619,055 97% 759.3 675.8 
CGPLPA81 Normal 150 1,148,752,800 1,063,345,050 93% 548,237,313 52% 618,682 97% 838.0 755.5 
CGPLPA82 Tumor 150 1,030,927,800 841,387,800 82% 466,002,645 55% 613,502 96% 713.0 532.9 
CGPLPA82 Normal 150 1,085,075,700 996,816,600 92% 510,624,495 51% 618,557 97% 780.9 708.3 
CGPLPA83 Tumor 150 1,185,284,700 1,010,383,650 85% 549,141,680 54% 615,386 96% 839.5 586.9 
CGPLPA83 Normal 150 1,100,280,600 1,023,636,450 93% 517,833,703 51% 618,434 97% 791.8 714.4 
CGPLPA84 Tumor 150 1,476,325,800 1,336,581,750 91% 664,798,233 50% 619,904 97% 1013.2 887.2 
CGPLPA84 Normal 150 1,283,497,500 1,126,293,600 88% 394,197,633 35% 615,972 96% 603.1 541.5 
CGPLPA88 Tumor 150 1,167,415,500 1,066,878,300 91% 554,605,027 52% 620,645 97% 843.2 739.0 
CGPLPA88 Normal 150 1,864,864,200 1,635,930,750 88% 567,045,390 35% 619,465 97% 865.7 754.5 
CGPLPA89 Tumor 150 1,162,636,800 1,028,794,050 88% 541,294,076 53% 617,290 97% 822.5 722.2 
CGPLPA89 Normal 150 1,439,229,900 1,342,554,750 93% 697,132,331 52% 621,249 97% 1054.7 916.8 
CGPLPA90 Tumor 150 1,197,470,100 1,049,859,000 88% 568,299,409 54% 616,559 97% 860.9 758.2 









 Table 2.4.  Summary of pancreatic ductal adenoma cases analyzed with digital PCR pre-surgery 
 
Case Data Pre-Surgery CT Imaging 





























(1 - Positive,  
0 - Negative) 
CGPLPA13 KRAS G12V 1/21/2011 4.0 2,322 2,320 2 0.07% 10/28/2011 9.3 1 
CGPLPA14 KRAS G12V 1/27/2011 4.0 3,202 3,200 2 0.05% 8/16/2011 6.7 1 
CGPLPA15 KRAS G12D 3/2/2011 4.0 3,370 3,360 10 0.28% 9/25/2011 6.9 1 
CGPLPA16 KRAS G12D 3/22/2011 4.0 58,177 58,160 17 0.03% 9/8/2011 5.7 1 
CGPLPA17 KRAS G12I 5/4/2011 4.0 19,825 19,820 5 0.02% 3/6/2012 10.2 1 
CGPLPA19* KRAS G12R 5/31/2011 4.0 2,544 2,542 2 0.08% 12/25/2011 6.9 1 
CGPLPA20 KRAS G12R 6/27/2011 4.0 2,344 2,340 4 0.16% 4/26/2012 10.1 1 
CGPLPA23 KRAS G12D 8/30/2011 4.0 30,032 30,020 12 0.04% 1/4/2012 4.2 1 
CGPLPA24 KRAS G12D 9/7/2011 4.0 5,486 5,486 Not Detected N/A 9/2/2012 12.0 1 
CGPLPA25 KRAS G12D 9/15/2011 4.0 9,627 9,620 7 0.08% 1/29/2012 4.5 1 
CGPLPA26 KRAS G12R 9/28/2011 4.0 7,580 7,580 Not Detected N/A 11/20/2011 1.8 1 
CGPLPA27 KRAS G12D 10/6/2011 4.0 30,802 30,800 2 0.02% 12/20/2011 2.5 1 
CGPLPA28 KRAS G12V 10/27/2011 4.0 15,584 15,580 4 0.00% 2/4/2013 15.5 1 
CGPLPA29 KRAS G12V 11/9/2011 4.0 4,816 4,816 Not Detected N/A 12/2/2014 37.3 0 
CGPLPA30 KRAS G12D 11/11/2011 4.0 14,560 14,560 Not Detected N/A 8/26/2012 9.6 1 
CGPLPA31 KRAS G12D 11/15/2011 4.0 2,604 2,604 Not Detected N/A 5/19/2013 18.4 1 
CGPLPA33 KRAS G12R 12/8/2011 4.0 2,120 2,120 Not Detected N/A 5/13/2012 5.2 1 
CGPLPA34 KRAS G12C 12/29/2011 4.0 2,882 2,880 2 0.07% 6/5/2012 5.3 1 
CGPLPA35 KRAS G12D 1/2/2012 4.0 9,360 9,360 Not Detected N/A 9/2/2012 8.1 1 
CGPLPA36 KRAS G12D 1/12/2012 4.0 10,564 10,560 4 0.07% 12/2/2014 35.2 0 
CGPLPA37 KRAS G12D 2/6/2012 4.0 6,266 6,260 6 0.09% 6/14/2012 4.3 1 
CGPLPA39 KRAS G12S 2/23/2012 4.0 8,022 8,020 2 0.00% 12/2/2014 33.8 0 
CGPLPA40 KRAS G12V 2/29/2012 4.0 4,311 4,300 11 0.26% 4/28/2013 14.1 1 
CGPLPA41 KRAS G12D 3/21/2012 4.0 10,840 10,840 Not Detected N/A 10/30/2012 7.4 1 
CGPLPA42 KRAS G13D 4/2/2012 4.0 2,840 2,840 Not Detected N/A 2/18/2013 10.7 1 
CGPLPA43 KRAS G12R 4/11/2012 4.0 1,522 1,520 2 0.13% 6/23/2014 26.8 1 
CGPLPA45 KRAS G12D 6/6/2012 4.0 20,423 20,420 Not Detected N/A 8/31/2014 27.2 0 
CGPLPA50 KRAS G12V 7/6/2012 3.0 10,465 10,458 7 0.07% 5/11/2013 10.3 1 
CGPLPA51 KRAS G12V 7/9/2012 4.0 10,962 10,960 Not Detected N/A 12/2/2014 29.2 0 
CGPLPA55 KRAS G12V 10/22/2012 4.0 7,875 7,866 9 0.11% 6/12/2013 7.8 1 
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CGPLPA56 KRAS G12R 11/5/2012 4.0 6,434 6,434 Not Detected N/A 2/5/2014 15.2 1 
CGPLPA57 KRAS G12V 11/7/2012 4.0 15,384 15,380 4 0.00% 12/2/2014 25.2 0 
CGPLPA60 KRAS G12V 12/3/2012 2.2 1,252 1,252 Not Detected N/A 11/3/2013 11.2 1 
CGPLPA63 KRAS G12R 12/21/2012 3.0 2,920 2,920 Not Detected N/A 1/25/2014 13.3 1 
CGPLPA64 KRAS G13D 12/27/2012 2.5 1,096 1,096 Not Detected N/A 12/2/2014 23.5 0 
CGPLPA65 KRAS G12R 1/2/2013 2.5 8,764 8,748 16 0.18% 9/1/2013 8.1 1 
CGPLPA66 KRAS G12D 1/17/2013 2.5 7,516 7,516 Not Detected N/A 2/6/2014 12.8 1 
CGPLPA72 KRAS G12D 1/31/2013 3.0 3,930 3,920 10 0.25% 12/2/2014 22.3 0 
CGPLPA73 KRAS G12D 2/5/2013 2.5 4,982 4,980 2 0.00% 7/14/2013 5.3 1 
CGPLPA75 KRAS G12D 2/19/2013 3.0 3,543 3,540 3 0.10% 8/1/2013 5.4 1 
CGPLPA77 KRAS G12R 2/28/2013 2.2 1,946 1,944 2 0.08% 12/2/2014 21.4 0 
CGPLPA78 KRAS G12V 3/19/2013 3.2 8,020 8,020 Not Detected N/A 12/2/2014 20.8 0 
CGPLPA80 PIK3CA E542K 3/25/2013 2.7 1,636 1,636 Not Detected N/A 12/2/2014 20.6 0 
CGPLPA81 KRAS G12D 4/2/2013 3.0 4,260 4,238 22 0.52% 12/5/2013 8.2 1 
CGPLPA82 KRAS G12D 4/23/2013 3.0 2,182 2,182 Not Detected N/A 8/21/2013 4.0 1 
CGPLPA83 KRAS G12D 5/14/2013 2.5 2,847 2,840 7 0.25% 11/19/2013 6.3 1 
CGPLPA84 KRAS G12V 6/3/2013 3.0 4,110 4,110 Not Detected N/A 11/19/2013 5.6 1 
CGPLPA87 KRAS G13D 7/23/2013 2.5 1,980 1,980 Not Detected N/A 12/2/2014 16.6 0 
CGPLPA88 BRAF V600E 8/2/2013 2.5 1,128 1,128 Not Detected N/A 12/2/2014 16.2 0 
CGPLPA89 KRAS G12V 8/21/2013 3.2 24,062 24,060 2 0.00% 12/2/2014 15.6 0 
CGPLPA90 KRAS G12R 9/3/2013 2.5 5,260 5,260 Not Detected N/A 12/2/2014 15.2 0 















 Table 2.5.  Summary of pancreatic ductal adenoma cases analyzed with digital PCR post-surgery. 
 
Case Data Post-Surgery 
Case ID Mutation Analyzed 


















CGPLPA14 KRAS G12V 4/6/2011 2.3 4 6,776 6,776 Not Detected N/A 
CGPLPA16 KRAS G12D 6/1/2011 2.4 4 6,805 6,800 5 0.07% 
CGPLPA20 KRAS G12R 10/11/2011 3.5 3.5 9,990 9,988 2 0.02% 
CGPLPA24 KRAS G12D 10/19/2011 1.4 1.5 810 810 Not Detected N/A 
CGPLPA29 KRAS G12V 1/30/2012 2.7 1.5 1,648 1,648 Not Detected N/A 
CGPLPA30 KRAS G12D 12/30/2011 1.6 3.7 6,193 6,190 3 0.05% 
CGPLPA31 KRAS G12D 6/7/2012 6.8 4 10,880 10,874 6 0.05% 
CGPLPA33 KRAS G12R 2/15/2012 2.3 4 3,925 3,922 3 0.08% 
CGPLPA34 KRAS G12C 2/22/2012 1.8 4 6,786 6,784 2 0.03% 
CGPLPA36 KRAS G12D 2/10/2012 1.0 3.5 6,065 6,060 5 0.09% 
CGPLPA39 KRAS G12S 4/20/2012 1.9 3.5 1,984 1,984 Not Detected N/A 
CGPLPA51 KRAS G12V 11/13/2012 4.2 4 16,722 16,720 2 0.01% 
CGPLPA57 KRAS G12V 4/3/2013 4.9 4 5,744 5,742 2 0.03% 
CGPLPA60 KRAS G12V 3/26/2013 3.8 3 4,125 4,122 3 0.06% 
CGPLPA63 KRAS G12R 2/7/2013 1.6 4 4,618 4,616 2 0.04% 
CGPLPA64 KRAS G13D 4/12/2013 3.5 4 9,202 9,200 2 0.03% 
CGPLPA65 KRAS G12R 4/29/2013 3.9 3.5 6,198 6,196 2 0.03% 
CGPLPA66 KRAS G12D 4/12/2013 2.8 4 3,922 3,920 Not Detected N/A 
CGPLPA77 KRAS G12R 5/3/2013 2.1 3 9,638 9,638 Not Detected N/A 












DIRECT DETECTION OF EARLY-STAGE CANCERS 








This study presents a retrospective analysis of cf DNA using an ultrasensitive sequencing and 
analysis platform to detect somatic sequence alterations in early-stage cancers. We analyzed 250 
plasma samples from 244 individuals, including 44 healthy individuals and 200 patients with 
colorectal (n = 42), lung (n = 71), ovarian (n = 42), or breast (n =45) cancer over a range of 
stages, with most patients exhibiting localized disease. We estimated that analysis of at least 42 
patients for each tumor type would provide a 96% power to detect 50% of cases with a 95% CI of 
35 to 65%. We evaluated the sensitivity and specificity of the TEC-Seq method to detect ctDNA 
in early-stage patients without previous knowledge of alterations in their tumors. We detected 
sequence alterations in hematopoietic expansion genes in healthy individuals, established the 
sensitivity of the approach for detecting tumor-specific alterations in the blood of cancer patients, 
evaluated concordance be- tween alterations identified in cf DNA and tumor samples from the 
same patients, and assessed whether preoperative ctDNA can serve as a marker of patient 
outcome. 
 
Patient and sample characteristics 
 
Plasma samples from healthy individuals and plasma and tissue samples from patients with 
breast, lung, ovarian, and colorectal cancers were obtained from ILSBio/Bioreclamation, Aarhus 
University, the Academic Medical Center of the University of Amsterdam, and University of 
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California, San Diego. All samples were obtained under Institutional Review Board–approved 
protocols with informed consent for research use at participating institutions. 
Plasma samples from healthy individuals were obtained at the time of routine screening, 
including for colonoscopies or Pap smears. Individuals were considered healthy if they had no 
previous history of cancer and negative screening results. Plasma samples from individuals with 
colorectal, lung, ovarian, or breast cancer were obtained at the time of diagnosis, before tumor 
resection. Serially collected plasma samples from lung cancer patients were collected over a 
course of treatment during which the patients experienced stable or progressive disease. Matched 
formalin-fixed, paraffin-embedded (FFPE) or frozen tumor tissue and buffy coat (as a source of 
germline DNA) were obtained from patients whenever available. Tumor specimens were obtained 
from primary resection, with the exception of stage IV colorectal cancer patients with liver-only 
metastases, for whom the samples were obtained from the liver metastases. All tumor samples 
had ≥10% viable tumor cell content by histopathologic assessment. Clinical data for all patients 
included and sample data for the tissue types assayed in this study are listed in Tables 3.1 and 3.2. 
 
Sample preparation and NGS of cfDNA 
 
Whole blood was collected in EDTA tubes and processed immediately or within 2 hours after 
storage at 4°C to separate plasma and cellular components by centrifugation at 800g for 10 min at 
4°C. Plasma was centrifuged a second time at 18,000g at room temperature to remove any 
remaining cellular debris and stored at −80°C until the time of DNA extraction. DNA was 
isolated from plasma using the Qiagen Circulating Nucleic Acids Kit (Qiagen GmbH) and eluted 
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in LoBind tubes (Eppendorf AG). Concentration and quality of cf DNA were assessed using the 
Bioanalyzer 2100 (Agilent Technologies). 
TEC-Seq NGS cf DNA libraries were prepared from 5 to 250 ng of cf DNA. Genomic libraries 
were prepared using the NEBNext DNA Library Prep Kit for Illumina [New England Biolabs 
(NEB)] with four main modifications to the manufacturer’s guidelines: (i) The library purification 
steps used the on-bead AMPure XP approach to minimize sample loss during elution and tube 
transfer steps (38); (ii) NEBNext End Repair, A-tailing, and adapter ligation enzyme and buffer 
volumes were adjusted as appropriate to accommodate the on-bead AMPure XP purification 
strategy; (iii) a pool of eight unique Illumina dual index adapters with 8–base pair (bp) barcodes 
was used in the ligation reaction instead of the standard Illumina single or dual index adapters 
with 6- or 8-bp barcodes, respectively; and (iv) cf DNA libraries were amplified with Phusion 
Hot Start Polymerase. Incorporation of these modifications improved conversion efficiency from 
13.4% before modifications to 34.1% in validation analyses of 38 cases incorporating these 
changes. Analysis of plasma samples from healthy individuals and cancer patients revealed a 
conversion efficiency of 40%, with a significant correlation between input DNA amount and the 
number of distinct molecules analyzed (Pearson correlation r = 0.55; 95% CI, 0.46 to 0.64; P < 
0.0001; Figure 3.1). 
Briefly, cf DNA was combined with End Repair Reaction Buffer (NEB) and End Repair Enzyme 
Mix (NEB) and incubated for 30 min at 20°C. The end-repair reaction was purified with 
Agencourt AMPure XP Beads (Beckman Coulter). A-tailing was performed by adding 6 ml of 
dA-Tailing Reaction Buffer (NEB) and 3.6 ml of Klenow (NEB) to the end-repaired cf DNA and 
incubating for 30 min at 37°C. A-tailed cf DNA was purified using Agencourt AMPure XP 
Buffer (Beckman Coulter). Adaptor oligonucleotides containing the TEC-Seq dual index pools 
and Quick T4 DNA Ligase (NEB) were mixed with A-tailed, on-bead cf DNA and incubated for 
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15 min at 20°C. Ligated cf DNA was purified with two rounds of Agencourt AMPure XP Buffer. 
The cf DNA library was amplified using Phusion Hot Start DNA polymerase (Thermo Fisher 
Scientific) and PCR primers published for the Nextera DNA Library Prep Kit: 5′-
AATGATACGGCGACCACCGA-3′ and 5′-CAAGCAGAAGACGGCATACGA-3′ (Illumina 
Inc.). For each genomic library, PCRs contained 2 ml of cf DNA library, 15.5 ml of H2O, 
1.25 ml of dimethyl sulfoxide, 5.0 ml of 5X Phusion HF Buffer, 0.5 ml of deoxynucleoside 
triphosphate (dNTP) mix containing 10 mM each dNTP (Life Technologies), 0.5 ml of each 
primer, and 0.25 ml of Phusion Hot Start Polymerase. The following PCR conditions were used: 
98°C for 30 s; 12 cycles of 98°C for 10 s, 60°C for 30 s, and 72°C for 30 s; and 72°C for 5 min. 
Purification of the amplified cf DNA library was per- formed using Agencourt AMPure XP 
Beads. Concentration and quality of cf DNA libraries were assessed using the Bioanalyzer 2100 
(Agilent Technologies). 
Targeted capture was performed using the Agilent SureSelect reagents and a custom set of 
hybridization probes targeting 58 genes (Table 3.3) per the manufacturer’s guidelines. The 
captured library was amplified with Phusion Hot Start Polymerase (NEB). The concentration and 
quality of captured cf DNA libraries were assessed on the Bioanalyzer 2100 using the DNA 1000 
Kit (Agilent Technologies). TEC-Seq libraries were sequenced using 100-bp paired-end runs on 







Sample preparation and NGS of tumor-normal pairs 
 
Sample preparation, library construction, targeted capture, NGS, and bioinformatic analyses of 
tumor and normal samples were performed as previously described (36, 37). Briefly, DNA was 
extracted from matched FFPE or frozen tumor tissue and buffy coat samples using the Qiagen 
DNA FFPE Tissue Kit or Qiagen DNA Blood Mini Kit (Qiagen GmbH). Genomic DNA from 
tumor and normal samples was fragmented and used for Illumina TruSeq library construction 
(Illumina) as previously described (36, 37). Targeted regions of interest were captured using 
Agilent SureSelect in-solution capture reagents and a custom-targeted panel for genes of interest 
according to the manufacturer’s instructions (Agilent). Paired-end sequencing, resulting in 150 
bases from each end of the fragment for targeted libraries, was performed using Illumina MiSeq 
(Illumina). 
 
Analyses of NGS data from cfDNA 
 
Primary processing of NGS data for cf DNA samples was performed using Illumina CASAVA 
(Consensus Assessment of Sequence and Variation) software (version 1.8), including 
demultiplexing and masking of dual-index adapter sequences. Sequence reads were aligned 
against the human reference genome (version hg18 or hg19) using NovoAlign with additional 
realignment of select regions using the Needleman- Wunsch method (37). The positions of the 
alterations we have identified have not been affected by the different genome builds. 
Next, candidate somatic mutations, consisting of point mutations, small insertions, and deletions, 
were identified using VariantDx (37) across the targeted regions of interest. VariantDx examined 
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sequence alignments of cf DNA plasma samples while applying filters to exclude alignment and 
sequencing artifacts. Specifically, an alignment filter was applied to exclude quality-failed reads, 
unpaired reads, and poorly mapped reads in the plasma. A base quality filter was applied to only 
include bases with a reported Phred quality score >30. 
A mutation identified in cf DNA was considered a candidate somatic mutation only when (i) 
three distinct paired reads contained the mutation in the plasma (each redundantly sequenced at 
least three times) with a distribution of start and cycle positions when compared to the reference 
genome, and the number of distinct paired reads containing a particular mutation in the plasma 
was at least 0.1% of the total distinct read pairs; or (ii) four distinct paired reads contained the 
mutation in the plasma (each redundantly sequenced at least four times) with a distribution of 
start and cycle positions when compared to the reference genome, and the number of distinct 
paired reads containing a particular mutation in the plasma was at least 0.05% and less than 0.1% 
of the total distinct read pairs; and (iii) the mismatched base was not present in >1% of the reads 
in a panel of unmatched normal samples and not present in a custom database of common 
germline variants derived from dbSNP (The Single Nucleotide Polymorphism Database). 
Mutations arising from misplaced genome alignments, including paralogous sequences, were 
identified and excluded by searching the reference genome. Candidate somatic mutations were 
further filtered on the basis of gene annotation to identify those occurring in protein- coding 
regions. Functional consequences were predicted using snpEff and a custom database of CCDS 
(Consensus Coding Sequence), RefSeq, and Ensembl annotations using the latest transcript 
versions available on hg18 and hg19 from the University of California, Santa Cruz 
(https://genome.ucsc.edu/). Predictions were ordered to prefer transcripts with canonical start and 
stop codons and CCDS or RefSeq transcripts over Ensembl when available. Finally, mutations 
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were filtered to exclude intronic and silent changes, while retaining mutations resulting in 
missense mutations, nonsense mutations, frameshifts, or splice site alterations. 
Candidate alterations were defined as somatic hotspots if the nucleotide change and amino acid 
change were identical to an alteration observed in ≥20 cancer cases reported in the COSMIC 
database. Alterations that were not hotspots were retained only if either (i) seven or more distinct 
paired reads contained the mutation in the plasma, and the number of distinct paired reads 
containing a particular mutation in the plasma was at least 0.1% and less than 0.2% of the total 
distinct read pairs, or (ii) six or more distinct paired reads contained the mutation in the plasma, 
and the number of distinct paired reads containing a particular mutation in the plasma was at least 
0.2% of the total distinct read pairs. 
Candidate mutations were further limited through identification and removal of common 
germline variants present in ≥25% of reads or <25% of reads if the variant was recurrent and 
most of the alterations at that position had a mutant allele fraction of ≥25%. Variants known to be 
at a somatic hotspot position or producing a truncating mutation in a tumor suppressor gene were 
not excluded as germline changes. Because of the high frequency of mutations in specific genes 
and the possible confounding between somatic and germline changes, we limited analyses in the 
APC gene to frameshift or nonsense mutations and in KRAS, HRAS, and NRAS to positions 12, 
13, 61, and 146.  Finally, we excluded hematopoietic expansion-related variants that have been 
previously described, including those in DNMT3A, IDH1, and IDH2 and specific alterations 
within ATM (residue 3008), GNAS (residue 202), or JAK2 (residue 617) (39-41). 
To evaluate the sensitivity of the TEC-Seq approach using dilutions of cell lines with known 
mutations, we used a mixture of cell lines obtained from American Type Culture Collection and 
combined in ratios to reflect the mutant allele frequency. The cell lines in the mutant pool 
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included CCL-237, CRL-2158, CRL-2547, CRL-7585, CRL-9068, CRL-2177, CCL-231, CRL-
2871, CRL-5908, CRL-5908, CCL-224, and CRL-5894. To evaluate sensitivity and specificity, 
we used dilutions of a cell line (CGBR4C, CRL-2338), which had been previously sequenced to 
examine both mutant and wild-type bases in the 58 genes in our panel (42). For analyses at all 
dilutions, we considered those alterations where the mutant allele fraction was expected to be at 
0.1% or higher. To calculate the per-base error rate for conventional sequencing in samples from 
healthy individuals, we summed the number of false-positive calls at each genomic position and 
divided this by the total coverage at that base for the 44 healthy individuals. The upper limit of 
the per-base error rate of TEC-Seq was determined by assuming one alteration per base if no error 
was identified and dividing by the total coverage at each base for the 44 healthy individuals 
analyzed. 
To compare the TEC-Seq bioinformatic approach to iDES-enhanced CAPP-Seq (cancer 
personalized profiling by deep sequencing), we used the bioinformatic components of iDES 
combined with the requirement of multiple distinct read families based on endogenous and 
exogenous barcodes (10, 11) (https://cappseq.stanford.edu/ides/). 
 
Analyses of NGS data from tumor-normal pairs 
 
Primary processing of NGS data from tumor-normal pairs and identification of putative somatic 
mutations were completed using Illumina CASAVA software (version 1.8) and VariantDx 







We used a variety of methods for determining significance.  To test the linear association between 
expected and observed mutant allele fractions (Figure 3.2), we used Pearson’s product moment 
correlation coefficient. To quantify the difference in mean error rate by genomic position for 
conventional sequencing and TEC-Seq, we used a paired (by genomic position) t test assuming 
equal variances. Differences in means of unpaired (independent) samples were tested using a two- 
sample t test assuming equal variances (such as for comparisons involving the concentration of cf 
DNA in plasma between healthy and cancer populations). To assess whether high mutant allele 
fractions are associated with patient outcomes, we defined patients with high mutant allele 
fractions as those with values >3 median absolute deviations from the median mutant allele 
fraction observed in 31 colorectal cancer patients analyzed. We used a median absolute deviation 
rather than an SD because the mutant allele fractions were skewed, and the median absolute 
deviation provides a more robust-to-outlier measure of the SD. We compared PFS and OS 
between patients with low and high mutant allele fraction using the log-rank test in univariate 






Targeted error correction sequencing 
 
We developed a methodology for comprehensive analysis of sequence alterations in driver genes 
that are commonly mutated in colorectal, lung, ovarian, breast, and other cancers. Similar to 
targeted analyses of cancer tissues (37), we first selected genes that were frequently mutated in 
these tumors and focused our analyses on either the entire coding regions or the most highly 
mutated exons of these genes. An analysis of the frequency of these alterations in the COSMIC 
database of somatic mutations in cancer (45) revealed that more than three quarters of patients 
would be expected to have at least one mutation in 55 genes among the intended cancers as well 
as other common tumor types (Tables 3.1 and 3.4). We hypothesized that a larger panel of genes 
would increase the probability of detecting at least one gene alteration in the plasma from any 
given cancer patient. Because alterations in the blood have previously been reported in healthy 
individuals, we examined three additional genes as well as specific sequence positions in three 
genes of the 55-gene panel (Table 3.3) that were known to be somatically altered in clonal 
hematopoietic expansion, myelodysplasia, or other hematological malignancies (39-41). 
Detection of sequence alterations using conventional NGS is limited to a relatively high fraction 
of mutant to wild-type DNA (>1%) and, as such, is typically not useful for analyses of ctDNA, 
which may be present in minute amounts in the blood. Although methods have been developed 
for analysis of ctDNA in late-stage cancer patients (4-12), no method has been systematically 
applied for analysis of early-stage disease. We developed a custom capture and sequencing 
approach called targeted error correction sequencing (TEC-Seq) to allow sensitive and specific 
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detection of low-abundance sequence alterations using NGS (Figure 3.3). This methodology is 
based on targeted capture of multiple regions of the genome and deep sequencing (~30,000×) of 
DNA fragments. The 58 genes analyzed in this study comprised 80,930 aptured bases. Specific 
steps were performed for analysis of rare tumor-specific alterations in DNA molecules and for 
elimination of potential amplification, sequencing, and contamination errors as well as other 
sources of alterations in the blood. These included (i) optimizing library generation and capture 
for conversion of cf DNA for subsequent analyses; (ii)  maximizing representation of unique cf 
DNA molecules analyzed using mapping positions and a small number of prespecified barcodes; 
(iii) redundant sequencing, where multiple identical DNA molecules are generated and sequenced 
and any sequence changes are reconciled; (iv) filtering of mapping and sequencing artifacts; and 
(v) identifying and removing germline and hematopoietic cell proliferation alterations. 
Conceptually, the number of genome equivalents analyzed provides a lower limit of detection for 
any genomic analysis. A high sensitivity approach would aim to maximize the number of unique 
molecules assessed while allowing for a broad and facile analysis in a range that is above the 
actual number of fragments present in a biologic sample. We optimized methodologies for 
extraction and conversion of cf DNA to genomic libraries. Initially, we considered using the start 
and end genome mapping positions of paired-end sequenced fragments as “endogenous barcodes” 
to distinguish between individual molecules. However, Monte Carlo simulations suggested that 
the tight size distribution of cf DNA molecules observed in the plasma would result in a smaller 
number of possible end mapping combinations and therefore underestimate the true complexity of 
cf DNA in the circulation (Figure 3.4). To extend the complexity of endogenous barcodes, we 
introduced a limited set of sequence indices as “exogenous barcodes” in the initial steps of library 
generation. Kinde et al. (46) reported the use of a large number of random exogenous barcodes as 
unique identifiers for analysis of rare mutations in DNA populations. However, simulations with 
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a relatively small number of long prespecified exogenous barcodes (n=4-16) suggested that these, 
in combination with endogenous barcodes, would be sufficient to distinguish among different cf 
DNA molecules in the plasma from a typical blood draw (Figure 3.4). Extending the number of 
barcodes substantially beyond this number has the theoretical disadvantage of misassignment 
among barcodes through sequencing errors and of primer dimers that can form during library 
formation. 
We first evaluated the characteristics of the TEC-Seq approach for detecting known tumor-
specific alterations from a mixture of DNA from tumor cell lines at different dilutions (ranging 
from 100 to 0.1%) with unrelated wild-type DNA. Libraries with eight exogenous barcodes were 
sequenced with an average of ~32,224 sequence reads at each position among the 58 genes 
analyzed (Tables 3.5 and 3.6). We designed thresholds that were expected to identify >99% of 
alterations with a mutant allele fraction of 0.5% at the anticipated sequencing depth. Alterations 
were considered if they were present in all copies of multiple sequences of each DNA molecule 
with identical endogenous and exogenous barcodes and were not removed by additional error 
filtering steps. Hotspot alterations at positions previously observed to be frequently altered in 
cancer patients were evaluated with more sensitive thresholds because the a priori probability that 
these alterations were tumor-derived is higher than that of other alterations. Alterations present in 
common germline variant databases or in 25% or greater of reads were considered germline and 
removed from further analysis, unless the mutations were identical to known hotspot alterations 
or represented truncating mutations in common tumor suppressor genes. Analysis of the altered 
positions in the dilution samples revealed high concordance to the expected fraction of mutant 
molecules (r = 0.93; P < 0.0001, Pearson correlation; Figure 3.2 and Tables 3.5 and 3.6), as well 
as high sensitivity and specificity. The analytical sensitivity was 97.4% overall and 100 and 89% 
for detecting mutations present at 0.2 and 0.1%, respectively, using minimum thresholds of 
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0.05% in hotspot positions and 0.1% at all other locations. No false positives were detected over 
the 80,930 bases analyzed in 38 dilution analyses, resulting in less than one error in 3 million 
bases sequenced (error rate of <3.3 × 10−7  false-positive mutation calls per base; specificity, 
>99.9999%; Tables 3.5 and 3.6). 
 
Evaluation of plasma from healthy individuals 
 
We used TEC-Seq to examine plasma specimens from 44 healthy individuals (Tables 3.1, 3.2 and 
3.7). These individuals were not known to have cancer and provided their blood samples as part 
of a routine cancer screening visit (colonoscopy or Papanicolaou test). Samples were processed 
within 2 hours from collection and centrifuged twice at high speed to ensure that cells and cellular 
debris were removed and that only cf DNA was analyzed. From the ~4 ml of plasma obtained 
from each individual, we generated TEC-Seq libraries and sequenced these to ~30,000-fold 
coverage. Through these analyses, no mutations were observed in the cancer driver genes 
analyzed in our panel, consistent with the estimated specificity observed in our dilution analyses. 
Although conventional sequencing of these samples would have resulted in thousands of putative 
alterations among the regions analyzed, the TEC-Seq analyses significantly reduced the 
sequencing error rate to fewer than one false positive per 3 million bases sequenced (<3 × 10−7 
false-positive mutation calls per base; P < 0.0001, paired t test; Figure 3.5). We compared the 
TEC-Seq error rate to those obtained through other liquid biopsy analyses. Reanalysis of our 
sequence data from 15 healthy individuals using the recently developed integrated digital error 
suppression (iDES) method (10, 11) resulted in multiple false-positive alterations in the healthy 
cases, consistent with the reported error rate of this approach (11). 
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Analysis of six genes related to hematopoietic proliferation identified six individuals with a single 
mutation in their plasma samples, and a seventh individual had two detectable alterations (16% of 
patients analyzed; Table 3.8). All of the alterations were identified in DNA methyltransferase 3a 
(DNMT3A), a gene that is clonally altered under preleukemic conditions and myelodysplasia (39-
41). Three of the mutations were predicted to result in the R882C change previously observed in 
clonal hematopoiesis, but other alterations have not been previously reported. These mutations 
were identified at mutant allele fractions of 0.16 to 5.3%, substantially lower than previous 
observations in blood cells of healthy individuals (39-41). Our analyses suggest that a higher 
fraction of asymptomatic individuals may harbor such somatic alterations than had been 
previously reported through cellular analyses of these genes in the blood. 
 
Analysis of plasma from patients with cancer 
 
We next analyzed plasma samples from 194 patients with breast cancer (n = 45), colorectal 
cancer (n = 42), lung cancer (n = 65), and ovarian cancer (n = 42). The cohort consisted of 
untreated patients who had localized or metastatic dis- ease, with most of the patients diagnosed 
at stages I and II (Tables 3.5 and 3.6). We found that the concentration of cf DNA in plasma from 
cancer patients was ~29 ng/ml, significantly higher than that observed in healthy individuals 
(average of 7 ng/ml; P = 0.001, unpaired t test; Figure 3.6 A). In the colorectal cancer cohort, 
where a larger number of later-stage patients were analyzed, we found that samples from patients 
with metastatic disease had higher concentration of cf DNA than those from patients with earlier 
stages of disease (average of 66 ng/ml for stage IV patients versus 21 ng/ml for stages I to III; P = 
0.006, unpaired t test; Figure 3.6 B). 
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We examined the cf DNA from these patients using the TEC-Seq approach. Of the 194 patients 
analyzed, more than three quarters of colorectal cancer patients, two-thirds of ovarian cancer 
patients, and most of the lung and breast cancer patients had detectable alterations in driver genes 
(Table 3.9). These detection rates were higher in some cases than the theoretical estimates for 
these cancer types (Tables 3.4 and 3.9). More than three quarters of patients with advanced 
disease (stages III and IV) and 62% of patients with localized disease (stages I and II) were 
detected among all tumor types (Table 3.9). The amounts of ctDNA varied among cancer types, 
with breast cancer having the lowest mutant allele fraction (P = 0.028, unpaired t test; Figure 3.6 
C). Similar to observations of cf DNA, the amounts of ctDNA were higher in metastatic disease 
compared to earlier-stage disease among all cancer types (P < 0.0001, unpaired t test; Figure 3.6 
D and 3.7). Eighty of 128 detected cases had at least one alteration in a gene hotspot position 
(Figure 3.7). The affected genes and distribution of alterations for each tumor type were similar to 
common driver gene alterations that have previously been reported in these cancers (Figure 3.8). 
On average, 2.1 alterations, including 0.9 changes at hotspot positions, were observed in each 
patient with detectable ctDNA, with lung and colorectal cancers having a higher number of 
alterations per case (Figure 3.7). By limiting analysis only to a specific set of hotspot variants as 
others have reported (11), the fraction of cases detected was reduced to 56% of those identified 
by TEC-Seq. These observations highlight the benefit of analyzing a broader panel of driver gene 
regions to increase the possibility of detecting tumor-specific alterations in the plasma. 
Comparison of mutations in plasma with those in matched tumor and blood cells of the 194 
patients in our study, 152 cases had matched tumor and normal tissues that we analyzed using an 
independent targeted NGS approach (Tables 3.5, 3.6 and 3.7). We examined these cases to 
determine whether the mutations identified in the plasma were tumor-specific or may have 
originated during blood cell expansion. The plasma analyses performed using TEC-Seq were 
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performed separately and did not rely on any knowledge of alterations identified through these 
parallel tissue analyses. 
We detected 87 changes in the circulation of 194 patients at allele fractions >25% and considered 
these to be likely germline variants. Analysis of 63 of these variants in the available 
corresponding blood cells identified all these changes to be germline (Table 3.10). These 
observations suggested that cf DNA can be used to accurately identify germline changes in the 
context of tumor-derived and blood cell proliferation alterations and, similarly, that this approach 
can be used to distinguish these changes from somatic alterations. 
Similar to our observations in healthy individuals, we identified alterations in DNMT3A and five 
other genes involved in blood cell proliferation in the plasma of cancer patients (Table 3.8). The 
fraction of patients with detectable changes in these genes correlated with age, as previously 
observed (P = 0.013, unpaired t test) (39-41). Unlike tumor- specific alterations, the allele 
fractions of blood cell proliferation alterations in cf DNA were similar among healthy individuals 
and patients with cancer, regardless of stage. Analysis of matched white blood cells from 
individuals with alterations in these genes identified the corresponding mutation in most of the 
cases, consistent with the notion that the alterations in cf DNA originated from these cells (Table 
3.8). 
After accounting for blood cell proliferation and germline alterations, we identified 313 candidate 
tumor-specific changes in the plasma samples from 128 of the 194 patients analyzed. We further 
evaluated 216 of these alterations in 100 patients where matched tumor tissue and blood cells 
were available. We found that 155 of the 216 (72%) alterations were identical in both plasma and 
tumor samples (Figure 3.9). Among stage III and IV patients, 65 of 84 (77%) variants were 
concordant, whereas for early-stage patients, 90 of 132 (68%) alterations were concordant. In line 
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with these observations, we found that 70 of the 75 (93%) alterations with a mutant allele fraction 
>1% in the plasma were detected in the tumor tissue of the same individual. Overall, 82 of the 
100 (82%) patients had at least one alteration observed in the circulation that was identical to that 
in the tumor specimen. 
To evaluate reproducibility of the approach between separate blood draws in the same patients, 
we assessed six late-stage patients with lung cancer where blood was obtained early during the 
course of treatment. These patients were undergoing treatment but were observed to have 
progressive or stable disease. Despite the difference in time between the blood draws, we found 
that 90% of the alterations observed in the second blood draw were present at the time of the first 
blood draw (17 of 19 alterations), with one patient having no alterations at both time points 
(Figure 3.10). All alterations present with a mutant allele fraction ≥1% were observed at both 
time points. 
In a subset of colorectal cancer patients, we evaluated whether the observations we detected in the 
plasma could be independently confirmed using droplet digital polymerase chain reaction 
(ddPCR), a method that is highly sensitive for detection of single-base substitutions (47). We 
examined six driver alterations detected in the plasma: two that were also detected in matched 
tumors and four that were absent. Five of the six driver alterations were detected in the plasma by 
ddPCR at levels similar to those observed by TEC-Seq (Figure 3.11 A). Those not detected in 
tumors by targeted sequencing were similarly not identified through ddPCR approaches. We also 
evaluated 10 mutations that corresponded to the most common changes in KRAS, PIK3CA, and 
BRAF that we detected in these tumors but were not present in the plasma of these patients. 
Although we confirmed that these alterations were in the tumors of these patients, we found that 
those not detected by TEC-Seq analyses remained undetected by ddPCR in the plasma, 
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presumably because the amounts of ctDNA corresponding to these alterations were extremely 
low in these patients (Figure 3.11 B). 
To assess the possibility that tumor heterogeneity may be responsible for the apparent lack of 
concordance between specific alterations in the plasma and those in the tumor, we analyzed 
multiple tumor sites from colorectal cancer patient CGCRC307 using ddPCR. We characterized 
10 different regions of the tumor as well as a subsequent metastatic site for an R201C alteration 
in the GNAS gene that we detected in the plasma but not in the tumor of this patient. Although 
we found a BRAF V600E alteration in all samples analyzed, the GNAS R201C substitution was 
not detected in the original tumor biopsy but was detected as a subclonal change in only a portion 
of the primary tumor, suggesting that it developed later in tumorigenesis (Figure 3.12). The 
GNAS R201C change identified had been previously reported in colorectal cancers (42) and has 
been shown to promote intestinal tumorigenesis through activation of both Wnt and ERK 
pathways (48). Consistent with this notion, we found the GNAS alteration to be clonal in the 
metastatic lesion that was identified 2 years after the primary tumor in this patient (Figure 3.12). 
These results suggest that plasma alterations not detected in the matched tumor specimens may 
represent bona fide somatic mutations in ctDNA derived from heterogeneous primary or occult 
lesions. 
 
ctDNA and disease progression 
 
Tumor-specific markers may be useful for evaluating disease progression. In colorectal cancer, 
CEA is commonly used to monitor patients after therapy to determine recurrence or progressive 
disease (23, 49). Of the 29 colorectal cancer patients for whom CEA values were available, all 10 
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cases with CEA concentrations >5 ng/ml had detectable ctDNA (Tables 3.5, 3.6 and 3.10). 
However, among the 19 patients with negative or borderline CEA results, 13 had detectable 
ctDNA, including patients of all stages (Tables 3.11 and 3.12). There was no significant 
correlation be- tween ctDNA and CEA concentrations (Pearson correlation coefficient = −0.017; 
P = 0.93). 
We next examined whether preoperative ctDNA analyses may be related to disease recurrence 
and survival after surgical resection. We hypothesized that elevated amounts of ctDNA were 
more likely to be associated with large primary lesions that were incompletely resected or with 
occult metastases. A total of 31 colorectal cancer patients had potentially curative resections, 
including 8 stage I, 9 stage II, 10 stage III, and 4 stage IV patients with liver-only metastases. For 
these patients, the median mutant allele fraction was 0.21%. However, several patients had 
mutant allele fractions >3 median absolute deviations from the median mutant allele fraction, or 
>2%. As predicted, we found that high amounts of ctDNA correlated with poor prognosis (Figure 
3.13). Patients with increased ctDNA had a shorter progression-free survival (PFS) and overall 
survival (OS) compared to those with lower ctDNA amounts (P < 0.0001 for PFS and OS, log-
rank test; Figure 3.14 A and B). The prognostic value for PFS was statistically significant in 
multivariate models, adjusted for stage as a categorical covariate (hazard ratio, 36.3; 95% 
confidence interval (CI), 2.8 to 471.1; P = 0.006, Cox proportional hazards model). These same 
predictions were observed in patients with resectable stage I to III disease (P = 0.0006 for PFS 
and P < 0.0001 for OS, log-rank test; Figure 3.14 C and D). We also evaluated other thresholds of 
increased amounts of ctDNA and found that these were statistically significantly associated with 
worse outcome (P = 0.008 for 0.5% mutant allele fraction and P = 0.0001 for 1% mutant allele 
fraction, log-rank test). In addition, we found that considering ctDNA amounts as a continuous 
variable correlated with outcome (hazard ratio, 1.13; 95% CI, 1.03 to 1.24; P =0.01 for PFS and 
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OS, Cox univariate test). Together, these results indicate that liquid biopsy analyses offer both a 
quantitative and qualitative assessment of disease progression. Although previous analyses have 
found a limited association between preoperative CEA concentrations and OS (23, 49), CEA 
concentrations among our patients were not associated with disease outcome (P = 0.75 for PFS 
and P = 0.73 for OS, log- rank test; Figure 3.15). These analyses from a limited and 
heterogeneous cohort of patients suggest that preoperative ctDNA amounts may provide a useful 
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Figure 3.4.  Simulations using limited exogenous barcodes.  Monte Carlo simulations were 
performed to evaluate the effect of varying the quantity of exogenous barcodes on the number of 
genomic equivalents that can be distinguished through next-generation sequencing as compared 
to the expected number of genomic equivalents. (A) Representative distribution of cfDNA 
fragment sizes observed from sequencing data of ten colorectal cancer patients. (B)  Using a 
sliding number of expected genomic equivalents (F), we sampled F fragment lengths from the 
distribution in (A) with replacement.  Sample fragments were then randomly assigned start and 
end positions relative to an arbitrary base (x).    Exogenous barcodes were randomly assigned to 
each fragment for simulation of 1, 4, 8, 12, and 16 barcodes.  The number of observed genomic 
equivalents was then calculated from the unique combinations of endogenous (start and end 
position) and exogenous barcodes.  These analyses indicate that a limited number of exogenous 
barcodes with endogenous barcodes improves the number of genome equivalents that can be 






























Figure 3.5. TEC-Seq error correction. Sequencing error rates of conventional NGS and theoretical upper limit for TEC-Seq are indicated at each 
base in the captured regions of interest (P < 0.0001, paired t test). Error rates are determined by identifying the number of alterations at each base 
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Figure 3.8.  Mutation frequencies in cancer genes.  Bar charts depict the fraction of patients with an alteration in a cancer driver gene observed 
in the plasma using TEC-Seq for breast (A), colorectal (B), ovarian (C), and lung (D) cancer cohorts.  The fraction of cancer cases reported in the 
COSMIC database with an alteration in the same genes is shown in the overlaid dot plot. The fraction of patients in our study and in the COSMIC 
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Figure 3.9.  Concordance between alterations in plasma and tissue. Mutant allele fractions observed in the plasma are indicated for each 
alteration identified with a black bar at the mean. The presence of alterations in matched tumor specimens is indicated with green dots, whereas 
nonconcordant alterations are indicated in orange, and those that are not assessed are indicated in gray. Stage and cancer type for each patient are 
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Figure 3.14. Preoperative ctDNA amounts and outcome in colorectal cancer patients. Kaplan-Meier curves depict PFS (A) (P < 0.0001, log-
rank test) and OS (B) (P < 0.0001, log-rank test) of 31 colorectal cancer patients, stages I to IV, stratified on the basis of a ctDNA mutant allele 
fraction threshold of 2%. Kaplan-Meier analyses of the 27 patients with stage I to III disease for PFS (C), (P = 0.0006, log-rank test) and OS (D) 
(P < 0.0001, log-rank test) were performed using the same threshold to examine the association of ctDNA with outcome in patients without stage 
IV disease.  
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Figure 3.15. Pre-operative CEA in colorectal cancer patients. Kaplan-Meier curves depict progression-free survival (A, p = 0.7533, Log-rank 
test) and overall survival (B, p = 0.7329, Log-rank test) of 31 CRC patients, stage I – IV, stratified based on a CEA threshold of 5 ng/ml.  Kaplan-
Meier analyses of the 27 patients with stage I – III disease for progression-free survival (C, Log-rank test p = 0.4282) and overall survival (D, Log-
rank test p = 7345) were performed using the same threshold in order to examine the association of CEA with outcome in patients without stage 
IV disease.  Similar results were obtained using CEA thresholds of 2.5 ng/ml and 3 ng/ml.    
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Table 3.1.  Summary of clinical data for patients analyzed. 




















CGPLBR53 Breast Cancer 57 F III T2N3M0 Right Breast Right Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGPLH80 Healthy 37 F NA NA NA NA NA NA NA 
CGPLH78 Healthy 34 F NA NA NA NA NA NA NA 
CGPLH79 Healthy 37 F NA NA NA NA NA NA NA 
CGPLBR49 Breast Cancer 37 F II T2N1M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Poor None 
CGPLH82 Healthy 38 F NA NA NA NA NA NA NA 
CGPLBR38 Breast Cancer 54 F I T1N0M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGPLBR55 Breast Cancer 53 F III T3N1M0 Right Breast Right Breast 
Infiltrating Ductal 
Carcinoma Poor None 
CGPLBR69 Breast Cancer 43 F II T2N0M0 Breast Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGPLH85 Healthy 34 F NA NA NA NA NA NA NA 
CGPLBR39 Breast Cancer 33 F II T2N0M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Poor None 
CGPLBR57 Breast Cancer 54 F III T2N2M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma NA None 
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CGPLBR72 Breast Cancer 67 F II T2N0M0 Breast Breast 
Infiltrating Ductal 
Carcinoma Well None 
CGPLBR48 Breast Cancer 47 F II T2N1M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Poor None 
CGPLH86 Healthy 50 F NA NA NA NA NA NA NA 
CGPLH76 Healthy 53 F NA NA NA NA NA NA NA 
CGPLBR71 Breast Cancer 65 F II T2N0M0 Breast Breast 
Infiltrating Ductal 
Carcinoma Poor None 





CGPLOV15 Ovarian Cancer 54 F III T3N1M0 Ovary Ovary Adenocarcinoma Poor None 
CGPLH84 Healthy 45 F NA NA NA NA NA NA NA 
CGPLBR103 Breast Cancer 48 F II T2N1M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGPLOV17 Ovarian Cancer 42 F I T1aN0M0 Ovary Ovary 
Endometrioid 
Adenoarcinoma Moderate None 
CGCRC301 Colorectal Cancer 76 F I T2N0M0 Rectum Rectum Adenocarcinoma Moderate None 
CGPLBR75 Breast Cancer 63 F II T2N1M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGPLBR76 Breast Cancer 53 F II T2N0M0 Right Breast Right Breast 
Infiltrating Ductal 
Carcinoma Well None 
CGPLLU176 Lung Cancer 58 M I T2N0M0 Lung Lung 
Adenosquamous 
Carcinoma Moderate None 
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CGCRC332 Colorectal Cancer NA NA IV NA Colorectal 
Liver-only 
metastasis Adenocarcinoma NA Liver 
CGPLBR70 Breast Cancer 60 F II T2N1M0 Breast Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGCRC293 Colorectal Cancer 55 M IV T3N2M1 Rectum 
Liver-only 
metastasis Adenocarcinoma Moderate 
Synchronous 
Liver 
CGPLOV18 Ovarian Cancer 57 F I T1cN0M0 Ovary Ovary 
Clear Cell 
Adenocarcinoma Moderate None 
CGPLBR68 Breast Cancer 64 F III T4N1M0 Breast Breast 
Infiltrating Ductal 
Carcinoma Poor None 
CGPLBR41 Breast Cancer 51 F III T3N1M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGPLOV20 Ovarian Cancer 52 F II T2aN0M0 Left Ovary Left Ovary 
Endometrioid 
Adenoarcinoma Poor None 
CGPLLU145 Lung Cancer 53 M II T2aN0M0 Lung Lung Adenocarcinoma Poor None 
CGPLLU178 Lung Cancer 58 F I T2aN0M0 Right Lung Right Lung 
Squamous Cell 
Carcinoma Moderate None 
CGPLH75 Healthy 46 F NA NA NA NA NA NA NA 
CGPLOV24 Ovarian Cancer 14 F I T1aN0M0 Ovary Ovary Germ Cell Tumor Poor None 
CGPLBR63 Breast Cancer 48 F II T2N1M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Moderate None 





CGPLBR100 Breast Cancer 44 F III T2N2M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma NA None 
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CGPLLU147 Lung Cancer 60 M III T3N2M0 Lung Lung 
Adenosquamous 
Carcinoma Poor None 
CGCRC311 Colorectal Cancer 59 M I T2N0M0 Sigmoideum Sigmoideum Adenocarcinoma Moderate None 
CGPLBR73 Breast Cancer 60 F II T2N1M0 Breast Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGPLOV25 Ovarian Cancer 18 F I T1aN0M0 Ovary Ovary Germ Cell Tumor Poor None 
CGPLBR40 Breast Cancer 66 F III T2N2M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Poor None 
CGCRC312 Colorectal Cancer 75 M III T3N1M0 Ascending Ascending Adenocarcinoma Moderate None 
CGPLLU169 Lung Cancer 64 M I T1bN0M0 Lung Lung 
Squamous Cell 
Carcinoma Moderate None 
CGPLLU197 Lung Cancer 55 M I T1N0M0 Left Lung Left Lung Adenocarcinoma NA None 
CGPLH81 Healthy 54 F NA NA NA NA NA NA NA 
CGPLBR99 Breast Cancer 41 F III T3N3M0 Right Breast Right Breast 
Infiltrating Ductal 
Carcinoma Poor None 
CGPLBR44 Breast Cancer 61 F III T2N2M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Poor None 
CGPLBR59 Breast Cancer 42 F I T1N0M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGPLOV10 Ovarian Cancer 48 F I T1aN0MX Right Ovary Right Ovary 
Serous 
Adenocarcinoma Poor None 
CGCRC291 Colorectal Cancer 69 F IV T3N2M1 Coecum 
Liver-only 





CGPLLU179 Lung Cancer 66 M I T2N0M0 Lung Lung 
Large Cell 
Carcinoma   Poor None 
CGCRC321 Colorectal Cancer 68 M I T2N0M0 Rectum Rectum Adenocarcinoma Moderate None 
CGCRC298 Colorectal Cancer 64 M II T3N0M0 Rectum Rectum Adenocarcinoma Moderate None 
CGCRC292 Colorectal Cancer 51 M IV T3N2M1 Sigmoideum 
Liver-only 
metastasis Adenocarcinoma Moderate 
Synchronous 
Liver and Lung 
CGPLLU204 Lung Cancer 50 M I T1aN0M0 Left Lung Left Lung 
Squamous Cell 
Carcinoma Moderate None 
CGPLLU170 Lung Cancer 46 M II T3N0M0 Lung Lung 
Squamous Cell 
Carcinoma Poor None 
CGPLBR61 Breast Cancer 67 F II T2N1M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGPLBR102 Breast Cancer 47 F II T2N1M0 Right Breast Right Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGPLOV12 Ovarian Cancer 45 F I T1aN0MX Ovary Ovary 
Endometrioid 
Adenoarcinoma NA None 
CGPLBR43 Breast Cancer 49 F II T2N0M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Moderate None 




lobe Adenocarcinoma Moderate NA 
CGCRC297 Colorectal Cancer 68 F III T3N1M0 Ascending Ascending Adenocarcinoma Moderate None 
CGPLLU4 Lung Cancer 62 M II T2bN1M0 Lung Lung Adenocarcinoma Moderate None 
CGPLH83 Healthy 60 F NA NA NA NA NA NA NA 
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CGPLLU146 Lung Cancer 58 M II T3N0M0 Lung Lung 




CGPLOV2 Ovarian Cancer 19 F I NA Ovary Ovary 
Mucinous 
Adenocarcinoma NA None 
CGPLBR91 Breast Cancer 62 F III T2N2M0 Breast Breast 
Infiltrating Lobular 
Carcinoma Poor None 
CGCRC295 Colorectal Cancer 76 F IV NA Colorectal 
Liver-only 
metastasis Adenocarcinoma NA 
Metachronous 
Liver 
CGCRC314 Colorectal Cancer 67 F I T2N0M0 Sigmoideum Sigmoideum Adenocarcinoma Moderate None 
CGPLBR67 Breast Cancer 61 F III T4N1M0 Breast Breast 
Infiltrating Ductal 
Carcinoma Well None 
CGPLBR80 Breast Cancer 54 F II T2N1M0 Breast Breast 
Infiltrating Lobular 
Carcinoma Moderate None 
CGPLH77 Healthy 46 F NA NA NA NA NA NA NA 
CGPLLU205 Lung Cancer 65 M II T3N0M0 Left Lung Left Lung Adenocarcinoma Poor None 
CGCRC300 Colorectal Cancer 65 M I T2N0M0 Rectum Rectum Adenocarcinoma Moderate None 
CGPLOV44 Ovarian Cancer 69 F I T1aN0M0 Ovary Ovary 
Mucinous 
adenocarcinoma NA None 
CGPLH90 Healthy 43 F NA NA NA NA NA NA NA 
CGPLLU214 Lung Cancer 54 M II T2N1M0 Lung Lung 
Squamous Cell 
Carcinoma NA None 
CGPLOV6 Ovarian Cancer 56 F II T2aN0M0 Ovary Ovary 
Serous 
Adenocarcinoma Moderate None 
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CGPLLU207 Lung Cancer 60 F II T2N1M0 Lung Lung Adenocarcinoma Well None 
CGPLBR64 Breast Cancer 60 F II T2N0M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Poor None 
CGPLLU208 Lung Cancer 56 F II T2N1M0 Lung Lung Adenocarcinoma Moderate None 
CGPLBR77 Breast Cancer 56 F III T2N2M0 Right Breast Right Breast 
Infiltrating Lobular 
Carcinoma Moderate None 
CGPLOV11 Ovarian Cancer 51 F IV T3cN0M1 Right Ovary Right Ovary 
Endometrioid 
Adenoarcinoma Moderate Omentum 
CGPLOV22 Ovarian Cancer 64 F III T1cNXMX Left Ovary Left Ovary 
Serous 
Adenocarcinoma Well None 
CGPLOV28 Ovarian Cancer 63 F I T1aNxM0 Right Ovary Right Ovary Serous carcinoma NA NA 
CGCRC303 Colorectal Cancer 64 M III T3N1M0 Ascending Ascending Adenocarcinoma Moderate None 
CGPLH91 Healthy 36 F NA NA NA NA NA NA NA 
CGPLLU177 Lung Cancer 45 M II T3N0M0 Right Lung Right Lung Adenocarcinoma NA None 
CGPLLU168 Lung Cancer 70 F I T2aN0M0 Lung Lung Adenocarcinoma Poor None 
CGCRC299 Colorectal Cancer 71 M I T1N0M0 Rectum Rectum Adenocarcinoma Moderate None 
CGPLLU198 Lung Cancer 49 F I T2N0M0 Left Lung Left Lung Adenocarcinoma Moderate None 
CGPLLU5 Lung Cancer 73 M II T3N0M0 Lung Lung 
Squamous Cell 
Carcinoma Poor None 
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CGPLLU174 Lung Cancer 56 M I T2N0M0 Lung Lung Adenocarcinoma Poor None 
CGCRC313 Colorectal Cancer 64 M III T4N1M0 Sigmoideum Sigmoideum Adenocarcinoma Well None 
CGPLBR93 Breast Cancer 59 F II T1N0M0 Breast Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGPLLU173 Lung Cancer 72 F I T2N0M0 Right Lung Right Lung Adenocarcinoma Moderate None 
CGPLLU206 Lung Cancer 55 M III T3N1M0 Right Lung Right Lung 
Squamous Cell 
Carcinoma Poor None 
CGPLBR82 Breast Cancer 70 F I  T1N0M0 Right Breast Right Breast 
Infiltrating Lobular 
Carcinoma Moderate None 
CGPLLU115 Lung Cancer 59 M I T2aN0M0 Lung Lung Adenocarcinoma Poor None 
CGCRC305 Colorectal Cancer 83 F II T3N0M0 Transversum Transversum Adenocarcinoma Moderate None 
CGPLOV43 Ovarian Cancer 30 F I T1aN0M0 Ovary Ovary 
Mucinous 
cystadenocarcinoma NA None 
CGPLH55 Healthy 46 F NA NA NA NA NA NA NA 
CGPLOV46 Ovarian Cancer 58 F I T1bN0M0 Ovary Ovary Serous carcinoma NA None 
CGPLLU180 Lung Cancer 57 M I T2N0M0 Right Lung Right Lung 
Large Cell 
Carcinoma   Poor None 
CGPLLU175 Lung Cancer 47 M I T2N0M0 Lung Lung 
Squamous Cell 
Carcinoma Moderate None 
CGPLOV27 Ovarian Cancer 25 F I T1aN0MX Ovary Ovary Germ Cell Tumor Moderate None 
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CGPLLU30 Lung Cancer 55 M III T2bN0M0 Lung Lung 
Squamous Cell 
Carcinoma Moderate None 
CGCRC315 Colorectal Cancer 74 M III T3N1M0 Sigmoideum Sigmoideum Adenocarcinoma Moderate None 
CGPLLU6 Lung Cancer 75 M I T2N0M0 Left Lung Left Lung 
Large Cell 
Carcinoma   Poor None 
CGPLOV1 Ovarian Cancer 48 F I T1N0M0 Ovary Ovary 
Mucinous 
Adenocarcinoma Poor None 




CGPLBR104 Breast Cancer 68 F II T2N0M0 Right Breast Right Breast 
Infiltrating Lobular 
Carcinoma Moderate None 
CGPLLU165 Lung Cancer 68 F II T1N1M0 Right Lung Right Lung Adenocarcinoma Well None 
CGPLLU144 Lung Cancer 52 M II T2aN1M0 Lung Lung Adenocarcinoma Poor None 
CGPLOV16 Ovarian Cancer 40 F III T3aN0M0 Ovary Ovary 
Serous 
Adenocarcinoma Moderate None 
CGPLOV50 Ovarian Cancer 30 F III T3cN0M0 Ovary Ovary Serous carcinoma NA None 
CGPLBR86 Breast Cancer 51 F II T2N1M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Poor None 








Carcinoma NA NA 
CGPLOV19 Ovarian Cancer 52 F II T2aN0M0 Ovary Ovary 
Endometrioid 
Adenoarcinoma Moderate None 
CGPLOV31 Ovarian Cancer 45 F III T3aNxM0 Right Ovary Right Ovary 
Clear cell 
adenocarcinoma NA None 
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CGPLLU66 Lung Cancer 71 M I T2N0M0 Left Lung Left Lung Adenocarcinoma Poor None 
CGPLH50 Healthy 55 F NA NA NA NA NA NA NA 
CGPLLU203 Lung Cancer 66 M II T3N0M0 Right Lung Right Lung 
Squamous Cell 
Carcinoma Well None 
CGCRC340 Colorectal Cancer NA NA IV NA Colorectal 
Liver-only 
metastasis Adenocarcinoma NA Liver 
CGPLLU29 Lung Cancer 65 F I T1bN0M0 Lung Lung Adenocarcinoma Poor None 
CGPLH59 Healthy 34 F NA NA NA NA NA NA NA 
CGPLLU54 Lung Cancer 55 M II T2N1M0 Right Lung Right Lung Adenocarcinoma Poor None 
CGPLLU119 Lung Cancer 67 M II T2bN1M0 Lung Lung 
Squamous Cell 
Carcinoma Moderate None 
CGPLBR96 Breast Cancer 78 F II T2N0M0 Left Breast Left Breast 
Infiltrating Lobular 
Carcinoma Moderate None 
CGPLOV14 Ovarian Cancer 46 F I T1bN0MX Ovary Ovary 
Serous 
Adenocarcinoma Poor None 
CGPLLU116 Lung Cancer 64 M I T1bN0M0 Lung Lung 
Squamous Cell 
Carcinoma NA None 
CGPLH60 Healthy 31 F NA NA NA NA NA NA NA 
CGCRC304 Colorectal Cancer 86 F II T3N0M0 Rectum Rectum Adenocarcinoma Moderate None 
CGPLLU162 Lung Cancer 38 M II T1N1M0 Right Lung Right Lung Adenocarcinoma Moderate None 
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CGCRC307 Colorectal Cancer 78 F II T3N0M0 Ascending Ascending Adenocarcinoma Moderate None 
CGPLLU65 Lung Cancer 54 F II T2N1M0 Lung Lung Adenocarcinoma Well None 
CGPLOV47 Ovarian Cancer 41 F I T1aN0M0 Ovary Ovary Serous cystadenoma NA None 
CGPLLU19 Lung Cancer 47 F I T1N0M0 Lung Lung Adenocarcinoma Poor None 
CGCRC317 Colorectal Cancer 74 M III T3N2M0 Descending Descending Adenocarcinoma Moderate None 
CGPLOV13 Ovarian Cancer 62 F IV T1bN0M1 Right Ovary Right Ovary 
Endometrioid 
Adenoarcinoma Poor Omentum 
CGCRC294 Colorectal Cancer 67 F II T3N0M0 Sigmoideum CRC Adenocarcinoma Moderate None 
CGCRC296 Colorectal Cancer 76 F II T4N0M0 Coecum Coecum Adenocarcinoma Poor None 
CGPLLU31 Lung Cancer 59 M II T2aN1M0 Lung Lung 
Squamous Cell 
Carcinoma Moderate None 
CGCRC320 Colorectal Cancer 73 F I T2N0M0 Ascending Ascending Adenocarcinoma Moderate None 
CGPLOV38 Ovarian Cancer 46 F I T1cN0M0 Ovary Ovary Serous carcinoma NA None 
CGPLOV49 Ovarian Cancer 68 F III T3bN0M0 Ovary Ovary Serous carcinoma NA None 
CGPLLU202 Lung Cancer 68 M I T2aN0M0 Right Lung Right Lung Adenocarcinoma NA None 
CGPLLU138 Lung Cancer 32 M II T2N1M0 Lung Lung 
Large Cell 
Carcinoma Poor None 
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CGCRC309 Colorectal Cancer 83 F III T3N2M0 Transversum Transversum Adenocarcinoma Poor None 
CGPLLU135 Lung Cancer 54 F II T2N1M0 Lung Lung Adenocarcinoma Well None 
CGPLH45 Healthy 58 F NA NA NA NA NA NA NA 
CGPLLU117 Lung Cancer 59 M III T3N1M0 Lung Lung Carcinoma Moderate None 
CGPLOV26 Ovarian Cancer 35 F I T1aN0M0 Ovary Ovary Germ Cell Tumor Poor None 
CGPLOV23 Ovarian Cancer 47 F I T1aN0M0 Ovary Ovary 
Serous 
Adenocarcinoma Poor None 
CGPLOV32 Ovarian Cancer 53 F I T1aNxM0 Left Ovary Left Ovary 
Mucinous 
cystadenoma NA None 
CGPLLU64 Lung Cancer 55 F I T2N0M0 Lung Lung Adenocarcinoma Poor None 
CGCRC306 Colorectal Cancer 80 F II T4N0M0 Ascending Ascending Adenocarcinoma Moderate None 
CGPLH48 Healthy 38 F NA NA NA NA NA NA NA 
CGCRC318 Colorectal Cancer 81 M I T2N0M0 Coecum Coecum Adenocarcinoma Moderate None 
CGPLBR101 Breast Cancer 46 F II T2N1M0 Left Breast Left Breast 
Infiltrating Lobular 
Carcinoma Moderate None 








Carcinoma NA NA 
CGPLH52 Healthy 40 F NA NA NA NA NA NA NA 
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CGPLH56 Healthy 42 F NA NA NA NA NA NA NA 
CGCRC302 Colorectal Cancer 73 M II T3N0M0 Transversum Transversum Adenocarcinoma Moderate None 
CGPLLU20 Lung Cancer 61 F II T1N1M0 Lung Lung Adenocarcinoma Moderate None 
CGPLLU59 Lung Cancer NA NA IV T1bN0 Lung Lung Adenocarcinoma NA NA 
CGPLH37 Healthy 39 F NA NA NA NA NA NA NA 
CGPLBR97 Breast Cancer 44 F II T2N0M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGCRC308 Colorectal Cancer 72 F III T4N2M0 Ascending Ascending Adenocarcinoma Moderate None 
CGPLH54 Healthy 47 F NA NA NA NA NA NA NA 
CGPLH53 Healthy 50 F NA NA NA NA NA NA NA 
CGPLH57 Healthy 39 F NA NA NA NA NA NA NA 
CGPLBR88 Breast Cancer 48 F II T1N1M0 Left Breast Left Breast 
Infiltrating Ductal 
Carcinoma Poor None 
CGCRC316 Colorectal Cancer 80 M III T3N2M0 Transversum Transversum Adenocarcinoma Moderate None 
CGPLBR66 Breast Cancer 57 F III T4N1M0 Breast Breast 
Infiltrating Ductal 
Carcinoma Well None 
CGPLLU137 Lung Cancer 35 F I T2N0M0 Lung Lung 
Squamous Cell 
Carcinoma NA None 
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CGPLH49 Healthy 39 F NA NA NA NA NA NA NA 
CGCRC339 Colorectal Cancer NA NA IV NA Colorectal 
Liver-only 
metastasis Adenocarcinoma NA Liver 





CGPLLU118 Lung Cancer 60 M II T2bN0M0 Lung Lung 
Small Cell 
Carcinoma Poor None 
CGPLH58 Healthy 45 F NA NA NA NA NA NA NA 





CGPLOV7 Ovarian Cancer 28 F I T1aN0M0 Right Ovary Right Ovary 
Mucinous 
Adenocarcinoma Moderate None 
CGCRC334 Colorectal Cancer NA NA IV NA Colorectal 
Liver-only 
metastasis Adenocarcinoma NA Liver 
CGPLOV48 Ovarian Cancer 52 F I T1bN0M0 Ovary Ovary Serous carcinoma NA None 
CGPLH46 Healthy 35 F NA NA NA NA NA NA NA 
CGPLH62 Healthy 41 F NA NA NA NA NA NA NA 
CGPLLU28 Lung Cancer 38 M I T2aN0M0 Lung Lung 
Squamous Cell 
Carcinoma Poor None 
CGPLLU161 Lung Cancer 41 F II T3N0M0 Lung Lung Adenocarcinoma Well None 
CGPLH43 Healthy 49 F NA NA NA NA NA NA NA 
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CGPLLU163 Lung Cancer 66 M II T1N1M0 Left Lung Left Lung Adenocarcinoma Poor None 
CGPLH47 Healthy 50 F NA NA NA NA NA NA NA 
CGPLOV8 Ovarian Cancer 43 F I T1N0M0 Left Ovary Left Ovary 
Mucinous 
Adenocarcinoma NA None 
CGPLLU166 Lung Cancer 52 F II T2N1M0 Right Lung Right Lung Adenocarcinoma Poor None 
CGPLLU209 Lung Cancer 65 M II T2aN0M0 Lung Lung 
Large Cell 
Carcinoma   Poor None 
CGCRC319 Colorectal Cancer 80 F III T2N1M0 Descending Descending Adenocarcinoma Moderate None 
CGPLOV37 Ovarian Cancer 40 F I T1cN0M0 Ovary Ovary Serous carcinoma NA None 
CGPLLU139 Lung Cancer 57 M II T2N1M0 Lung Lung 
Large Cell 
Carcinoma Poor None 
CGPLH63 Healthy 47 F NA NA NA NA NA NA NA 
CGPLH64 Healthy 55 F NA NA NA NA NA NA NA 
CGPLLU136 Lung Cancer 51 F II T2N1M0 Lung Lung Adenocarcinoma Moderate None 
CGPLOV3 Ovarian Cancer 59 F III T3bN0M0 Ovary Ovary 
Serous 
Adenocarcinoma Poor None 
CGPLH42 Healthy 54 F NA NA NA NA NA NA NA 
CGPLLU47 Lung Cancer 65 NA IV NA Lung Lung 
Squamous Cell 
Carcinoma NA NA 
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CGCRC342 Colorectal Cancer NA NA IV NA Colorectal 
Liver-only 
metastasis Adenocarcinoma NA Liver 
CGPLLU57 Lung Cancer NA NA III NA Lung Lung 
Squamous Cell 
Carcinoma NA None 
CGPLH51 Healthy 48 F NA NA NA NA NA NA NA 
CGPLLU21 Lung Cancer 63 F I T2N0M0 Lung Lung Adenocarcinoma Moderate None 








Carcinoma NA Liver / Bone 
CGPLH40 Healthy 37 F NA NA NA NA NA NA NA 
CGPLH35 Healthy 48 F NA NA NA NA NA NA NA 
CGPLLU26 Lung Cancer 56 M I T2aN0M0 Lung Lung Adenocarcinoma Moderate None 
CGPLOV42 Ovarian Cancer 52 F I T3aN0M0 Ovary Ovary Serous carcinoma NA None 
CGPLH39 Healthy 41 F NA NA NA NA NA NA NA 








Carcinoma NA Liver / Bone 
CGPLLU57 Lung Cancer NA NA III NA Lung Lung 
Squamous Cell 
Carcinoma NA None 
CGPLLU59 Lung Cancer NA NA IV T1bN0 Lung Lung Adenocarcinoma NA NA 







CGCRC310 Colorectal Cancer 85 M II T4N0M0 Coecum Coecum Adenocarcinoma Moderate None 
CGPLLU47 Lung Cancer 65 NA IV NA Lung Lung 
Squamous Cell 
Carcinoma NA NA 




CGPLH41 Healthy 49 F NA NA NA NA NA NA NA 
CGPLLU22 Lung Cancer 76 M I T2N0M0 Left Lung Left Lung 
Large Cell 
Carcinoma   Poor None 
CGPLOV9 Ovarian Cancer 47 F II T2cN0M0 Left Ovary Left Ovary 
Endometrioid 
Adenoarcinoma Well None 
CGPLH36 Healthy 36 F NA NA NA NA NA NA NA 
CGPLH44 Healthy 30 F NA NA NA NA NA NA NA 
CGPLLU63 Lung Cancer 46 F I T1N0M0 Left Lung Left Lung Adenocarcinoma Poor None 
CGPLLU164 Lung Cancer 66 M II T1N1M0 Left Lung Left Lung Adenocarcinoma Poor None 
CGPLH61 Healthy 32 F NA NA NA NA NA NA NA 
CGPLLU23 Lung Cancer 56 M I T2N0M0 Left Lung Left Lung 
Adenosquamous 
Carcinoma Moderate None 
CGPLLU2 Lung Cancer 72 M II T1bN0M0 Lung Lung Adenocarcinoma Moderate None 
CGPLLU67 Lung Cancer 67 M II T2N1M0 Left Lung Left Lung Adenocarcinoma Poor None 
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CGPLH38 Healthy 47 F NA NA NA NA NA NA NA 




lobe Adenocarcinoma Moderate NA 
CGCRC338 Colorectal Cancer NA NA IV NA Colorectal 
Liver-only 
metastasis Adenocarcinoma NA Liver 
CGCRC335 Colorectal Cancer NA NA IV NA Colorectal 
Liver-only 
metastasis Adenocarcinoma NA Liver 
CGPLLU3 Lung Cancer 55 M I T2aN0M0 Lung Lung 
Squamous Cell 
Carcinoma Moderate None 
CGPLBR87 Breast Cancer 80 F II T2N1M0 Righ Breast Righ Breast 
Papillary 
Carcinoma Well None 
CGCRC333 Colorectal Cancer NA NA IV NA Colorectal 
Liver-only 
metastasis Adenocarcinoma NA Liver 
CGCRC341 Colorectal Cancer NA NA IV NA Colorectal 
Liver-only 
metastasis Adenocarcinoma NA Liver 
CGPLLU68 Lung Cancer 61 M II T2N1M0 Lung Lung Adenocarcinoma Moderate None 
CGPLBR83 Breast Cancer 53 F II T2N1M0 Right Breast Right Breast 
Infiltrating Ductal 
Carcinoma Moderate None 
CGCRC337 Colorectal Cancer NA NA IV NA Colorectal 
Liver-only 
metastasis Adenocarcinoma NA Liver 
CGCRC336 Colorectal Cancer NA NA IV NA Colorectal 
Liver-only 
metastasis Adenocarcinoma NA Liver 
CGPLLU1 Lung Cancer 67 M I T1N0M0 Right Lung Right Lung Adenocarcinoma NA None 
CGPLOV4 Ovarian Cancer 13 F III T3bN0M0 Ovary Ovary Granulosa Poor None 
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*NA denotes either not available or in the case of healthy samples not applicable.  All samples were from patients that had not been previously treated with the exception of lung 
cancer cases CPPLLU14, CPPLLU44, CPPLLU47, CPPLLU57, CPPLLU59, and CPPLLU9.   Multiple values for volume of plasma and cfDNA extracted are indicated for cases 


















   Table 3.2.  Summary of sample data for patients analyzed. 





CGPLBR53 TEC-Seq and Targeted NGS 4.20 1.26 1.26 
CGPLH80 TEC-Seq 4.00 1.94 1.94 
CGPLH78 TEC-Seq 4.00 2.51 2.51 
CGPLH79 TEC-Seq 4.00 3.68 3.68 
CGPLBR49 TEC-Seq and Targeted NGS 4.00 5.74 5.74 
CGPLH82 TEC-Seq 4.00 3.30 3.30 
CGPLBR38 TEC-Seq and Targeted NGS 4.00 5.77 5.77 
CGPLBR55 TEC-Seq and Targeted NGS 4.30 4.57 4.57 
CGPLBR69 TEC-Seq and Targeted NGS 4.40 4.07 4.07 
CGPLH85 TEC-Seq 4.00 2.58 2.58 
CGPLBR39 TEC-Seq and Targeted NGS 4.30 7.53 7.53 
CGPLBR57 TEC-Seq and Targeted NGS 4.30 4.02 4.02 
CGPLBR72 TEC-Seq and Targeted NGS 3.90 4.43 4.43 
CGPLBR48 TEC-Seq and Targeted NGS 3.90 7.07 7.07 
CGPLH86 TEC-Seq 4.00 4.23 4.23 
CGPLH76 TEC-Seq 4.00 4.03 4.03 
CGPLBR71 TEC-Seq and Targeted NGS 3.10 7.64 7.64 
CGPLBR42 TEC-Seq 4.00 6.34 6.34 
CGPLOV15 TEC-Seq and Targeted NGS 5.00 4.77 4.77 
CGPLH84 TEC-Seq 4.00 3.33 3.33 
CGPLBR103 TEC-Seq 3.60 7.11 7.11 
CGPLOV17 TEC-Seq and Targeted NGS 4.50 3.76 3.76 
CGCRC301 TEC-Seq and Targeted NGS 4.10 6.51 6.51 
CGPLBR75 TEC-Seq and Targeted NGS 4.50 5.89 5.89 
CGPLBR76 TEC-Seq and Targeted NGS 4.90 8.71 8.71 
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CGPLLU176 TEC-Seq and Targeted NGS 3.20 7.86 7.86 
CGCRC332 TEC-Seq and Targeted NGS 3.30 4.46 4.46 
CGPLBR70 TEC-Seq and Targeted NGS 3.40 11.94 11.94 
CGCRC293 TEC-Seq and Targeted NGS 7.20 3.83 3.83 
CGPLOV18 TEC-Seq and Targeted NGS 3.10 7.81 7.81 
CGPLBR68 TEC-Seq and Targeted NGS 3.40 10.41 10.41 
CGPLBR41 TEC-Seq 4.50 11.56 11.56 
CGPLOV20 TEC-Seq and Targeted NGS 4.20 5.67 5.67 
CGPLLU145 TEC-Seq 3.00 10.30 10.30 
CGPLLU178 TEC-Seq and Targeted NGS 3.00 10.78 10.78 
CGPLH75 TEC-Seq 4.00 3.87 3.87 
CGPLOV24 TEC-Seq 4.20 10.71 10.71 
CGPLBR63 TEC-Seq and Targeted NGS 4.00 6.19 6.19 
CGPLBR74 TEC-Seq and Targeted NGS 4.50 8.13 8.13 
CGPLBR100 TEC-Seq and Targeted NGS 4.00 4.25 4.25 
CGPLLU147 TEC-Seq and Targeted NGS 3.80 6.72 6.72 
CGCRC311 TEC-Seq and Targeted NGS 8.50 3.91 3.91 
CGPLBR73 TEC-Seq and Targeted NGS 3.30 14.69 14.69 
CGPLOV25 TEC-Seq 4.80 6.78 6.78 
CGPLBR40 TEC-Seq and Targeted NGS 4.60 15.69 15.69 
CGCRC312 TEC-Seq and Targeted NGS 8.90 2.91 2.91 
CGPLLU169 TEC-Seq and Targeted NGS 4.20 13.70 13.70 
CGPLLU197 TEC-Seq and Targeted NGS 4.40 6.87 6.87 
CGPLH81 TEC-Seq 4.00 5.16 5.16 
CGPLBR99 TEC-Seq and Targeted NGS 4.50 6.78 6.78 
CGPLBR44 TEC-Seq and Targeted NGS 3.70 12.81 12.81 
CGPLBR59 TEC-Seq and Targeted NGS 4.10 8.24 8.24 
CGPLOV10 TEC-Seq and Targeted NGS 3.40 7.09 7.09 
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CGCRC291 TEC-Seq and Targeted NGS 7.90 7.80 7.80 
CGPLLU179 TEC-Seq and Targeted NGS 3.40 12.13 12.13 
CGCRC321 TEC-Seq and Targeted NGS 9.30 4.25 4.25 
CGCRC298 TEC-Seq and Targeted NGS 4.20 14.09 14.09 
CGCRC292 TEC-Seq and Targeted NGS 7.90 6.73 6.73 
CGPLLU204 TEC-Seq and Targeted NGS 4.10 10.64 10.64 
CGPLLU170 TEC-Seq 4.50 12.46 12.46 
CGPLBR61 TEC-Seq 4.10 13.25 13.25 
CGPLBR102 TEC-Seq 3.60 13.67 13.67 
CGPLOV12 TEC-Seq 3.20 12.44 12.44 
CGPLBR43 TEC-Seq 4.20 13.35 13.35 
CGPLLU14 TEC-Seq 2.00 2.55 2.55 
CGCRC297 TEC-Seq and Targeted NGS 4.40 8.83 8.83 
CGPLLU4 TEC-Seq 4.50 5.18 5.18 
CGPLH83 TEC-Seq 4.00 5.04 5.04 
CGPLLU146 TEC-Seq and Targeted NGS 3.60 13.72 13.72 
CGPLOV2 TEC-Seq and Targeted NGS 4.09 9.66 9.66 
CGPLBR91 TEC-Seq and Targeted NGS 3.20 22.41 22.41 
CGCRC295 TEC-Seq and Targeted NGS 8.50 5.02 5.02 
CGCRC314 TEC-Seq and Targeted NGS 8.50 5.77 5.77 
CGPLBR67 TEC-Seq and Targeted NGS 3.70 15.59 15.59 
CGPLBR80 TEC-Seq and Targeted NGS 4.30 9.70 9.70 
CGPLH77 TEC-Seq 4.00 5.89 5.89 
CGPLLU205 TEC-Seq and Targeted NGS 4.00 18.56 18.56 
CGCRC300 TEC-Seq and Targeted NGS 4.30 10.48 10.48 
CGPLOV44 TEC-Seq 4.50 8.79 8.79 
CGPLH90 TEC-Seq 3.60 9.79 9.79 
CGPLLU214 TEC-Seq 4.80 7.45 7.45 
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CGPLOV6 TEC-Seq and Targeted NGS 3.50 11.03 11.03 
CGPLLU207 TEC-Seq and Targeted NGS 4.00 17.29 17.29 
CGPLBR64 TEC-Seq and Targeted NGS 4.50 9.42 9.42 
CGPLLU208 TEC-Seq and Targeted NGS 3.00 24.34 24.34 
CGPLBR77 TEC-Seq and Targeted NGS 4.65 14.58 14.58 
CGPLOV11 TEC-Seq and Targeted NGS 3.40 17.35 17.35 
CGPLOV22 TEC-Seq and Targeted NGS 4.60 17.42 17.42 
CGPLOV28 TEC-Seq 3.20 10.74 10.74 
CGCRC303 TEC-Seq and Targeted NGS 9.20 7.65 7.65 
CGPLH91 TEC-Seq 3.60 7.81 7.81 
CGPLLU177 TEC-Seq and Targeted NGS 3.90 19.07 19.07 
CGPLLU168 TEC-Seq and Targeted NGS 4.30 19.38 19.38 
CGCRC299 TEC-Seq and Targeted NGS 8.80 10.18 10.18 
CGPLLU198 TEC-Seq and Targeted NGS 4.20 14.09 14.09 
CGPLLU5 TEC-Seq and Targeted NGS 4.50 7.91 7.91 
CGPLLU174 TEC-Seq and Targeted NGS 3.00 18.16 18.16 
CGCRC313 TEC-Seq and Targeted NGS 8.70 6.65 6.65 
CGPLBR93 TEC-Seq 3.30 27.94 27.94 
CGPLLU173 TEC-Seq 4.50 13.76 13.76 
CGPLLU206 TEC-Seq and Targeted NGS 3.50 18.24 18.24 
CGPLBR82 TEC-Seq and Targeted NGS 4.75 23.39 23.39 
CGPLLU115 TEC-Seq and Targeted NGS 5.00 10.80 10.80 
CGCRC305 TEC-Seq and Targeted NGS 8.60 9.10 9.10 
CGPLOV43 TEC-Seq 4.40 9.09 9.09 
CGPLH55 TEC-Seq 4.00 7.35 7.35 
CGPLOV46 TEC-Seq 4.10 8.97 8.97 
CGPLLU180 TEC-Seq and Targeted NGS 3.20 19.31 19.31 
CGPLLU175 TEC-Seq and Targeted NGS 4.40 16.84 16.84 
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CGPLOV27 TEC-Seq 4.00 19.39 19.39 
CGPLLU30 TEC-Seq and Targeted NGS 5.00 14.20 14.20 
CGCRC315 TEC-Seq and Targeted NGS 8.60 9.67 9.67 
CGPLLU6 TEC-Seq and Targeted NGS 4.39 11.57 11.57 
CGPLOV1 TEC-Seq and Targeted NGS 4.70 9.98 9.98 
CGPLOV41 TEC-Seq 4.40 10.03 10.03 
CGPLBR104 TEC-Seq 4.70 19.89 19.89 
CGPLLU165 TEC-Seq and Targeted NGS 4.50 20.13 20.13 
CGPLLU144 TEC-Seq and Targeted NGS 3.50 31.51 31.51 
CGPLOV16 TEC-Seq and Targeted NGS 4.50 27.28 27.28 
CGPLOV50 TEC-Seq 4.50 8.89 8.89 
CGPLBR86 TEC-Seq and Targeted NGS 3.70 19.89 19.89 
CGPLLU9 TEC-Seq 6.00 12.48 12.48 
CGPLOV19 TEC-Seq and Targeted NGS 5.00 23.46 23.46 
CGPLOV31 TEC-Seq 4.00 14.45 14.45 
CGPLLU66 TEC-Seq and Targeted NGS 5.00 3.40 3.40 
CGPLH50 TEC-Seq 4.00 7.05 7.05 
CGPLLU203 TEC-Seq and Targeted NGS 4.20 26.24 26.24 
CGCRC340 TEC-Seq and Targeted NGS 3.50 9.57 9.57 
CGPLLU29 TEC-Seq 5.00 8.00 8.00 
CGPLH59 TEC-Seq 4.00 6.03 6.03 
CGPLLU54 TEC-Seq and Targeted NGS 4.00 9.75 9.75 
CGPLLU119 TEC-Seq and Targeted NGS 5.00 16.00 16.00 
CGPLBR96 TEC-Seq and Targeted NGS 3.80 24.45 24.45 
CGPLOV14 TEC-Seq and Targeted NGS 3.70 24.43 24.43 
CGPLLU116 TEC-Seq and Targeted NGS 5.00 17.20 17.20 
CGPLH60 TEC-Seq 4.00 1.48 1.48 
CGCRC304 TEC-Seq and Targeted NGS 4.10 30.19 30.19 
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CGPLLU162 TEC-Seq and Targeted NGS 3.10 40.32 40.32 
CGCRC307 TEC-Seq and Targeted NGS 8.50 14.26 14.26 
CGPLLU65 TEC-Seq and Targeted NGS 5.00 12.20 12.20 
CGPLOV47 TEC-Seq 4.50 19.35 19.35 
CGPLLU19 TEC-Seq and Targeted NGS 3.50 12.46 12.46 
CGCRC317 TEC-Seq and Targeted NGS 8.80 16.08 16.08 
CGPLOV13 TEC-Seq and Targeted NGS 3.80 27.00 27.00 
CGCRC294 TEC-Seq and Targeted NGS 8.40 18.87 18.87 
CGCRC296 TEC-Seq and Targeted NGS 4.30 31.24 31.24 
CGPLLU31 TEC-Seq and Targeted NGS 4.80 4.38 4.38 
CGCRC320 TEC-Seq and Targeted NGS 4.50 30.37 30.37 
CGPLOV38 TEC-Seq 2.40 34.29 34.29 
CGPLOV49 TEC-Seq 4.20 16.48 16.48 
CGPLLU202 TEC-Seq and Targeted NGS 4.40 24.72 24.72 
CGPLLU138 TEC-Seq and Targeted NGS 5.00 4.60 4.60 
CGCRC309 TEC-Seq and Targeted NGS 8.50 17.46 17.46 
CGPLLU135 TEC-Seq and Targeted NGS 5.00 13.80 13.80 
CGPLH45 TEC-Seq 4.00 10.85 10.85 
CGPLLU117 TEC-Seq and Targeted NGS 5.00 7.00 7.00 
CGPLOV26 TEC-Seq 4.50 27.90 27.90 
CGPLOV23 TEC-Seq 5.00 26.73 26.73 
CGPLOV32 TEC-Seq 3.20 27.36 27.36 
CGPLLU64 TEC-Seq and Targeted NGS 5.00 15.60 15.60 
CGCRC306 TEC-Seq and Targeted NGS 4.50 24.31 24.31 
CGPLH48 TEC-Seq 4.00 6.38 6.38 
CGCRC318 TEC-Seq and Targeted NGS 9.80 18.24 18.24 
CGPLBR101 TEC-Seq 4.00 37.88 37.88 
CGPLLU9 TEC-Seq 6.00 9.78 9.78 
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CGPLH52 TEC-Seq 4.00 9.90 9.90 
CGPLH56 TEC-Seq 4.00 5.20 5.20 
CGCRC302 TEC-Seq and Targeted NGS 4.30 52.13 52.13 
CGPLLU20 TEC-Seq and Targeted NGS 4.39 15.49 15.49 
CGPLLU59 TEC-Seq 3.00 12.00 12.00 
CGPLH37 TEC-Seq 4.00 9.73 9.73 
CGPLBR97 TEC-Seq and Targeted NGS 4.20 43.21 43.21 
CGCRC308 TEC-Seq and Targeted NGS 4.30 46.87 46.87 
CGPLH54 TEC-Seq 4.00 14.18 14.18 
CGPLH53 TEC-Seq 4.00 4.78 4.78 
CGPLH57 TEC-Seq 4.00 7.15 7.15 
CGPLBR88 TEC-Seq and Targeted NGS 3.60 49.75 49.75 
CGCRC316 TEC-Seq and Targeted NGS 4.90 52.16 52.16 
CGPLBR66 TEC-Seq and Targeted NGS 4.80 24.11 24.11 
CGPLLU137 TEC-Seq and Targeted NGS 5.00 19.80 19.80 
CGPLH49 TEC-Seq 4.00 6.60 6.60 
CGCRC339 TEC-Seq and Targeted NGS 4.50 15.56 15.56 
CGPLBR92 TEC-Seq and Targeted NGS 3.10 81.00 81.00 
CGPLLU118 TEC-Seq and Targeted NGS 4.00 13.50 13.50 
CGPLH58 TEC-Seq 4.00 5.55 5.55 
CGPLOV21 TEC-Seq and Targeted NGS 4.30 56.32 56.32 
CGPLOV7 TEC-Seq and Targeted NGS 5.00 10.80 10.80 
CGCRC334 TEC-Seq and Targeted NGS 4.50 21.36 21.36 
CGPLOV48 TEC-Seq 3.50 22.8 22.80 
CGPLH46 TEC-Seq 4.00 8.25 8.25 
CGPLH62 TEC-Seq 4.00 2.28 2.28 
CGPLLU28 TEC-Seq and Targeted NGS 5.00 30.20 30.20 
CGPLLU161 TEC-Seq 4.00 83.04 62.50 
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CGPLH43 TEC-Seq 4.00 8.50 8.50 
CGPLLU163 TEC-Seq and Targeted NGS 5.00 54.03 50.00 
CGPLH47 TEC-Seq 4.00 7.43 7.43 
CGPLOV8 TEC-Seq and Targeted NGS 5.00 14.80 14.80 
CGPLLU166 TEC-Seq and Targeted NGS 5.00 46.14 46.14 
CGPLLU209 TEC-Seq and Targeted NGS 5.50 53.95 45.45 
CGCRC319 TEC-Seq and Targeted NGS 4.20 53.54 53.54 
CGPLOV37 TEC-Seq 3.20 46.88 46.88 
CGPLLU139 TEC-Seq and Targeted NGS 5.00 22.00 22.00 
CGPLH63 TEC-Seq 4.00 10.10 10.10 
CGPLH64 TEC-Seq 4.00 8.03 8.03 
CGPLLU136 TEC-Seq and Targeted NGS 5.00 25.80 25.80 
CGPLOV3 TEC-Seq and Targeted NGS 4.51 13.53 13.53 
CGPLH42 TEC-Seq 4.00 14.30 14.30 
CGPLLU47 TEC-Seq 7.00 22.29 22.29 
CGCRC342 TEC-Seq 3.90 56.09 56.09 
CGPLLU57 TEC-Seq 3.00 11.43 11.43 
CGPLH51 TEC-Seq 4.00 7.85 7.85 
CGPLLU21 TEC-Seq and Targeted NGS 2.00 44.00 44.00 
CGPLLU44 TEC-Seq 5.00 35.08 35.08 
CGPLH40 TEC-Seq 4.00 2.70 2.70 
CGPLH35 TEC-Seq 4.00 13.15 13.15 
CGPLLU26 TEC-Seq and Targeted NGS 5.00 4.60 4.60 
CGPLOV42 TEC-Seq 4.20 49.51 49.51 
CGPLH39 TEC-Seq 5.00 3.08 3.08 
CGPLLU44 TEC-Seq 5.00 43.40 43.40 
CGPLLU57 TEC-Seq 3.00 25.00 25.00 
CGPLLU59 TEC-Seq 3.00 10.13 10.13 
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CGPLOV5 TEC-Seq 4.50 36.42 36.42 
CGCRC310 TEC-Seq and Targeted NGS 4.60 72.12 72.12 
CGPLLU47 TEC-Seq 8.00 24.00 24.00 
CGPLOV40 TEC-Seq 1.60 193.6 156.25 
CGPLH41 TEC-Seq 4.00 4.73 4.73 
CGPLLU22 TEC-Seq and Targeted NGS 5.00 44.00 44.00 
CGPLOV9 TEC-Seq and Targeted NGS 5.00 8.4 8.40 
CGPLH36 TEC-Seq 4.00 13.00 13.00 
CGPLH44 TEC-Seq 4.00 9.08 9.08 
CGPLLU63 TEC-Seq and Targeted NGS 5.00 41.40 41.40 
CGPLLU164 TEC-Seq and Targeted NGS 4.80 79.54 52.08 
CGPLH61 TEC-Seq 4.00 7.15 7.15 
CGPLLU23 TEC-Seq and Targeted NGS 5.00 29.00 29.00 
CGPLLU2 TEC-Seq and Targeted NGS 4.50 44.22 44.22 
CGPLLU67 TEC-Seq and Targeted NGS 5.00 80.00 80.00 
CGPLH38 TEC-Seq 4.00 8.38 8.38 
CGPLLU14 TEC-Seq 3.00 14.33 14.33 
CGCRC338 TEC-Seq and Targeted NGS 2.30 109.76 109.76 
CGCRC335 TEC-Seq and Targeted NGS 4.60 59.07 59.07 
CGPLLU3 TEC-Seq and Targeted NGS 4.50 52.76 52.76 
CGPLBR87 TEC-Seq and Targeted NGS 3.60 277.39 69.44 
CGCRC333 TEC-Seq and Targeted NGS 4.00 113.88 113.88 
CGCRC341 TEC-Seq 4.60 156.62 156.62 
CGPLLU68 TEC-Seq 4.00 120.25 120.25 
CGPLBR83 TEC-Seq and Targeted NGS 3.70 100.17 100.17 
CGCRC337 TEC-Seq and Targeted NGS 3.40 208.66 208.66 
CGCRC336 TEC-Seq and Targeted NGS 4.40 211.74 211.74 
CGPLLU1 TEC-Seq and Targeted NGS 5.12 223.07 223.07 
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 Table 3.3.  Genes analyzed using TEC-Seq. 
 
Gene Region Analyzed Gene Category* 
ABL1 Specific Exons Cancer Driver Gene 
AKT1 Specific Exons Cancer Driver Gene 
ALK Full Coding Region Cancer Driver Gene 
APC Specific Exons Cancer Driver Gene 
AR Full Coding Region Cancer Driver Gene 
ATM Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
BRAF Full Coding Region Cancer Driver Gene 
CDH1 Specific Exons Cancer Driver Gene 
CDK4 Full Coding Region Cancer Driver Gene 
CDK6 Full Coding Region Cancer Driver Gene 
CDKN2A Specific Exons Cancer Driver Gene 
CSF1R Specific Exons Cancer Driver Gene 
CTNNB1 Specific Exons Cancer Driver Gene 
DNMT3A Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
EGFR Full Coding Region Cancer Driver Gene 
ERBB2 Specific Exons Cancer Driver Gene 
ERBB4 Full Coding Region Cancer Driver Gene 
ESR1 Full Coding Region Cancer Driver Gene 
EZH2 Specific Exons Cancer Driver Gene 
FBXW7 Specific Exons Cancer Driver Gene 
FGFR1 Specific Exons Cancer Driver Gene 
FGFR2 Specific Exons Cancer Driver Gene 
FGFR3 Specific Exons Cancer Driver Gene 
FLT3 Specific Exons Cancer Driver Gene 
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GNA11 Specific Exons Cancer Driver Gene 
GNAQ Specific Exons Cancer Driver Gene 
GNAS Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
HNF1A Specific Exons Cancer Driver Gene 
HRAS Full Coding Region Cancer Driver Gene 
IDH1 Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
IDH2 Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
JAK2 Full Coding Region Cancer Driver and Clonal Hematopoiesis Gene 
JAK3 Specific Exons Cancer Driver Gene 
KDR Specific Exons Cancer Driver Gene 
KIT Full Coding Region Cancer Driver Gene 
KRAS Full Coding Region Cancer Driver Gene 
MAP2K1 Specific Exons Cancer Driver Gene 
MET Specific Exons Cancer Driver Gene 
MLH1 Specific Exons Cancer Driver Gene 
MPL Specific Exons Cancer Driver Gene 
MYC Specific Exons Cancer Driver Gene 
NPM1 Specific Exons Cancer Driver Gene 
NRAS Full Coding Region Cancer Driver Gene 
PDGFRA Full Coding Region Cancer Driver Gene 
PIK3CA Full Coding Region Cancer Driver Gene 
PIK3R1 Specific Exons Cancer Driver Gene 
PTEN Full Coding Region Cancer Driver Gene 
PTPN11 Specific Exons Cancer Driver Gene 
RB1 Specific Exons Cancer Driver Gene 
RET Specific Exons Cancer Driver Gene 
SMAD4 Specific Exons Cancer Driver Gene 
SMARCB1 Specific Exons Cancer Driver Gene 
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SMO Specific Exons Cancer Driver Gene 
SRC Specific Exons Cancer Driver Gene 
STK11 Full Coding Region Cancer Driver Gene 
TERT Specific Exons Cancer Driver Gene 
TP53 Full Coding Region Cancer Driver Gene 
VHL Specific Exons Cancer Driver Gene 
* Analyzed genes inlcuded those that have been commonly implicated in cancer (22).  Specific genes (DNMT3A, IDH1, and 
IDH2) or certain alterations with genes (ATM amino acid residue 3008, GNAS amino acid residue 202 and JAK2 amino acid 













    Table 3.4.  Cancer cases containing alterations in driver genes. 
Tissue Type Cases in COSMIC Detectable Cases* Detectable Fraction 
Breast 1,002 719 72% 
Colorectal 1,248 1,071 86% 
Lung 1,198 932 78% 
Ovarian 647 524 81% 











































CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 20.00% 15.32% 13.03% Detected True Positive 3322 433 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 20.00% 19.94% 12.10% Detected True Positive 7977 965 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 20.00% 15.32% 12.34% Detected True Positive 1418 175 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 20.00% 19.94% 13.50% Detected True Positive 1474 199 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 0.50% 0.77% 2.64% Detected True Positive 2651 70 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 0.50% 1.00% 2.66% Detected True Positive 8482 226 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 2.00% 1.53% 1.41% Detected True Positive 4249 60 Yes 
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CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 2.00% 1.99% 1.16% Detected True Positive 10583 123 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 0.20% 0.31% 0.79% Detected True Positive 3305 26 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 0.20% 0.40% 0.77% Detected True Positive 10351 80 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 1.00% 0.77% 0.71% Detected True Positive 4505 32 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 1.00% 1.00% 0.50% Detected True Positive 10377 52 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 0.10% 0.15% 0.38% Detected True Positive 4222 16 Yes 




















































55259515_T_G 858L>R 1.00% 0.79% 1.12% Detected True Positive 6081 68 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 5.00% 7.66% 18.11% Detected True Positive 2623 475 Yes 


















































55259515_T_G 858L>R 0.50% 0.39% 0.55% Detected True Positive 5092 28 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 2.00% 3.06% 5.80% Detected True Positive 2466 143 Yes 
















































115258747_C_A 12G>V 0.20% 0.11% 0.06% 
Not 




25380276_T_A 61Q>L 0.20% 0.15% NA 
Not 
Detected False Negative NA NA Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 1.00% 1.53% 2.96% Detected True Positive 2665 79 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 1.00% 1.99% 3.30% Detected True Positive 3149 104 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 2.00% 1.53% 1.39% Detected True Positive 4666 65 Yes 










































115258747_C_A 12G>V 0.10% 0.05% 0.06% 
Not 




115256529_T_C 61Q>R 0.10% 0.12% NA 
Not 




37880998__TGT 776G>VC 0.10% 0.09% NA 
Not 
Detected False Negative NA NA No 
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CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 0.50% 0.77% 1.34% Detected True Positive 2318 31 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 0.50% 1.00% 1.16% Detected True Positive 2929 34 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 1.00% 0.77% 1.09% Detected True Positive 4844 53 Yes 


















































55259515_T_G 858L>R 5.00% 3.95% 5.13% Detected True Positive 2455 126 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 5.00% 7.66% 20.16% Detected True Positive 2465 497 Yes 




















































55259515_T_G 858L>R 2.00% 1.58% 3.26% Detected True Positive 2238 73 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 2.00% 3.06% 5.50% Detected True Positive 2889 159 Yes 


















































55259515_T_G 858L>R 1.00% 0.79% 1.50% Detected True Positive 1665 25 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 1.00% 1.53% 2.86% Detected True Positive 2693 77 Yes 
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55259515_T_G 858L>R 1.00% 0.79% 1.51% Detected True Positive 6603 100 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 100.00% - 76.58% Detected True Positive 538 412 Yes 


















































55259515_T_G 858L>R 0.50% 0.39% 1.01% Detected True Positive 1885 19 Yes 
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CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 0.50% 0.77% 1.31% Detected True Positive 2210 29 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 0.50% 1.00% 1.34% Detected True Positive 2995 40 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 10.00% 7.66% 8.31% Detected True Positive 1228 102 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 10.00% 9.97% 7.22% Detected True Positive 1329 96 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 10.00% 7.66% 10.69% Detected True Positive 1076 115 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 10.00% 9.97% 8.30% Detected True Positive 1338 111 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 60.00% 45.95% 44.31% Detected True Positive 1607 712 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 60.00% 59.82% 47.05% Detected True Positive 4884 2298 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 25.00% 38.29% 55.61% Detected True Positive 624 347 Yes 
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CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 25.00% 49.85% 62.87% Detected True Positive 2769 1741 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 40.00% 30.63% 38.11% Detected True Positive 1257 479 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 40.00% 39.88% 40.23% Detected True Positive 4514 1816 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 20.00% 30.63% 48.98% Detected True Positive 831 407 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 20.00% 39.88% 53.94% Detected True Positive 3298 1779 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 60.00% 45.95% 29.40% Detected True Positive 2000 588 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 60.00% 59.82% 32.58% Detected True Positive 5547 1807 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 5.00% 7.66% 17.69% Detected True Positive 2481 439 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 5.00% 9.97% 17.97% Detected True Positive 7366 1324 Yes 
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CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 60.00% 45.95% 42.29% Detected True Positive 1336 565 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 60.00% 59.82% 42.94% Detected True Positive 1423 611 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 40.00% 30.63% 23.89% Detected True Positive 2704 646 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 40.00% 39.88% 20.96% Detected True Positive 5910 1239 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 2.00% 3.06% 8.58% Detected True Positive 2447 210 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 2.00% 3.99% 8.71% Detected True Positive 7809 680 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 40.00% 30.63% 30.50% Detected True Positive 1459 445 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 40.00% 39.88% 26.52% Detected True Positive 1463 388 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 20.00% 15.32% 10.11% Detected True Positive 3473 351 Yes 
117 
 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 20.00% 19.94% 9.68% Detected True Positive 8319 805 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 1.00% 1.53% 4.27% Detected True Positive 3749 160 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 1.00% 1.99% 4.67% Detected True Positive 9312 435 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 20.00% 15.32% 15.12% Detected True Positive 1435 217 Yes 


















































55259515_T_G 858L>R 100.00% NA 3.70% Detected True Positive 7032 260 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 0.50% 0.77% 2.61% Detected True Positive 3486 91 Yes 
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CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 0.50% 1.00% 2.45% Detected True Positive 9375 230 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 60.00% 45.95% 44.99% Detected True Positive 1336 601 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 60.00% 59.82% 46.00% Detected True Positive 1413 650 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 0.20% 0.31% 0.57% Detected True Positive 3306 19 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 0.20% 0.40% 0.51% Detected True Positive 9081 46 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 40.00% 30.63% 29.44% Detected True Positive 1505 443 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 40.00% 39.88% 27.94% Detected True Positive 1571 439 Yes 
CGBR4C PIK3CA chr3_178952085-178952085_A_G 1047H>R 0.10% 0.15% 0.29% Detected True Positive 5179 15 Yes 
CGBR4C TP53 chr17_7578442-7578442_T_C 163Y>C 0.10% 0.20% 0.39% Detected True Positive 12397 48 Yes 
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*Mutant pools represent a mixture of cell lines obtained from ATCC and combined in ratios to reflect the mutant allele frequency.  The cell lines include CCL-237, CRL-2158, 
CRL-2547, CRL-7585, CRL-9068, CRL-2177, CCL-231, CRL-2871, CRL-5908, CRL-5908, CCL-224, and CRL-5894.  Dilution replicates can be identified by distinct 















































CGBR4C TEC-Seq  HG19 250 100 6856574800 6812015300 99% 3214675331 47% 31980 12660 
CGBR4C TEC-Seq  HG19 25 100 6735169400 6651278500 99% 2612823217 39% 25984 2156 
CGBR4C TEC-Seq  HG19 250 100 6710441800 6611461900 99% 2594449575 39% 25764 10461 
CGBR4C TEC-Seq  HG19 250 100 7114561400 7041572000 99% 3198864566 45% 31659 10081 
CGBR4C TEC-Seq  HG19 250 100 6227890400 6169346900 99% 2823618330 46% 28033 10958 
CGBR4C TEC-Seq  HG19 250 100 7190500800 7112278700 99% 3193164477 45% 31592 9350 




Seq  HG19 250 100 7360101200 7291843600 99% 3569490069 49% 35090 10074 




Seq  HG19 250 100 7138154800 7038364300 99% 2966510847 42% 29544 11353 








Seq  HG19 250 100 7089526000 7022804100 99% 3307747509 47% 32957 10527 
CGBR4C TEC-Seq  HG19 25 100 6922188600 6872546100 99% 3158459299 46% 31326 3523 




Seq  HG19 250 100 7515707000 7445146400 99% 3467813924 47% 34525 11325 
CGBR4C TEC-Seq  HG19 25 100 6901678400 6846752700 99% 3093886686 45% 30679 2945 






Seq  HG19 25 100 7028013400 6990286200 99% 3657071276 52% 36433 2260 




Seq  HG19 25 100 7000288400 6947587900 99% 3389157517 49% 33746 2215 




Seq  HG19 25 100 6574107400 6523160400 99% 3123803265 48% 31109 1963 




Seq  HG19 250 100 6888519600 6839602800 99% 3399663697 50% 33754 10098 




Seq  HG19 25 100 6043536000 6003423400 99% 2899146002 48% 28872 1993 
CGBR4C TEC-Seq  HG19 25 100 5951876000 5886480200 99% 2490875896 42% 24765 3181 
CGBR4C TEC-Seq  HG19 25 100 7032340600 6986282200 99% 3133755150 45% 31111 1819 
CGBR4C TEC-Seq  HG19 25 100 6718561600 6677846600 99% 3035627349 45% 30107 1627 
CGBR4C TEC-Seq  HG19 250 100 8402040800 8362876000 100% 3890439877 47% 38555 13466 
CGBR4C TEC-Seq  HG19 250 100 8312266800 8273298600 100% 3850085281 47% 38164 16139 
CGBR4C TEC-Seq  HG19 250 100 7623931600 7578468100 99% 3435971145 45% 34092 14205 
CGBR4C TEC-Seq  HG19 250 100 7914309600 7875670900 100% 3653166119 46% 36204 15328 
CGBR4C TEC-Seq  HG19 250 100 7498391600 7435573600 99% 3582296548 48% 35502 11256 
CGBR4C TEC-Seq  HG19 250 100 8089340600 8036693300 99% 3787340645 47% 37548 14257 
CGBR4C TEC-Seq  HG19 25 100 7129435800 7093160200 99% 3231584828 46% 32109 3268 
CGBR4C TEC-Seq  HG19 250 100 7556623000 7479077700 99% 3431817875 46% 33986 10652 
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CGBR4C TEC-Seq  HG19 250 100 6409081000 6366777900 99% 3022620692 47% 29975 11921 
CGBR4C TEC-Seq  HG19 25 100 6717712400 6677656200 99% 3030471882 45% 30118 2678 
CGBR4C TEC-Seq  HG19 250 100 7395864800 7306951100 99% 3308676352 45% 32774 10615 
CGBR4C TEC-Seq  HG19 250 100 7175702200 7126131000 99% 3358722525 47% 33287 11117 




Seq  HG19 250 100 6334363200 6295098000 99% 3362894228 53% 33478 9227 
CGBR4C TEC-Seq  HG19 250 100 6964052000 6884217700 99% 2922966719 42% 28980 9915 
CGBR4C TEC-Seq  HG19 25 100 6391984800 6363907800 100% 2949774853 46% 29325 3179 
CGBR4C TEC-Seq  HG19 250 100 6476025200 6400463500 99% 2706820015 42% 26826 9558 
CGBR4C TEC-Seq  HG19 25 100 6864653400 6824745400 99% 3115598042 46% 30962 2950 
CGBR4C TEC-Seq  HG19 250 100 8167591600 8103370000 99% 3853829182 48% 38208 11502 
*Mutant pools represent a mixture of cell lines obtained from ATCC and combined in ratios to reflect the mutant allele frequency.  The cell lines include CCL-237, CRL-
2158, CRL-2547, CRL-7585, CRL-9068, CRL-2177, CCL-231, CRL-2871, CRL-5908, CRL-5908, CCL-224, and CRL-5894.  Dilution replicates can be identified by 









Table 3.7.  Summary of genomic analyses. 




























CGPLBR100 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7299964400 3750278051 51% 44794 3249 NA 




NGS 150 639291 587752350 303296797 52% 466 316 100% 




NGS 150 639291 989328900 456255327 46% 702 259 100% 
CGPLBR101 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7420822800 3810365416 51% 45565 9784 NA 
CGPLBR102 Breast Cancer cfDNA 
TEC-
Seq 100 80930 6679304900 3269688319 49% 38679 7613 NA 
CGPLBR103 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7040304400 3495542468 50% 41786 6748 NA 
CGPLBR104 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7188389200 3716096781 52% 44316 9448 NA 
CGPLBR38 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7810293900 4057576306 52% 48098 9868 NA 




NGS 150 639291 607162800 295989325 49% 453 312 100% 




NGS 150 639291 1300314150 653992005 50% 998 529 100% 
CGPLBR39 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7745701500 3805623239 49% 45084 11065 NA 




NGS 150 639291 536928000 258238473 48% 395 284 100% 




NGS 150 639291 1462893000 727470248 50% 1104 560 100% 
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CGPLBR40 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7558990500 3652442341 48% 43333 12948 NA 




NGS 150 639291 504208500 270658416 54% 410 298 100% 




NGS 150 639291 1265950500 761635668 60% 1154 457 100% 
CGPLBR41 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7900994600 3836600101 49% 45535 10847 NA 
CGPLBR42 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7756986400 3456255655 45% 40980 7211 NA 
CGPLBR43 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7561881700 3880346064 51% 46098 8588 NA 
CGPLBR44 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7017744200 3269110569 47% 38672 8344 NA 




NGS 150 639291 574791000 316417055 55% 484 331 100% 




NGS 150 639291 759286350 357135705 47% 542 112 100% 
CGPLBR48 Breast Cancer cfDNA 
TEC-
Seq 100 80930 5629044200 2611554623 46% 30860 8652 NA 




NGS 150 639291 635913150 357101607 56% 547 387 100% 




NGS 150 639291 1096215750 558883146 51% 857 289 100% 
CGPLBR49 Breast Cancer cfDNA 
TEC-
Seq 100 80930 5784711600 2673457893 46% 31274 10429 NA 




NGS 150 639291 594631950 337522575 57% 512 347 100% 




NGS 150 639291 1273922850 773715963 61% 1174 396 100% 
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CGPLBR53 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7223682000 3635203812 50% 43212 4722 NA 




NGS 150 639291 588261000 341304903 58% 518 348 100% 




NGS 150 639291 1543663050 928939469 60% 1408 651 100% 
CGPLBR55 Breast Cancer cfDNA 
TEC-
Seq 100 80930 8309154900 4306956261 52% 51143 8328 NA 




NGS 150 639291 428455950 119796448 28% 180 117 100% 




NGS 150 639291 1281568800 786549957 61% 1179 544 100% 
CGPLBR57 Breast Cancer cfDNA 
TEC-
Seq 100 80930 8636181000 4391502618 51% 52108 5857 NA 




NGS 150 639291 549441900 314057412 57% 481 330 100% 




NGS 150 639291 1014956550 514492105 51% 787 218 100% 
CGPLBR59 Breast Cancer cfDNA 
TEC-
Seq 100 80930 8799457700 4152328555 47% 49281 5855 NA 




NGS 150 639291 677024100 354381703 52% 537 346 100% 




NGS 150 639291 1502988750 722936771 48% 1075 206 100% 
CGPLBR61 Breast Cancer cfDNA 
TEC-
Seq 100 80930 8163706700 3952010628 48% 46755 8522 NA 
CGPLBR63 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7020533100 3542447304 50% 41956 4773 NA 




NGS 150 639291 504208500 270658416 54% 410 298 100% 
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NGS 150 639291 1265950500 761635668 60% 1154 457 100% 
CGPLBR64 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7300630900 3292529227 45% 38909 5202 NA 




NGS 150 639291 413363850 193561159 47% 291 186 100% 




NGS 150 639291 1511564550 760271556 50% 1137 119 100% 
CGPLBR66 Breast Cancer cfDNA 
TEC-
Seq 100 80930 6963339500 3554735108 51% 42011 6399 NA 




NGS 150 639291 603047250 339194896 56% 513 366 100% 




NGS 150 639291 1263813900 736742733 58% 1119 626 100% 
CGPLBR67 Breast Cancer cfDNA 
TEC-
Seq 100 80930 8264353900 3686093696 45% 43516 7752 NA 




NGS 150 639291 699562950 409741164 59% 623 410 100% 




NGS 150 639291 1218949500 732812428 60% 1112 326 100% 
CGPLBR68 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7629312300 4078969547 53% 48389 7402 NA 




NGS 150 639291 672,427,650 353,985,085 53% 539 332 100% 




NGS 150 639291 1,320,628,050 797,283,712 60% 1215 649 100% 
CGPLBR69 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7571501500 3857354512 51% 45322 7047 NA 




NGS 150 639291 591797550 327570487 55% 500 349 100% 
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NGS 150 639291 1254192750 670305026 53% 1016 331 100% 
CGPLBR70 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7251760700 3641333708 50% 43203 8884 NA 




NGS 150 639291 552791700 315920897 57% 483 335 100% 




NGS 150 639291 985165050 518833636 53% 789 284 100% 
CGPLBR71 Breast Cancer cfDNA 
TEC-
Seq 100 80930 8515402600 4496696391 53% 53340 6805 NA 




NGS 150 639291 675318450 386958218 57% 591 389 100% 




NGS 150 639291 1408808850 841106831 60% 1273 525 100% 
CGPLBR72 Breast Cancer cfDNA 
TEC-
Seq 100 80930 8556946900 4389761697 51% 52081 5632 NA 




NGS 150 639291 381478350 195981864 51% 295 181 100% 




NGS 150 639291 1980049200 1206509350 61% 1829 494 100% 
CGPLBR73 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7959392300 4006933338 50% 47555 8791 NA 




NGS 150 639291 1061212350 537918502 51% 824 229 100% 




NGS 150 639291 511075500 289986972 57% 446 316 100% 
CGPLBR74 Breast Cancer cfDNA 
TEC-
Seq 100 80930 8524536400 4063900599 48% 48252 7013 NA 




NGS 150 639291 696478500 204182619 29% 311 218 100% 
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NGS 150 639291 1444542150 831504089 58% 1266 520 100% 
CGPLBR75 Breast Cancer cfDNA 
TEC-
Seq 100 80930 8260379100 3960599885 48% 46955 6319 NA 




NGS 150 639291 658358550 242257252 37% 370 244 100% 




NGS 150 639291 1209742200 615931952 51% 926 418 100% 
CGPLBR76 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7774235200 3893622420 50% 46192 9628 NA 




NGS 150 639291 409580550 161155508 39% 236 148 100% 




NGS 150 639291 1404856200 808020500 58% 1222 300 100% 
CGPLBR77 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7572797600 3255963429 43% 38568 8263 NA 




NGS 150 639291 537431700 305330922 57% 470 332 100% 




NGS 150 639291 1297056000 507301668 39% 770 356 100% 
CGPLBR80 Breast Cancer cfDNA 
TEC-
Seq 100 80930 6845325800 3147476693 46% 37201 5595 NA 




NGS 150 639291 610652400 273064709 45% 413 269 100% 




NGS 150 639291 1744826850 861765758 49% 1264 384 100% 
CGPLBR82 Breast Cancer cfDNA 
TEC-
Seq 100 80930 8236705200 4170465005 51% 49361 12319 NA 




NGS 150 639291 721861350 404540286 56% 616 393 100% 
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NGS 150 639291 1162764150 528197785 45% 795 347 100% 
CGPLBR83 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7434568100 3676855019 49% 43628 5458 NA 




NGS 150 639291 NA NA NA NA NA NA 




NGS 150 639291 NA NA NA NA NA NA 
CGPLBR86 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7616282500 3644791327 48% 43490 7048 NA 




NGS 150 639291 365127450 175449534 48% 256 165 100% 




NGS 150 639291 1374528450 752315631 55% 1136 226 100% 
CGPLBR87 Breast Cancer cfDNA 
TEC-
Seq 100 80930 6194021300 3004882010 49% 35765 5306 NA 




NGS 150 639291 625919850 324734673 52% 493 305 100% 




NGS 150 639291 918553500 175004335 19% 265 157 100% 
CGPLBR88 Breast Cancer cfDNA 
TEC-
Seq 100 80930 6071567200 2847926237 47% 33945 10319 NA 




NGS 150 639291 474856950 101788416 21% 156 108 100% 




NGS 150 639291 1068209550 551606147 52% 846 394 100% 
CGPLBR91 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7192457700 3480203404 48% 41570 9912 NA 




NGS 150 639291 649309800 260265354 40% 397 292 100% 
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NGS 150 639291 1115092650 563337213 51% 865 391 100% 
CGPLBR92 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7678981800 3600279233 47% 42975 13580 NA 




NGS 150 639291 614417400 332144854 54% 505 301 100% 




NGS 150 639291 1231916700 741434698 60% 1136 478 100% 
CGPLBR93 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7605717800 3998713397 53% 47866 10329 NA 
CGPLBR96 Breast Cancer cfDNA 
TEC-
Seq 100 80930 6297446700 2463064737 39% 29341 7937 NA 




NGS 150 639291 601662300 226863962 38% 347 245 100% 




NGS 150 639291 1018240950 545472202 54% 834 227 100% 
CGPLBR97 Breast Cancer cfDNA 
TEC-
Seq 100 80930 7114921600 3557069027 50% 42488 10712 NA 




NGS 150 639291 635832150 330334979 52% 505 339 100% 




NGS 150 639291 1081210050 602942749 56% 916 373 100% 
CGPLBR99 Breast Cancer cfDNA 
TEC-
Seq 100 80930 6946513800 3223603304 46% 38391 5412 NA 




NGS 150 639291 1114707300 583697712 52% 892 438 100% 




NGS 150 639291 601828650 322598549 54% 496 312 100% 
CGCRC291 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7501485600 3771359756 50% 44345 10359 NA 
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NGS 150 639291 1074846000 479885292 45% 733 485 100% 




NGS 150 639291 1012582500 454866080 45% 696 448 100% 
CGCRC292 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 6736035200 3098886973 46% 36448 8603 NA 




NGS 150 639291 997109550 448775788 45% 685 452 100% 




NGS 150 639291 1058966700 467350094 44% 711 456 100% 
CGCRC293 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 6300244000 2818734206 45% 33117 5953 NA 




NGS 150 639291 956307150 428412364 45% 653 427 100% 




NGS 150 639291 962764950 424030808 44% 647 422 100% 
CGCRC294 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7786872600 3911796709 50% 46016 12071 NA 




NGS 150 639291 941706900 399120498 42% 609 410 100% 




NGS 150 639291 1028456550 439156889 43% 669 450 100% 
CGCRC295 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 8240660200 3478059753 42% 40787 5826 NA 




NGS 150 639291 1045862700 456802680 44% 697 469 100% 




NGS 150 639291 928288500 421984627 45% 644 423 100% 
CGCRC296 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 5718556500 2898549356 51% 33912 10180 NA 
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NGS 150 639291 726412050 329483654 45% 503 338 100% 




NGS 150 639291 796948200 343513710 43% 524 344 100% 
CGCRC297 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7550826100 3717222432 49% 43545 5870 NA 




NGS 150 639291 686847900 305825281 45% 467 313 100% 




NGS 150 639291 816835050 294168635 36% 448 299 100% 
CGCRC298 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 12501036400 6096393764 49% 71196 9617 NA 




NGS 150 639291 915267600 391756000 43% 601 401 100% 




NGS 150 639291 864069900 404835020 47% 621 396 100% 
CGCRC299 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7812602900 4121569690 53% 48098 10338 NA 




NGS 150 639291 962294850 410383252 43% 622 414 100% 




NGS 150 639291 1020461700 424930722 42% 643 439 100% 
CGCRC300 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 8648090300 3962285136 46% 46364 5756 NA 




NGS 150 639291 1088902200 464279410 43% 711 464 100% 




NGS 150 639291 831117750 368422619 44% 564 376 100% 
CGCRC301 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7538758100 3695480348 49% 43024 6618 NA 
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NGS 150 639291 915540150 400988996 44% 615 414 100% 




NGS 150 639291 973842300 423804347 44% 650 404 100% 
CGCRC302 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 8573658300 4349420574 51% 51006 13799 NA 




NGS 150 639291 811854000 351266173 43% 538 359 100% 




NGS 150 639291 1115477250 483033596 43% 739 466 100% 
CGCRC303 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 5224046400 2505714343 48% 29365 8372 NA 




NGS 150 639291 1060418400 442109304 42% 676 446 100% 




NGS 150 639291 1176646650 493560885 42% 756 490 100% 
CGCRC304 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 5762112600 2942170530 51% 34462 10208 NA 




NGS 150 639291 1007139450 431389782 43% 660 433 100% 




NGS 150 639291 1057360350 445316426 42% 681 441 100% 
CGCRC305 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7213384100 3726953480 52% 43516 8589 NA 




NGS 150 639291 1246122600 632083848 51% 957 623 100% 




NGS 150 639291 986335800 418119169 42% 634 406 100% 
CGCRC306 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7075579700 3552441899 50% 41507 7372 NA 
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NGS 150 639291 1018205250 425416271 42% 651 415 100% 




NGS 150 639291 895480950 384530177 43% 589 373 100% 
CGCRC307 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7572687100 3492191519 46% 40793 9680 NA 




NGS 150 639291 913508250 387133404 42% 591 396 100% 




NGS 150 639291 939545250 417034584 44% 637 419 100% 
CGCRC308 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7945738000 3895908986 49% 45224 11809 NA 




NGS 150 639291 938120700 425166128 45% 651 419 100% 




NGS 150 639291 1074720000 457076684 43% 699 481 100% 
CGCRC309 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 8487455800 3921079811 46% 45736 10739 NA 




NGS 150 639291 1025337600 447153051 44% 679 443 100% 




NGS 150 639291 1077028800 468056542 43% 712 456 100% 
CGCRC310 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 9003580500 4678812441 52% 54713 11139 NA 




NGS 150 639291 980782650 427168989 44% 648 419 100% 




NGS 150 639291 1456285350 624050285 43% 953 602 100% 
CGCRC311 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 6528162700 3276653864 50% 38324 6044 NA 
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NGS 150 639291 846414300 367848055 43% 563 373 100% 




NGS 150 639291 1046356050 469927791 45% 719 461 100% 
CGCRC312 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7683294300 3316719187 43% 38652 4622 NA 




NGS 150 639291 1045262100 465476158 45% 712 454 100% 




NGS 150 639291 1045012950 452684790 43% 693 448 100% 
CGCRC313 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 5874099200 2896148722 49% 33821 6506 NA 




NGS 150 639291 1411402200 622602217 44% 934 597 100% 




NGS 150 639291 1357397850 594057235 44% 894 571 100% 
CGCRC314 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 6883148500 3382767492 49% 39414 6664 NA 




NGS 150 639291 948293550 408431471 43% 625 409 100% 




NGS 150 639291 1059318450 470533351 44% 720 451 100% 
CGCRC315 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7497252500 3775556051 50% 44034 8666 NA 




NGS 150 639291 944269800 470119319 50% 714 469 100% 




NGS 150 639291 1329922500 668919352 50% 1022 633 100% 
CGCRC316 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 10684720400 5533857153 52% 64693 14289 NA 
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NGS 150 639291 1102555350 549138041 50% 837 551 100% 




NGS 150 639291 1008207750 469494561 47% 715 473 100% 
CGCRC317 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7086877600 3669434216 52% 43538 10944 NA 




NGS 150 639291 1099990350 547860243 50% 835 542 100% 




NGS 150 639291 1107316350 560348663 51% 855 552 100% 
CGCRC318 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 6880041100 3326357413 48% 39077 11571 NA 




NGS 150 639291 990188550 489300022 49% 746 483 100% 




NGS 150 639291 1434731100 691861596 48% 1050 669 100% 
CGCRC319 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7485342900 3982677483 53% 47327 10502 NA 




NGS 150 639291 1098523800 536937209 49% 816 533 100% 




NGS 150 639291 1258206600 610731063 49% 930 624 100% 
CGCRC320 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7058703200 3450648135 49% 40888 10198 NA 




NGS 150 639291 881784300 449537819 51% 680 431 100% 




NGS 150 639291 1067872350 538856991 50% 815 514 100% 
CGCRC321 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7203625900 3633396892 50% 43065 6499 NA 
138 
 




NGS 150 639291 1068635550 502245626 47% 768 486 100% 




NGS 150 639291 1114618650 514924981 46% 785 499 100% 
CGCRC332 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7202969100 3758323705 52% 44580 3243 NA 




NGS 150 639291 758356050 406546836 54% 621 354 100% 




NGS 150 639291 1274461350 744251805 58% 1135 508 100% 
CGCRC333 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 8767144700 4199126827 48% 49781 8336 NA 




NGS 150 639291 560436600 241285888 43% 368 225 100% 




NGS 150 639291 1407707550 796386336 57% 1212 501 100% 
CGCRC334 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7771869100 3944578280 51% 46518 5014 NA 




NGS 150 639291 562592100 287288732 51% 439 304 100% 




NGS 150 639291 1236847050 701921622 57% 1070 507 100% 
CGCRC335 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7972524600 4064901201 51% 48308 6151 NA 




NGS 150 639291 733030800 391132272 53% 596 355 100% 




NGS 150 639291 1123386600 441750380 39% 675 340 100% 
CGCRC336 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 8597346400 4333410573 50% 51390 7551 NA 
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NGS 150 639291 450245550 228507680 51% 351 246 100% 




NGS 150 639291 1112596650 647572679 58% 995 495 100% 
CGCRC337 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7399611700 3800666199 51% 45083 8092 NA 




NGS 150 639291 457483050 216543896 47% 330 228 100% 




NGS 150 639291 1206110850 665588725 55% 997 574 100% 
CGCRC338 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 8029493700 4179383804 52% 49380 5831 NA 




NGS 150 639291 654071250 285478494 44% 434 257 100% 




NGS 150 639291 1156258950 519228652 45% 780 361 100% 
CGCRC339 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7938963600 4095555110 52% 48397 3808 NA 




NGS 150 639291 NA NA NA NA NA NA 




NGS 150 639291 NA NA NA NA NA NA 
CGCRC340 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 7214889500 3706643098 51% 43805 3014 NA 




NGS 150 639291 579149550 234017537 40% 356 234 100% 




NGS 150 639291 1056358800 500654866 47% 761 363 100% 
CGCRC341 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 8803159200 3668208527 42% 43106 11957 NA 
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CGCRC342 Colorectal Cancer cfDNA 
TEC-
Seq 100 80930 8478811500 3425540889 40% 40328 9592 NA 
CGPLH35 Healthy cfDNA TEC-Seq 100 80930 6919126300 2312758764 33% 25570 1989 NA 
CGPLH36 Healthy cfDNA TEC-Seq 100 80930 6089923400 2038548115 33% 22719 1478 NA 
CGPLH37 Healthy cfDNA TEC-Seq 100 80930 5557270200 1935301929 35% 21673 2312 NA 
CGPLH38 Healthy cfDNA TEC-Seq 100 80930 5771193800 1963294894 34% 21816 784 NA 
CGPLH39 Healthy cfDNA TEC-Seq 100 80930 6002281900 2209984880 37% 24784 563 NA 
CGPLH40 Healthy cfDNA TEC-Seq 100 80930 6773660700 2713539772 40% 30611 409 NA 
CGPLH41 Healthy cfDNA TEC-Seq 100 80930 5660677000 1997748737 35% 23006 583 NA 
CGPLH42 Healthy cfDNA TEC-Seq 100 80930 5792045400 2388036949 41% 27197 2523 NA 
CGPLH43 Healthy cfDNA TEC-Seq 100 80930 5568321700 2017813329 36% 23228 1650 NA 
CGPLH44 Healthy cfDNA TEC-Seq 100 80930 6636969300 2424276812 37% 27040 1023 NA 
CGPLH45 Healthy cfDNA TEC-Seq 100 80930 8485593200 2770176078 33% 32829 3114 NA 
CGPLH46 Healthy cfDNA TEC-Seq 100 80930 5083171100 1899395790 37% 21821 1678 NA 
CGPLH47 Healthy cfDNA TEC-Seq 100 80930 6016388500 2062392156 34% 23459 1431 NA 
CGPLH48 Healthy cfDNA TEC-Seq 100 80930 4958945900 1809825992 36% 20702 1698 NA 
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CGPLH49 Healthy cfDNA TEC-Seq 100 80930 7953812200 2511365904 32% 27006 1440 NA 
CGPLH50 Healthy cfDNA TEC-Seq 100 80930 6989407600 2561288100 37% 29177 2591 NA 
CGPLH51 Healthy cfDNA TEC-Seq 100 80930 7862073200 2525091396 32% 29999 1293 NA 
CGPLH52 Healthy cfDNA TEC-Seq 100 80930 6939636800 2397922699 35% 27029 2501 NA 
CGPLH53 Healthy cfDNA TEC-Seq 100 80930 7563547300 2316943911 31% 24210 1109 NA 
CGPLH54 Healthy cfDNA TEC-Seq 100 80930 10611934700 2290823134 22% 27175 3306 NA 
CGPLH55 Healthy cfDNA TEC-Seq 100 80930 9912569200 2521962244 25% 27082 3161 NA 
CGPLH56 Healthy cfDNA TEC-Seq 100 80930 5777591900 2023874863 35% 22916 1301 NA 
CGPLH57 Healthy cfDNA TEC-Seq 100 80930 9234904800 1493926244 16% 15843 1655 NA 
CGPLH58 Healthy cfDNA TEC-Seq 100 80930 7571923100 2169535037 29% 22576 1174 NA 
CGPLH59 Healthy cfDNA TEC-Seq 100 80930 9726052100 2987875484 31% 35427 2143 NA 
CGPLH60 Healthy cfDNA TEC-Seq 100 80930 6812180400 2141533749 31% 23217 493 NA 
CGPLH61 Healthy cfDNA TEC-Seq 100 80930 7701716900 2225623104 29% 23858 724 NA 
CGPLH62 Healthy cfDNA TEC-Seq 100 80930 7565636200 2042450491 27% 22021 453 NA 
CGPLH63 Healthy cfDNA TEC-Seq 100 80930 8696405000 2521574759 29% 26689 1851 NA 
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CGPLH64 Healthy cfDNA TEC-Seq 100 80930 5438852600 996198502 18% 11477 1443 NA 
CGPLH75 Healthy cfDNA TEC-Seq 100 80930 3446444000 1505718480 44% 17805 3016 NA 
CGPLH76 Healthy cfDNA TEC-Seq 100 80930 7499116400 3685762725 49% 43682 4643 NA 
CGPLH77 Healthy cfDNA TEC-Seq 100 80930 6512408400 2537359345 39% 30280 3131 NA 
CGPLH78 Healthy cfDNA TEC-Seq 100 80930 7642949300 3946069680 52% 46316 5358 NA 
CGPLH79 Healthy cfDNA TEC-Seq 100 80930 7785475700 3910639227 50% 45280 6714 NA 
CGPLH80 Healthy cfDNA TEC-Seq 100 80930 7918361500 3558236955 45% 42171 5062 NA 
CGPLH81 Healthy cfDNA TEC-Seq 100 80930 6646268900 3112369850 47% 37119 3678 NA 
CGPLH82 Healthy cfDNA TEC-Seq 100 80930 7744065000 3941700596 51% 46820 5723 NA 
CGPLH83 Healthy cfDNA TEC-Seq 100 80930 6957686000 1447603106 21% 17280 2875 NA 
CGPLH84 Healthy cfDNA TEC-Seq 100 80930 8326493200 3969908122 48% 47464 3647 NA 
CGPLH85 Healthy cfDNA TEC-Seq 100 80930 8713042600 4461252536 51% 53246 3721 NA 
CGPLH86 Healthy cfDNA TEC-Seq 100 80930 8664194700 4470145091 52% 53398 5094 NA 
CGPLH90 Healthy cfDNA TEC-Seq 100 80930 7516078800 3841504088 51% 45907 4414 NA 
CGPLH91 Healthy cfDNA TEC-Seq 100 80930 7356314100 3796192344 52% 45369 3333 NA 
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CGPLLU1 Lung Cancer cfDNA 
TEC-
Seq 100 80930 6239458800 2329606202 37% 26443 5581 NA 




NGS 150 639291 677237100 268756748 40% 408 289 100% 




NGS 150 639291 1689013800 769286196 46% 1152 721 100% 
CGPLLU115 Lung Cancer cfDNA 
TEC-
Seq 100 80930 10979564000 3536107395 32% 38888 5934 NA 




NGS 150 639291 673939500 254019687 38% 386 263 100% 




NGS 150 639291 1249447950 555225070 44% 842 534 100% 
CGPLLU116 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8427732900 2666386481 32% 31382 7168 NA 




NGS 150 639291 536485350 194819603 36% 296 210 100% 




NGS 150 639291 1226021550 543715026 44% 826 520 100% 
CGPLLU117 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7722272300 2377605802 31% 27869 2500 NA 




NGS 150 639291 568698450 214221003 38% 327 227 100% 




NGS 150 639291 1346899650 607087256 45% 924 448 100% 
CGPLLU118 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8821329900 3017869157 34% 35234 2876 NA 




NGS 150 639291 824984250 340283945 41% 515 353 100% 




NGS 150 639291 1541356200 667852108 43% 1007 667 100% 
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CGPLLU119 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8224786400 2826168731 34% 32615 6973 NA 




NGS 150 639291 622004250 238879678 38% 362 254 100% 




NGS 150 639291 1248973650 509082004 41% 770 513 100% 
CGPLLU135 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7479506200 2465400664 33% 29106 4986 NA 




NGS 150 639291 689515950 271757497 39% 411 288 100% 




NGS 150 639291 1340064900 618218568 46% 939 554 100% 
CGPLLU136 Lung Cancer cfDNA 
TEC-
Seq 100 80930 9255976600 3044006428 33% 35637 5742 NA 




NGS 150 639291 570675300 226580792 40% 344 239 100% 




NGS 150 639291 802359600 428240472 53% 650 165 100% 
CGPLLU137 Lung Cancer cfDNA 
TEC-
Seq 100 80930 9182200700 2707533740 29% 32066 5436 NA 




NGS 150 639291 677915850 256959903 38% 390 275 100% 




NGS 150 639291 1363517850 612337794 45% 933 594 100% 
CGPLLU138 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8658694500 2845274314 33% 33349 1669 NA 




NGS 150 639291 764916750 375266555 49% 571 390 100% 




NGS 150 639291 1504663500 842387976 56% 1277 720 100% 
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CGPLLU139 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8269549200 2779580391 34% 32503 5050 NA 




NGS 150 639291 680111250 353773681 52% 532 197 100% 




NGS 150 639291 1390145700 801181359 58% 1207 650 100% 






Seq 100 80930 7398028800 1699011387 23% 20075 778 NA 






Seq 100 80930 5656145300 2098827088 37% 23699 995 NA 
CGPLLU144 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8716827400 4216576624 48% 49370 10771 NA 




NGS 150 639291 695037000 361563821 52% 550 366 100% 




NGS 150 639291 1200620250 549449256 46% 830 401 100% 
CGPLLU145 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8925580700 4416873069 49% 51680 6262 NA 
CGPLLU146 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8506844200 4195033049 49% 49084 6968 NA 




NGS 150 639291 608225100 316448889 52% 483 274 100% 




NGS 150 639291 1116711600 390267100 35% 592 383 100% 
CGPLLU147 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7416300600 3530746046 48% 41302 4691 NA 




NGS 150 639291 1174428600 536650801 46% 808 517 100% 
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NGS 150 639291 808104900 399673367 49% 608 388 100% 
CGPLLU161 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7789148700 3280139772 42% 38568 12229 NA 
CGPLLU162 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7625462000 3470147667 46% 40918 10099 NA 




NGS 150 639291 429861300 151297004 35% 226 188 100% 




NGS 150 639291 1334133150 732531538 55% 1111 619 100% 
CGPLLU163 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8019293200 3946533983 49% 46471 12108 NA 




NGS 150 639291 524,208,300 200,482,808 38% 301 236 100% 




NGS 150 639291 1,352,545,050 696,512,666 51% 1020 583 100% 
CGPLLU164 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8110030900 3592748235 44% 42161 6947 NA 




NGS 150 639291 509906100 220862753 43% 322 241 100% 




NGS 150 639291 1305960150 678924309 52% 1003 598 100% 
CGPLLU165 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8389514600 4147501817 49% 48770 8996 NA 




NGS 150 639291 535155150 224433873 42% 328 150 100% 




NGS 150 639291 1063652400 607101865 57% 912 211 100% 
CGPLLU166 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8040278000 3908624400 49% 45999 11030 NA 
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NGS 150 639291 NA NA NA NA NA NA 




NGS 150 639291 NA NA NA NA NA NA 
CGPLLU168 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7690630000 3868237773 50% 45625 9711 NA 




NGS 150 639291 510783000 285892642 56% 438 164 100% 




NGS 150 639291 1285271400 685373694 53% 1037 661 100% 
CGPLLU169 Lung Cancer cfDNA 
TEC-
Seq 100 80930 9378353000 4800407624 51% 56547 10261 NA 




NGS 150 639291 591105000 300994824 51% 457 326 100% 




NGS 150 639291 1285960650 685383054 53% 1041 666 100% 
CGPLLU170 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7276494400 3543816325 49% 41280 8803 NA 
CGPLLU173 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7592835800 2879843635 38% 34033 6924 NA 
CGPLLU174 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7481844600 3067532518 41% 36321 6137 NA 




NGS 150 639291 2072668200 1190204964 57% 1786 303 100% 




NGS 150 639291 645803700 355337091 55% 535 350 100% 
CGPLLU175 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8532324200 4002541569 47% 47084 7862 NA 




NGS 150 639291 618550950 339691335 55% 517 358 100% 
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NGS 150 639291 1449611550 855214102 59% 1308 391 100% 
CGPLLU176 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8143905000 4054098929 50% 47708 5588 NA 




NGS 150 639291 610189200 337041659 55% 516 332 100% 




NGS 150 639291 1095470850 567775337 52% 871 434 100% 
CGPLLU177 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8421611300 4197108809 50% 49476 8780 NA 




NGS 150 639291 659891250 372266268 56% 566 373 100% 




NGS 150 639291 1472590050 834893525 57% 1267 715 100% 
CGPLLU178 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8483124700 4169577489 49% 48580 6445 NA 




NGS 150 639291 694574700 380911029 55% 577 380 100% 




NGS 150 639291 1148297400 667857382 58% 1030 547 100% 
CGPLLU179 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7774358700 3304915738 43% 38768 6862 NA 




NGS 150 639291 1535136750 925596393 60% 1405 341 100% 




NGS 150 639291 664354500 339072044 51% 515 330 100% 
CGPLLU180 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8192813800 3937552475 48% 46498 6568 NA 




NGS 150 639291 1498872600 781889116 52% 1190 639 100% 
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NGS 150 639291 1086715200 600798880 55% 916 193 100% 
CGPLLU19 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7263539200 2547333392 35% 28493 3441 NA 




NGS 150 639291 591053700 223344073 38% 341 172 100% 




NGS 150 639291 1214483550 519092020 43% 787 315 100% 
CGPLLU197 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7996779200 3082397881 39% 36381 5388 NA 




NGS 150 639291 491469750 173278101 35% 266 132 100% 




NGS 150 639291 768799800 406238720 53% 619 111 100% 
CGPLLU198 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7175247200 3545719100 49% 42008 6817 NA 




NGS 150 639291 571152750 243139384 43% 369 259 100% 




NGS 150 639291 NA NA NA NA NA NA 
CGPLLU2 Lung Cancer cfDNA 
TEC-
Seq 100 80930 9495304600 3389293546 36% 40802 4853 NA 




NGS 150 639291 499588050 197204704 39% 300 221 100% 




NGS 150 639291 1632543150 749366432 46% 1128 609 100% 
CGPLLU20 Lung Cancer cfDNA 
TEC-
Seq 100 80930 12481073200 994477545 8% 10329 4129 NA 




NGS 150 639291 574141350 228443607 40% 347 248 100% 
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NGS 150 639291 1150028400 506414454 44% 758 475 100% 
CGPLLU202 Lung Cancer cfDNA 
TEC-
Seq 100 80930 6840112800 3427820669 50% 40670 7951 NA 




NGS 150 639291 645258450 207925335 32% 316 209 100% 




NGS 150 639291 1293518100 670182891 52% 1023 504 100% 
CGPLLU203 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7468749900 3762726574 50% 44500 9917 NA 




NGS 150 639291 557531850 297213725 53% 453 303 100% 




NGS 150 639291 1198142100 596099136 50% 910 563 100% 
CGPLLU204 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7445026400 3703545153 50% 44317 6856 NA 




NGS 150 639291 1178585700 582456480 49% 883 341 100% 




NGS 150 639291 661557450 348927002 53% 525 351 100% 
CGPLLU205 Lung Cancer cfDNA 
TEC-
Seq 100 80930 9205429100 4350573991 47% 51627 9810 NA 




NGS 150 639291 704826750 297031777 42% 453 294 100% 




NGS 150 639291 1259501400 676224830 54% 1028 545 100% 
CGPLLU206 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7397914600 3635210205 49% 43016 7124 NA 




NGS 150 639291 587897550 260243234 44% 396 265 100% 
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NGS 150 639291 936519600 84546885 9% 129 78 100% 
CGPLLU207 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7133043900 3736258011 52% 44291 8499 NA 




NGS 150 639291 635760000 252119850 40% 384 263 100% 




NGS 150 639291 1122284550 498538490 44% 759 438 100% 
CGPLLU208 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7346976400 3855814032 52% 45782 8940 NA 




NGS 150 639291 549011700 306386280 56% 472 327 100% 




NGS 150 639291 1061510250 574889056 54% 882 370 100% 
CGPLLU209 Lung Cancer cfDNA 
TEC-
Seq 100 80930 6723337800 3362944595 50% 39531 11946 NA 




NGS 150 639291 578241150 293725997 51% 450 302 100% 




NGS 150 639291 1041774600 505999221 49% 770 406 100% 
CGPLLU21 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7869841100 1317965426 17% 14215 3501 NA 




NGS 150 639291 589913250 196975420 33% 301 223 100% 




NGS 150 639291 1301333700 584929403 45% 894 523 100% 
CGPLLU214 Lung Cancer cfDNA 
TEC-
Seq 100 80930 6691661600 3406240415 51% 40249 4462 NA 
CGPLLU22 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7574547100 2108841152 28% 21572 6544 NA 
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NGS 150 639291 745022400 191686179 26% 291 211 100% 




NGS 150 639291 1223740200 573490645 47% 870 427 100% 
CGPLLU23 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7019961300 2276529333 32% 24728 3670 NA 




NGS 150 639291 621765750 243401140 39% 373 224 100% 




NGS 150 639291 1154575200 558861771 48% 855 333 100% 
CGPLLU26 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8423085100 2399668113 28% 25687 861 NA 




NGS 150 639291 826125900 249126153 30% 361 268 100% 




NGS 150 639291 NA NA NA NA NA NA 
CGPLLU28 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8381515900 2342788295 28% 24533 7424 NA 




NGS 150 639291 642068100 269574172 42% 407 321 100% 




NGS 150 639291 1253304300 536280022 43% 809 474 100% 
CGPLLU29 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7475284900 2387903088 32% 25788 3573 NA 
CGPLLU3 Lung Cancer cfDNA 
TEC-
Seq 100 80930 5628696000 2034607883 36% 22950 5122 NA 




NGS 150 639291 600536700 243416472 41% 371 195 100% 




NGS 150 639291 1283482650 587505537 46% 884 376 100% 
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CGPLLU30 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8699392200 2448312466 28% 26625 7523 NA 




NGS 150 639291 592419600 254080805 43% 384 289 100% 




NGS 150 639291 534800550 247881687 46% 376 105 100% 
CGPLLU31 Lung Cancer cfDNA 
TEC-
Seq 100 80930 4407055300 1196657814 27% 13701 1573 NA 




NGS 150 639291 658089150 222043322 34% 334 231 100% 




NGS 150 639291 1250134500 557178929 45% 841 426 100% 
CGPLLU4 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8456184600 3386153208 40% 39896 3346 NA 






Seq 100 80930 9744751800 2002428243 21% 21635 6924 NA 






Seq 100 80930 9622990500 3284300067 34% 39152 7788 NA 






Seq 100 80930 8463284700 2682429672 32% 28887 6048 NA 






Seq 100 80930 7710341500 3072111376 40% 36516 6875 NA 
CGPLLU5 Lung Cancer cfDNA 
TEC-
Seq 100 80930 6598676600 2581497896 39% 29200 4018 NA 




NGS 150 639291 566575050 218575022 39% 332 241 100% 
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NGS 150 639291 1128992550 543920310 48% 823 266 100% 
CGPLLU54 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8486375600 2682295256 32% 31317 3453 NA 




NGS 150 639291 324943500 108468275 33% 167 122 100% 




NGS 150 639291 2039507400 391222046 45% 593 123 100% 






Seq 100 80930 9291392600 3154714157 34% 37406 1502 NA 






Seq 100 80930 8244793600 2507050777 30% 29132 2655 NA 






Seq 100 80930 10938574300 692400779 6% 8033 1026 NA 






Seq 100 80930 5079072900 2009883319 40% 23141 2173 NA 
CGPLLU6 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7056975000 2654750988 38% 30203 5250 NA 




NGS 150 639291 498756750 194335181 39% 295 224 100% 




NGS 150 639291 1438016400 668585167 46% 1013 523 100% 
CGPLLU63 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7668552500 1044408270 14% 12325 5802 NA 




NGS 150 639291 667,878,450 309,382,277 46% 470 280 100% 
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NGS 150 639291 1,284,084,450 536,973,644 42% 816 334 100% 
CGPLLU64 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8088897900 3083234373 38% 36108 5320 NA 




NGS 150 639291 652960200 296973185 45% 450 309 100% 




NGS 150 639291 1415779950 574175656 41% 874 558 100% 
CGPLLU65 Lung Cancer cfDNA 
TEC-
Seq 100 80930 8699641600 2679059287 31% 30935 4831 NA 




NGS 150 639291 656203200 256082240 39% 387 271 100% 




NGS 150 639291 1226734500 555791782 45% 841 299 100% 
CGPLLU66 Lung Cancer cfDNA 
TEC-
Seq 100 80930 10396598700 3774873437 36% 43806 1603 NA 




NGS 150 639291 600045150 239464814 40% 363 250 100% 




NGS 150 639291 1498678200 638138245 43% 968 547 100% 
CGPLLU67 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7967355300 2652881488 33% 30996 9590 NA 




NGS 150 639291 596848350 230451277 39% 349 242 100% 




NGS 150 639291 1148746200 492136159 43% 747 388 100% 
CGPLLU68 Lung Cancer cfDNA 
TEC-
Seq 100 80930 7414515500 2339316921 32% 27348 7876 NA 






Seq 100 80930 7865706800 2818163586 36% 32789 7118 NA 
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Seq 100 80930 7632488500 2833849772 37% 33369 3716 NA 
CGPLOV1 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 6674383100 2571045006 39% 30944 4752 NA 




NGS 150 639291 739803600 260650215 35% 394 254 100% 




NGS 150 639291 1335971850 581484581 44% 880 416 100% 
CGPLOV10 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 7073534200 3402308123 48% 39820 4059 NA 




NGS 150 639291 639810000 321433448 50% 487 334 100% 




NGS 150 639291 1252083750 539790788 43% 821 350 100% 
CGPLOV11 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 6924062200 3324593050 48% 38796 7185 NA 




NGS 150 639291 703802550 353129590 50% 538 359 100% 




NGS 150 639291 1225966350 534080567 44% 813 238 100% 
CGPLOV12 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 6552080100 3181854993 49% 37340 6114 NA 
CGPLOV13 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 6796755500 3264897084 48% 38340 7931 NA 




NGS 150 639291 818085300 401088839 49% 607 389 100% 




NGS 150 639291 1330495800 655509142 49% 993 414 100% 
CGPLOV14 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 7856573900 3408425065 43% 39997 7712 NA 
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NGS 150 639291 791921100 385336441 49% 583 401 100% 




NGS 150 639291 1297177950 591287827 46% 894 541 100% 
CGPLOV15 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 7239201500 3322285607 46% 38953 6644 NA 




NGS 150 639291 701500350 360045925 51% 551 360 100% 




NGS 150 639291 1150070100 452417090 39% 692 378 100% 
CGPLOV16 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 8570755900 4344288233 51% 51009 11947 NA 




NGS 150 639291 734391000 314221694 43% 480 237 100% 




NGS 150 639291 968859000 495142955 51% 754 202 100% 
CGPLOV17 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 6910310400 2805243492 41% 32828 4307 NA 




NGS 150 639291 734076450 345696639 47% 529 357 100% 




NGS 150 639291 1315736700 713860251 54% 1089 500 100% 
CGPLOV18 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 8173037600 4064432407 50% 47714 5182 NA 




NGS 150 639291 583473150 302593210 52% 463 317 100% 




NGS 150 639291 891864900 557764532 63% 853 197 100% 
CGPLOV19 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 7732198900 3672564399 47% 43020 11127 NA 
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NGS 150 639291 653914950 257169658 39% 393 254 100% 




NGS 150 639291 1238679450 672750557 54% 1023 327 100% 
CGPLOV2 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 9365390900 3705407220 40% 43375 5495 NA 




NGS 150 639291 750964800 323428781 43% 489 309 100% 




NGS 150 639291 1286955600 606105596 47% 916 297 100% 
CGPLOV20 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 7559602000 3678700179 49% 43230 4872 NA 




NGS 150 639291 589255200 291459229 49% 443 316 100% 




NGS 150 639291 1163379600 632169517 54% 964 430 100% 
CGPLOV21 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 8949032900 4616255499 52% 54012 12777 NA 




NGS 150 639291 540460650 262969134 49% 401 274 100% 




NGS 150 639291 1373819100 743538836 54% 1136 341 100% 
CGPLOV22 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 8680136500 4049934586 47% 46912 9715 NA 




NGS 150 639291 588115950 289776467 49% 443 297 100% 




NGS 150 639291 1316281800 696435612 53% 1061 408 100% 
CGPLOV23 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 6660696600 3422631774 51% 40810 9460 NA 
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CGPLOV24 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 8634287200 4272258165 49% 50736 8689 NA 
CGPLOV25 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 6978295000 3390206388 49% 40188 5856 NA 
CGPLOV26 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 7041038300 3728879661 53% 44341 8950 NA 
CGPLOV27 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 7036348000 3126621660 44% 36944 8226 NA 
CGPLOV3 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 5666658900 1644257965 29% 18549 2703 NA 




NGS 150 639291 565973400 199491765 35% 296 198 100% 




NGS 150 639291 1661075700 780726926 47% 1173 581 100% 
CGPLOV4 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 7652138800 2958089057 39% 34791 3453 NA 
CGPLOV5 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 6846268800 2569276432 38% 30795 5514 NA 
CGPLOV6 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 5802806700 2285641930 39% 25954 4766 NA 




NGS 150 639291 778602000 297048515 38% 452 296 100% 




NGS 150 639291 1453338900 778245944 54% 1187 307 100% 
CGPLOV7 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 5104003900 1911759262 37% 22053 2832 NA 




NGS 150 639291 690537300 211116154 31% 316 208 100% 




NGS 150 639291 1415413950 681644124 48% 1017 429 100% 
160 
 
CGPLOV8 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 6247060500 2119191732 34% 23377 3541 NA 




NGS 150 639291 555609900 288758931 52% 443 232 100% 




NGS 150 639291 1546324800 782429622 51% 1169 545 100% 
CGPLOV9 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 4440232900 1135063183 26% 12542 1199 NA 




NGS 150 639291 558193200 276211578 49% 413 235 100% 




NGS 150 639291 1346789400 603639598 45% 919 596 100% 
CGPLOV28 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 7429236900 3753051715 51% 45430 4155 NA 
CGPLOV31 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 8981384000 4621838729 51% 55429 5458 NA 
CGPLOV32 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 9344536800 4737698323 51% 57234 6165 NA 
CGPLOV37 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 8158083200 4184432898 51% 50648 6934 NA 
CGPLOV38 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 8654435400 4492987085 52% 53789 6124 NA 
CGPLOV40 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 9868640700 4934400809 50% 59049 7721 NA 
CGPLOV41 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 7689013600 3861448829 50% 46292 4469 NA 
CGPLOV42 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 9836516300 4864154366 49% 58302 7632 NA 
CGPLOV43 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 8756507100 4515479918 52% 54661 4310 NA 
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CGPLOV44 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 7576310800 4120933922 54% 49903 4969 NA 
CGPLOV46 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 9346036300 5037820346 54% 61204 3927 NA 
CGPLOV47 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 10880620200 5491357828 50% 66363 6895 NA 
CGPLOV48 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 7658787800 3335991337 44% 40332 4066 NA 
CGPLOV49 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 10076208000 5519656698 55% 67117 5097 NA 
CGPLOV50 Ovarian Cancer cfDNA 
TEC-
Seq 100 80930 8239290400 4472380276 54% 54150 3836 NA 












 Table 3.8.  Alterations in blood cell proliferation genes in healthy individuals and cancer patients. 




















CGCRC304 ATM chr11_108236086-108236086_C_T HG19 3008R>C 0.43% 6303 27 Yes No 
CGCRC316 ATM chr11_108236087-108236087_G_C HG19 3008R>P 0.13% 9855 13 Yes No 
CGPLLU31 DNMT3A chr2_25321027-25321027_T_A HG18 1555-2A>T 0.58% 2580 15 Yes No 
CGPLLU22 DNMT3A chr2_25317105-25317105_T_C HG18 2083-2A>G 3.59% 3675 132 Yes No 
CGCRC303 DNMT3A chr2_25463508-25463508_C_T HG19 2173+1G>A 0.17% 4172 7 No No 
CGPLLU177 DNMT3A chr2_25463508-25463508_C_T HG19 2173+1G>A 0.13% 5299 7 No No 
CGPLBR42 DNMT3A chr2_25463320-25463320_C_ HG19 2174-1delG 0.99% 3145 31 Not Assessed No 
CGPLLU175 DNMT3A chr2_25457290-25457290_C_T HG19 2598-1G>A 0.21% 5281 11 No No 
CGPLLU163 DNMT3A chr2_25467494-25467494_A_C HG19 528Y>D 0.15% 7953 12 Yes No 
CGPLBR96 DNMT3A chr2_25467484-25467484_T_C HG19 531D>G 5.81% 3685 214 Yes No 
CGPLBR104 DNMT3A chr2_25467437-25467437_G_A HG19 547L>F 0.35% 5141 18 Not Assessed No 
CGPLLU214 DNMT3A chr2_25467428-25467428_C_T HG19 550G>R 0.37% 2429 9 Not Assessed No 
CGPLLU205 DNMT3A chr2_25463596-25463596_G_A HG19 696Q>X 3.47% 7468 259 Yes No 
CGCRC318 DNMT3A chr2_25463589-25463589_C_T HG19 698W>X 0.25% 6888 17 Yes No 
CGPLBR44 DNMT3A chr2_25463568-25463568_A_G HG19 705I>T 0.41% 5409 22 Yes No 
CGPLLU68 DNMT3A chr2_25317070-25317070_C_T HG18 706G>R 0.21% 5365 11 Not Assessed No 
CGPLLU173 DNMT3A chr2_25463563-25463563_C_T HG19 707G>S 0.25% 4814 12 Not Assessed No 
CGCRC299 DNMT3A chr2_25463553-25463553_C_G HG19 710C>S 0.12% 8240 10 Yes No 
CGCRC298 DNMT3A chr2_25463541-25463541_G_C HG19 714S>C 0.11% 7980 9 No No 
CGPLBR104 DNMT3A chr2_25463541-25463541_G_C HG19 714S>C 0.14% 6497 9 Not Assessed No 
CGPLLU174 DNMT3A chr2_25463537-25463537_G_C HG19 715I>M 0.26% 4567 12 Yes No 
CGCRC300 DNMT3A chr2_25463524-25463524_G_C HG19 720R>G 0.15% 4663 7 No No 
CGCRC319 DNMT3A chr2_25463316-25463316_C_A HG19 726G>V 0.62% 4519 28 Yes No 
CGPLLU67 DNMT3A chr2_25316811-25316811_C_T HG18 729R>Q 0.24% 4202 10 No No 
CGPLBR42 DNMT3A chr2_25463298-25463300_AAG_ HG19 731FF>F 0.31% 3584 11 Not Assessed No 
CGPLH51 DNMT3A chr2_25316802-25316804_AAG_ HG18 731FF>F 1.39% 1227 17 NA No 
CGPLH84 DNMT3A chr2_25463298-25463300_AAG_ HG19 731FF>F 0.42% 2151 9 NA No 
CGCRC299 DNMT3A chr2_25463289-25463289_T_C HG19 735Y>C 0.30% 5307 16 Yes No 
CGPLLU176 DNMT3A chr2_25463289-25463289_T_C HG19 735Y>C 0.21% 3292 7 Yes No 
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CGPLLU65 DNMT3A chr2_25316793-25316793_T_C HG18 735Y>C 3.24% 3668 119 Yes No 
CGPLOV8 DNMT3A chr2_25316793-25316793_T_G HG18 735Y>S 0.24% 3725 9 No No 
CGPLBR61 DNMT3A chr2_25463288-25463288_G_T HG19 735Y>X 0.29% 4162 12 Not Assessed No 
CGPLLU205 DNMT3A chr2_25463287-25463287_G_A HG19 736R>C 0.70% 5295 37 Yes No 
CGPLLU57 DNMT3A chr2_25316790-25316790_C_T HG18 736R>H 0.48% 1678 8 Not Assessed No 
CGPLLU57 DNMT3A chr2_25316790-25316790_C_T HG18 736R>H 0.51% 2921 15 Not Assessed No 
CGPLBR59 DNMT3A chr2_25463287-25463287_G_T HG19 736R>S 0.27% 4069 11 No No 
CGPLLU168 DNMT3A chr2_25463287-25463287_G_T HG19 736R>S 0.39% 5088 20 No No 
CGPLLU146 DNMT3A chr2_25463283-25463283_A_T HG19 737L>H 0.84% 4052 34 Yes No 
CGCRC314 DNMT3A chr2_25463280-25463280_A_T HG19 738L>Q 2.50% 4008 100 Yes No 
CGPLBR55 DNMT3A chr2_25463266-25463266_G_A HG19 743P>S 0.18% 5118 9 No No 
CGPLLU176 DNMT3A chr2_25463245-25463245_G_A HG19 750P>S 0.92% 3700 34 Yes No 
CGPLLU175 DNMT3A chr2_25463230-25463230_A_G HG19 755F>L 0.15% 5365 8 Yes No 
CGCRC303 DNMT3A chr2_25463229-25463229_A_G HG19 755F>S 0.21% 3838 8 No No 
CGPLH38 DNMT3A chr2_25316688-25316688_G_A HG18 770S>L 3.09% 970 30 NA No 
CGPLBR57 DNMT3A chr2_25463182-25463182_G_A HG19 771R>X 0.37% 4321 16 Yes No 
CGPLH63 DNMT3A chr2_25316686-25316686_G_A HG18 771R>X 1.26% 2061 26 NA No 
CGPLLU173 DNMT3A chr2_25463182-25463182_G_A HG19 771R>X 4.18% 3854 161 Not Assessed No 
CGPLBR69 DNMT3A chr2_25463172-25463172_T_A HG19 774E>V 0.29% 4168 12 No No 
CGPLLU179 DNMT3A chr2_25457252-25457252_T_C HG19 879N>D 0.38% 4213 16 Yes No 
CGPLLU197 DNMT3A chr2_25457252-25457252_T_C HG19 879N>D 0.38% 3721 14 No No 
CGPLBR57 DNMT3A chr2_25457243-25457243_G_A HG19 882R>C 1.17% 5025 59 Yes Yes 
CGPLH42 DNMT3A chr2_25310747-25310747_G_A HG18 882R>C 0.78% 2561 20 NA Yes 
CGPLH76 DNMT3A chr2_25457243-25457243_G_A HG19 882R>C 5.28% 3446 182 NA Yes 
CGPLH84 DNMT3A chr2_25457243-25457243_G_A HG19 882R>C 0.16% 2534 4 NA Yes 
CGPLLU118 DNMT3A chr2_25310747-25310747_G_A HG18 882R>C 7.60% 3317 252 Yes Yes 
CGPLLU177 DNMT3A chr2_25457243-25457243_G_A HG19 882R>C 0.29% 5872 17 No Yes 
CGPLLU197 DNMT3A chr2_25457243-25457243_G_A HG19 882R>C 0.16% 3843 6 No Yes 
CGCRC298 DNMT3A chr2_25457242-25457242_C_T HG19 882R>H 0.08% 7666 6 Yes Yes 
CGCRC308 DNMT3A chr2_25457242-25457242_C_T HG19 882R>H 0.06% 7259 4 No Yes 
CGCRC311 DNMT3A chr2_25457242-25457242_C_T HG19 882R>H 0.86% 4992 43 No Yes 
CGCRC321 DNMT3A chr2_25457242-25457242_C_T HG19 882R>H 0.08% 5297 4 No Yes 
CGPLBR101 DNMT3A chr2.fa:25457242-25457242_C_T HG19 882R>H 0.08% 13567 5 Not Assessed Yes 
CGPLBR44 DNMT3A chr2_25457242-25457242_C_T HG19 882R>H 1.82% 4777 87 Yes Yes 
CGPLBR59 DNMT3A chr2.fa:25457242-25457242_C_T HG19 882R>H 0.08% 7113 4 No Yes 
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CGPLBR67 DNMT3A chr2_25457242-25457242_C_T HG19 882R>H 0.11% 5579 6 Yes Yes 
CGPLBR87 DNMT3A chr2_25457242-25457242_C_T HG19 882R>H 0.31% 3228 10 No Yes 
CGPLBR97 DNMT3A chr2_25457242-25457242_C_T HG19 882R>H 0.11% 6299 7 Yes Yes 
CGPLOV11 DNMT3A chr2_25457216-25457221_GGCCCA_ HG19 889LGR>R 2.59% 5019 130 No No 
CGPLLU174 DNMT3A chr2_25457216-25457216_G_A HG19 891R>W 0.29% 4133 12 Yes No 
CGPLLU177 DNMT3A chr2_25457197-25457197_A_C HG19 897V>G 1.53% 5541 85 Yes No 
CGPLLU161 DNMT3A chr2_25457191-25457191_C_T HG19 899R>H 0.13% 5502 7 Not Assessed No 
CGPLLU139 DNMT3A chr2_25320920-25320920_A_ HG18 C554Afs*97 0.24% 3821 9 No No 
CGCRC338 DNMT3A chr2_25467443-25467444_CA_ HG19 E545Gfs*32 0.15% 5322 8 No No 
CGCRC296 DNMT3A chr2_25463301-25463301_A_ HG19 F731Sfs*48 0.27% 3774 10 No No 
CGPLBR72 DNMT3A chr2_25463301-25463301_A_ HG19 F731Sfs*48 0.74% 3761 28 No No 
CGPLLU22 DNMT3A chr2_25316794-25316795_AG_ HG18 F734Lfs*6 2.75% 2876 79 Yes No 
CGCRC314 DNMT3A chr2_25467513-25467513_A_ HG19 L522Wfs*129 0.15% 5440 8 No No 
CGPLLU57 DNMT3A chr2_25316676-25316679_TCGA_ HG18 L773Rfs*5 0.50% 2380 12 Not Assessed No 
CGPLBR63 DNMT3A chr2_25463596-25463596__G HG19 Q696Pfs*17 0.28% 3248 9 No No 
CGPLLU6 DNMT3A chr2_25310695-25310695_C_ HG18 R899Pfs*7 0.18% 4517 8 No No 
CGPLBR92 DNMT3A chr2_25463572-25463572_C_ HG19 V704* 0.16% 8195 13 Yes No 
CGPLLU174 DNMT3A chr2_25463532-25463536_TTGAC_ HG19 V716Pfs*16 0.27% 4474 12 Yes No 
CGPLLU68 DNMT3A chr2_25310792-25310792_C_ HG18 V867Yfs*14 0.33% 4600 15 Not Assessed No 
CGPLH55 DNMT3A chr2_25320975-25320975_G_ HG18 Y536Tfs*115 0.24% 2858 7 NA No 
CGCRC295 IDH1 chr2_209113196-209113196_C_A HG19 104G>V 0.34% 5362 18 Yes No 
CGPLBR59 IDH2 chr15_90631934-90631934_C_T HG19 140R>Q 0.20% 3420 7 No Yes 
CGPLOV9 IDH2 chr15_88432939-88432939_G_A HG18 140R>W 0.47% 1279 6 Yes No 
CGPLLU136 JAK2 chr9_5063770-5063770_G_T HG18 617V>F 0.32% 2799 9 No Yes 
CGPLLU146 JAK2 chr9_5073770-5073770_G_T HG19 617V>F 0.25% 4051 10 No Yes 
CGPLOV32 DNMT3A chr2_25463507-25463507_A_G HG19 2173+2T>C 0.15% 5213 8 Not Assessed No 
CGPLOV38 DNMT3A chr2_25463289-25463289_T_G HG19 735Y>S 0.33% 4852 16 Not Assessed No 
CGPLOV42 DNMT3A chr2_25463286-25463286_C_T HG19 736R>H 0.16% 6361 10 Not Assessed No 
CGPLOV43 DNMT3A chr2_25463248-25463248_G_A HG19 749R>C 7.08% 3797 269 Not Assessed No 
CGPLOV43 DNMT3A chr2_25463524-25463524_G_A HG19 720R>C 0.30% 3956 12 Not Assessed No 
CGPLOV47 DNMT3A chr2_25457243-25457243_G_A HG19 882R>C 1.77% 6156 109 Not Assessed Yes 




   Table 3.9.  Cancer patients detected using TEC-Seq. 
Cancer Type Patients (n) Patients with ctDNA Alterations (n) 
Fraction of patients with 
ctDNA Alterations (%) 
Colorectal    
I 8 4 50% 
II 9 8 89% 
III 10 9 90% 
IV 15 14 93% 
I-IV 42 35 83% 
Lung    
I 29 13 45% 
II 32 23 72% 
III 4 3 75% 
IV 6 5 83% 
I-IV 71 44 62% 
Ovarian    
I 24 16 67% 
II 4 3 75% 
III 8 6 75% 
IV 6 5 83% 
I-IV 42 30 71% 
Breast    
I 3 2 67% 
II 29 17 59% 
III 13 6 46% 
IV 0 NA NA 
I-IV 45 25 56% 
All    
I, II 138 86 62% 
III, IV 62 48 77% 
I-IV 200 134 67% 
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 Table 3.10. Germline alterations identified in cfDNA. 


















CGCRC292 EGFR chr7_55248982-55248982_C_G HG19 2284-4C>G 31.99% 8385 2682 Yes 
CGCRC296 EGFR chr7_55266472-55266472_G_A HG19 922E>K 30.48% 9919 3023 Yes 
CGCRC297 KIT chr4_55524233-55524233_C_T HG19 18L>F 41.39% 4921 2037 Yes 
CGCRC306 ERBB4 chr2_212251596-212251596_G_A HG19 1155R>X 38.70% 4530 1753 Yes 
CGCRC306 PDGFRA chr4_55130065-55130065_C_G HG19 200T>S 34.78% 6000 2087 Yes 
CGCRC308 EGFR chr7_55259485-55259485_C_T HG19 848P>L 27.69% 9481 2625 Yes 
CGCRC313 FBXW7 chr4_153332911-153332911__AGG HG19 15T>TL 38.42% 5331 2048 Yes 
CGCRC320 KIT chr4_55524233-55524233_C_T HG19 18L>F 34.76% 6997 2432 Yes 
CGCRC321 EGFR chr7_55229225-55229225_C_A HG19 511S>Y 41.86% 6457 2703 Yes 
CGCRC334 EGFR chr7_55238900-55238900_C_T HG19 638T>M 35.28% 2832 999 Yes 
CGCRC337 APC chr5_112162851-112162851_G_A HG19 485M>I 46.26% 4825 2232 Yes 
CGCRC342 ALK chr2_29606646-29606646_G_A HG19 412R>C 48.98% 5878 2879 Not Assessed 
CGCRC342 APC chr5_112175211-112175211_T_A HG19 1307I>K 45.67% 4705 2149 Not Assessed 
CGCRC342 TP53 chr17_7579316-7579316__C HG19 C124Wfs*25 63.52% 1576 1001 Not Assessed 
CGPLBR40 AR chrX_66766163-66766163_C_G HG19 392P>R 28.99% 7141 2070 Yes 
CGPLBR41 MET chr7_116423378-116423378_T_G HG19 1236V>G 36.19% 3987 1443 Not Assessed 
CGPLBR42 KIT chr4_55594248-55594248_A_T HG19 651M>L 39.02% 4600 1795 Not Assessed 
CGPLBR42 STK11 chr19_1223125-1223125_C_G HG19 354F>L 42.32% 3840 1625 Not Assessed 
CGPLBR43 ERBB4 chr2_212566755-212566755_T_C HG19 476T>A 39.79% 5411 2153 Not Assessed 
CGPLBR48 ALK chr2_29436901-29436901_C_T HG19 1231R>Q 34.61% 4938 1709 Yes 
CGPLBR59 STK11 chr19_1223125-1223125_C_G HG19 354F>L 44.53% 4393 1956 Yes 
CGPLBR61 STK11 chr19_1223125-1223125_C_G HG19 354F>L 40.14% 5598 2247 Not Assessed 
CGPLBR63 FGFR3 chr4_1806188-1806188_A_G HG19 403K>E 34.82% 2967 1033 Yes 
CGPLBR67 ESR1 chr6_152129399-152129399_T_C HG19 118S>P 33.30% 4643 1546 Not Assessed 
CGPLBR69 CTNNB1 chr3_41266092-41266092_A_C HG19 30Y>S 41.74% 5287 2207 Yes 
CGPLBR69 IDH1 chr2_209108158-209108158_A_T HG19 231Y>N 41.66% 3317 1382 Yes 
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CGPLBR70 APC chr5_112176022-112176022_A_C HG19 1577E>D 40.28% 4057 1634 Yes 
CGPLBR72 APC chr5_112175886-112175886_A_G HG19 1532D>G 44.03% 3607 1588 Yes 
CGPLBR73 ERBB4 chr2_212652833-212652833_G_T HG19 158A>E 35.58% 4461 1587 Yes 
CGPLBR74 AR chrX_66788865-66788865_G_T HG19 20+1G>T 36.23% 4770 1728 Yes 
CGPLBR76 KDR chr4_55946310-55946310_C_T HG19 1290S>N 36.57% 4607 1685 Yes 
CGPLBR79 STK11 chr19_1223125-1223125_C_G HG19 354F>L 45.17% 2267 1024 Not Assessed 
CGPLBR83 AR chrX_66937328-66937328_A_G HG19 728N>D 42.66% 4646 1982 Yes 
CGPLBR83 ERBB4 chr2_212543783-212543783_T_G HG19 539Y>S 44.91% 2035 914 Yes 
CGPLBR86 SMARCB1 chr22_24159126-24159126_A_G HG19 795+3A>G 43.38% 3926 1703 Yes 
CGPLBR86 STK11 chr19_1223125-1223125_C_G HG19 354F>L 42.32% 4421 1871 Yes 
CGPLBR87 AR chrX_66931310-66931310_G_A HG19 651S>N 42.94% 2762 1186 Yes 
CGPLBR88 APC chr5_112174665-112174665_T_C HG19 1125V>A 31.19% 5775 1801 Yes 
CGPLBR93 ALK chr2_29451911-29451911_T_C HG19 885D>G 34.03% 5078 1728 Not Assessed 
CGPLBR93 JAK2 chr9_5090536-5090536_T_C HG19 951I>T 41.23% 3810 1571 Not Assessed 
CGPLBR97 PDGFRA chr4_55136880-55136880_C_A HG19 401A>D 34.12% 6134 2093 Yes 
CGPLH36 STK11 chr19_1174125-1174125_C_G HG18 354F>L 47.41% 1447 686 NA 
CGPLH38 ATM chr11_107623008-107623008_C_T HG18 337R>C 42.42% 396 168 NA 
CGPLH41 ALK chr2_29310038-29310038_A_G HG18 795I>T 41.58% 606 252 NA 
CGPLH42 ALK chr2_29269863-29269863_T_C HG18 1532N>D 45.86% 2608 1196 NA 
CGPLH42 FLT3 chr13_27506341-27506341_T_C HG18 572Y>C 47.36% 1588 752 NA 
CGPLH43 STK11 chr19_1174125-1174125_C_G HG18 354F>L 45.16% 1384 625 NA 
CGPLH46 ALK chr2_29996673-29996673_C_A HG18 119E>D 46.86% 1242 582 NA 
CGPLH47 ALK chr2_29269863-29269863_T_C HG18 1532N>D 46.78% 1678 785 NA 
CGPLH48 ALK chr2_29327569-29327569_C_T HG18 704A>T 45.58% 1505 686 NA 
CGPLH48 APC chr5_112203557-112203557_A_C HG18 1456K>T 44.92% 1672 751 NA 
CGPLH50 APC chr5_112202635-112202635_G_A HG18 1149E>K 47.29% 2252 1065 NA 
CGPLH51 DNMT3A chr4_55292273-55292273_A_G HG18 722M>V 46.62% 1109 517 NA 
CGPLH55 STK11 chr19_1177588-1177588_G_A HG18 415R>H 46.11% 1503 693 NA 
CGPLH58 STK11 chr19_1174125-1174125_C_G HG18 354F>L 47.55% 1060 504 NA 
CGPLH59 ATM chr11_107680672-107680672_G_A HG18 1853D>N 43.55% 1621 706 NA 
CGPLH61 STK11 chr19_1174125-1174125_C_G HG18 354F>L 42.48% 565 240 NA 
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CGPLH64 ATM chr11_107627849-107627849_A_T HG18 561Q>H 47.13% 942 444 NA 
CGPLH76 APC chr5_112179623-112179623_G_T HG19 2778A>S 47.22% 3530 1667 NA 
CGPLH76 STK11 chr19_1223125-1223125_C_G HG19 354F>L 43.93% 2859 1256 NA 
CGPLH77 PDGFRA chr4_55138642-55138642_C_T HG19 440T>M 43.63% 3516 1534 NA 
CGPLH91 TP53 chr17_7577612-7577612_G_A HG19 673-4C>T 45.32% 1390 630 NA 
CGPLLU115 ERBB4 chr2_212003965-212003965_C_A HG18 865A>S 40.24% 5030 2024 Yes 
CGPLLU116 APC chr5_112203604-112203604_G_A HG18 1472V>I 39.15% 6117 2395 Yes 
CGPLLU118 ALK chr2_29996561-29996561_G_A HG18 157P>S 45.16% 2655 1199 Yes 
CGPLLU118 APC chr5_112203139-112203139_G_C HG18 1317E>Q 47.73% 2793 1333 Yes 
CGPLLU119 ATM chr11_107680672-107680672_G_A HG18 1853D>N 34.56% 2951 1020 Yes 
CGPLLU136 ALK chr2_29269863-29269863_T_C HG18 1532N>D 40.61% 5555 2256 Yes 
CGPLLU136 PDGFRA chr4_54833314-54833314_G_A HG18 1238-4G>A 39.68% 5993 2378 Yes 
CGPLLU147 PDGFRA chr4_55130065-55130065_C_G HG19 200T>S 43.47% 3391 1474 Yes 
CGPLLU164 STK11 chr19_1223125-1223125_C_G HG19 354F>L 42.52% 4567 1942 Yes 
CGPLLU165 STK11 chr19_1223125-1223125_C_G HG19 354F>L 36.62% 7248 2654 Yes 
CGPLLU166 CDKN2A chr9_21974529-21974529_T_C HG19 100R>G 35.62% 6125 2182 Yes 
CGPLLU175 ATM chr11_108117798-108117798_C_T HG19 337R>C 43.84% 3741 1640 Yes 
CGPLLU179 APC chr5_112179123-112179123_C_T HG19 2611T>I 39.91% 3112 1242 Yes 
CGPLLU207 ALK chr2_29606625-29606625_A_G HG19 419F>L 34.58% 6469 2237 Yes 
CGPLLU208 EGFR chr7_55220281-55220281_G_A HG19 224R>H 39.34% 6075 2390 Yes 
CGPLLU209 EGFR chr7_55231493-55231493_A_G HG19 567M>V 30.41% 8339 2536 Yes 
CGPLLU209 STK11 chr19_1223125-1223125_C_G HG19 354F>L 26.84% 7365 1977 Yes 
CGPLLU214 STK11 chr19_1223125-1223125_C_G HG19 354F>L 44.26% 2822 1249 Not Assessed 
CGPLLU26 ALK chr2_29771364-29771364_A_G HG18 270F>L 46.69% 906 423 Yes 
CGPLLU26 APC chr5_112203139-112203139_G_C HG18 1317E>Q 49.94% 811 405 Yes 
CGPLLU28 ATM chr11_107680672-107680672_G_A HG18 1853D>N 29.16% 2507 731 Yes 
CGPLLU30 ALK chr2_29996561-29996561_G_A HG18 157P>S 35.57% 3399 1209 Not Assessed 
CGPLLU30 ATM chr11_107680672-107680672_G_A HG18 1853D>N 30.78% 2752 847 Not Assessed 
CGPLLU30 ERBB4 chr2_212278315-212278315_C_T HG18 391V>I 31.90% 2301 734 Not Assessed 
CGPLLU3 ATM chr11_107680672-107680672_G_A HG18 1853D>N 6.62% 1950 129 Yes 
CGPLLU65 APC chr5_112207522-112207522_G_T HG18 2778A>S 44.64% 4715 2105 Yes 
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CGPLLU66 ERBB2 chr17_35121793-35121793_C_T HG18 330R>W 42.17% 1513 638 Yes 
CGPLLU68 RET chr10_42930095-42930095_C_G HG18 681Q>E 36.15% 5948 2150 Not Assessed 
CGPLLU6 JAK2 chr9_5012112-5012112_A_G HG18 42Y>C 42.68% 3997 1706 Yes 
CGPLOV11 TP53 chr17_7579499-7579499_G_A HG19 63A>V 37.77% 4226 1596 Yes 
CGPLOV13 PDGFRA chr4_55136880-55136880_C_A HG19 401A>D 37.98% 5721 2173 Yes 
CGPLOV17 PDGFRA chr4_55161380-55161380_G_A HG19 1071D>N 44.10% 4370 1927 Yes 
CGPLOV18 APC chr5_112174665-112174665_T_C HG19 1125V>A 40.81% 4700 1918 Yes 
CGPLOV19 AR chrX_66765516-66765516_C_A HG19 176S>R 65.29% 10349 6757 Yes 
CGPLOV19 FGFR3 chr4_1806188-1806188_A_G HG19 403K>E 23.80% 7734 1841 Yes 
CGPLOV1 APC chr5_112205737-112205737_T_A HG18 2183S>T 40.48% 2473 1001 Yes 
CGPLOV20 EGFR chr7_55221714-55221714_A_G HG19 253K>R 44.05% 5092 2243 Yes 
CGPLOV21 STK11 chr19_1223125-1223125_C_G HG19 354F>L 7.68% 11974 919 Yes 
CGPLOV25 APC chr5_112177982-112177982_A_T HG19 2231I>F 43.86% 3785 1660 Not Assessed 
CGPLOV2 STK11 chr19_1174125-1174125_C_G HG18 354F>L 44.29% 4213 1866 Yes 
CGPLLU44 APC chr5_112201775-112201775_A_G HG18 862N>S 41.71% 6004 2504 Not Assessed 
CGPLLU44 APC chr5_112201775-112201775_A_G HG18 862N>S 41.00% 3984 1637 Not Assessed 
CGPLLU47 KIT chr4_55288221-55288221_A_C HG18 541M>L 45.20% 3898 1762 Not Assessed 
CGPLOV32 EGFR chr7_55221714-55221714_A_G HG19 253K>R 40.94% 7697 3151 Not Assessed 
CGPLOV49 ALK chr2_29450454-29450454_G_T HG19 967T>N 37.87% 4814 1823 Not Assessed 
CGPLOV49 CDK4 chr12_58145379-58145379_T_C HG19 41N>S 45.58% 5448 2483 Not Assessed 








Table 3.11. Somatic alterations detected in cfDNA of cancer patients. 
Patient Gene Symbol Nucleotide 
Genome 
















CGCRC309 AKT1 chr14_105246551-105246551_C_T HG19 17E>K 2.70% 6154 166 Yes Yes 
CGPLLU147 ALK chr2_29416343-29416343_C_T HG19 1537G>E 0.94% 4034 38 Yes No 
CGPLBR97 ALK chr2_30143420-30143420__GGA HG19 36->S 0.14% 5060 7 Not Assessed No 
CGPLLU203 ALK chr2_30143420-30143420__GGA HG19 36->S 0.11% 6627 7 Not Assessed No 
CGPLOV14 ALK chr2_30143420-30143420__GGA HG19 36->S 0.12% 5784 7 Not Assessed No 
CGPLOV13 ALK chr2_29551298-29551298_C_A HG19 444W>C 0.12% 6814 8 Yes No 
CGPLBR73 ALK chr2_29474053-29474053_A_G HG19 708S>P 0.27% 6205 17 No No 
CGPLLU67 ALK chr2_29308683-29308683_C_T HG18 875G>R 13.19% 6597 870 No No 
CGCRC291 APC chr5_112175069-112175069_C_T HG19 1260Q>X 11.23% 4193 471 Yes No 
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CGCRC336 APC chr5_112175147-112175147_G_T HG19 1286E>X 81.61% 2827 2307 Yes No 
CGCRC340 APC chr5_112175207-112175207_G_T HG19 1306E>X 22.57% 1750 395 Yes Yes 
CGCRC294 APC chr5_112175390-112175390_C_T HG19 1367Q>X 0.13% 5421 7 Yes Yes 
CGPLOV19 APC chr5_112175423-112175423_C_T HG19 1378Q>X 46.35% 5640 2614 Yes Yes 
CGCRC314 APC chr5_112175426-112175426_G_T HG19 1379E>X 0.38% 4523 17 Yes Yes 
CGCRC291 APC chr5_112175639-112175639_C_T HG19 1450R>X 11.05% 7518 831 Yes Yes 
CGCRC308 APC chr5_112175729-112175729_C_T HG19 1480Q>X 0.11% 6664 7 Yes No 
CGCRC310 APC chr5_112175828-112175828_G_T HG19 1513E>X 0.11% 7287 8 Yes No 
CGCRC310 APC chr5_112175852-112175852_G_T HG19 1521E>X 0.15% 6204 9 Yes No 
CGCRC294 APC chr5_112116592-112116592_C_T HG19 213R>X 0.14% 2952 4 Yes Yes 
CGCRC317 APC chr5_112128143-112128143_C_T HG19 216R>X 0.29% 1381 4 No Yes 
172 
 
CGCRC342 APC chr5_112151204-112151204_C_T HG19 283R>X 21.93% 4286 940 Not Assessed Yes 
CGCRC313 APC chr5_112173917-112173917_C_T HG19 876R>X 0.07% 5390 4 Yes Yes 
CGCRC339 APC chr5_112173917-112173917_C_T HG19 876R>X 2.35% 2888 68 Yes Yes 
CGCRC312 APC chr5_112174170-112174170_C_G HG19 960S>X 0.59% 3580 21 Yes No 
CGCRC337 APC chr5_112128170-112128170_G_ HG19 E225Kfs*68 39.28% 1423 559 Yes No 
CGCRC342 APC chr5_112175208-112175208__A HG19 I1307Nfs*8 30.72% 4756 1461 Not Assessed No 
CGCRC317 APC chr5_112175438-112175438__A HG19 M1383Nfs*3 0.14% 5705 8 Yes No 
CGCRC334 APC chr5_112175294-112175294__A HG19 S1335Kfs*7 16.24% 3208 521 Yes No 
CGCRC338 APC chr5_112175536-112175536_T_ HG19 S1415Rfs*4 36.00% 5497 1979 Yes No 
CGPLBR96 AR chrX_66765026-66765026_G_A HG19 13R>Q 0.60% 3147 19 No No 
CGCRC317 ATM chr11_108142132-108142132_T_C HG19 1026W>R 0.23% 5713 13 Yes No 
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CGCRC301 ATM chr11_108199847-108199847_C_T HG19 2397Q>X 0.21% 3865 8 No No 
CGPLBR70 ATM chr11_108216546-108216546_G_A HG19 2832R>H 0.36% 3622 13 No No 
CGPLLU117 ATM chr11_107721788-107721788_G_T HG18 2843A>S 0.47% 1899 9 No No 
CGPLLU144 ATM chr11_108115727-108115727_C_T HG19 292P>L 0.22% 2743 6 No No 
CGCRC304 ATM chr11_108142134-108142134_G_A HG19 3077+1G>A 0.27% 4827 13 No No 
CGPLBR42 ATM chr11_108142134-108142134_G_A HG19 3077+1G>A 0.37% 4299 16 Not Assessed No 
CGPLBR83 ATM chr11_108117753-108117753_G_A HG19 322E>K 0.28% 2130 6 No No 
CGPLBR70 ATM chr11_108117756-108117756_A_G HG19 323I>V 0.36% 2490 9 Not Assessed No 
CGPLLU146 ATM chr11_108122699-108122699_A_T HG19 581L>F 0.20% 4534 9 No No 
CGPLBR70 ATM chr11_108115513-108115513_A_G HG19 663-2A>G 0.26% 3448 9 Not Assessed No 
CGCRC342 BRAF chr7_140624473-140624473__CAGGCT HG19 11->SL 0.36% 3056 11 Not Assessed No 
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CGCRC342 BRAF chr7_140624413-140624413_C_G HG19 31A>P 0.21% 3370 7 Not Assessed No 
CGCRC291 BRAF chr7_140624404-140624409_CGGCGC_ HG19 32GAA>A 0.24% 2472 6 Not Assessed No 
CGPLLU162 BRAF chr7_140494187-140494187_C_T HG19 354R>Q 0.14% 5176 7 No No 
CGCRC302 BRAF chr7_140453136-140453136_A_T HG19 600V>E 0.12% 5002 6 Yes Yes 
CGCRC307 BRAF chr7_140453136-140453136_A_T HG19 600V>E 0.38% 4488 17 Yes Yes 
CGCRC309 BRAF chr7_140453136-140453136_A_T HG19 600V>E 3.00% 5192 156 Yes Yes 
CGCRC333 BRAF chr7_140453136-140453136_A_T HG19 600V>E 22.26% 7026 1564 Yes Yes 
CGCRC335 BRAF chr7_140453136-140453136_A_T HG19 600V>E 0.32% 3754 12 Yes Yes 
CGPLBR102 BRAF chr7_140449173-140449173_G_A HG19 636Q>X 0.21% 3302 7 Not Assessed No 
CGPLLU178 CDH1 chr16_68844164-68844164_C_T HG19 251T>M 0.29% 4196 12 No No 
CGPLLU161 CDK6 chr7_92462557-92462557__GAACGGAGG HG19 27V>VLRS 0.16% 5040 8 Not Assessed No 
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CGPLLU162 CDK6 chr7_92462557-92462557__GAACGGAGG HG19 27V>VLRS 0.14% 5095 7 No No 
CGPLBR43 CDK6 chr7_92462495-92462495_T_C HG19 48Q>R 0.27% 3011 8 Not Assessed No 
CGPLBR88 CDK6 chr7_92462487-92462487_C_T HG19 51E>K 0.13% 6043 8 No No 
CGPLBR88 CDK6 chr7_92462424-92462424_C_T HG19 72E>K 0.38% 1570 6 Not Assessed No 
CGCRC306 CDKN2A chr9_21971039-21971039_G_A HG19 107R>C 8.02% 5925 475 Yes No 
CGCRC321 CDKN2A chr9_21974792-21974792_G_A HG19 12S>L 0.20% 3027 6 No No 
CGPLBR80 CDKN2A chr9_21974792-21974792_G_A HG19 12S>L 0.54% 1673 9 No No 
CGPLBR87 CDKN2A chr9_21974792-21974792_G_A HG19 12S>L 0.45% 1330 6 Not Assessed No 
CGPLLU161 CDKN2A chr9_21974792-21974792_G_A HG19 12S>L 0.20% 3007 6 Not Assessed No 
CGPLLU162 CDKN2A chr9_21974792-21974792_G_A HG19 12S>L 0.22% 3171 7 No No 
CGPLLU163 CDKN2A chr9_21974792-21974792_G_A HG19 12S>L 0.21% 3298 7 No No 
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CGCRC316 CDKN2A chr9_21974825-21974825_A_C HG19 1M>R 5.74% 2577 148 Yes No 
CGPLLU47 CDKN2A chr9_21964759-21964759_C_A HG18 23G>V 10.30% 4385 450 Not Assessed No 
CGPLLU47 CDKN2A chr9_21964759-21964759_C_A HG18 23G>V 8.70% 2208 192 Not Assessed No 
CGPLLU9 CDKN2A chr9_21964679-21964679_G_A HG18 50Q>X 2.30% 2921 66 Not Assessed No 
CGPLLU9 CDKN2A chr9_21964679-21964679_G_A HG18 50Q>X 1.42% 4779 68 Not Assessed No 
CGPLOV8 CDKN2A chr9_21961116-21961116_G_T HG18 81P>H 0.22% 4020 9 Yes No 
CGPLLU209 CDKN2A chr9_21971096-21971096_C_A HG19 88E>X 9.13% 7127 651 Yes Yes 
CGPLLU206 CDKN2A chr9_21968233-21968233_C_ HG19 D156Ifs 14.59% 2379 347 Yes No 
CGPLLU175 CDKN2A chr9_21974768-21974774_GCGGCCG_ HG19 T18Rfs*6 7.14% 4807 343 Yes No 
CGPLLU67 CTNNB1 chr3_41241105-41241105_C_G HG18 33S>C 0.11% 5442 6 Yes Yes 
CGCRC316 CTNNB1 chr3_41266113-41266113_C_G HG19 37S>C 5.47% 8673 474 Yes Yes 
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CGCRC292 CTNNB1 chr3_41266124-41266124_A_G HG19 41T>A 0.13% 5936 8 Yes Yes 
CGPLOV22 CTNNB1 chr3_41266124-41266124_A_G HG19 41T>A 0.34% 6983 24 Yes Yes 
CGCRC304 EGFR chr7_55273068-55273068_A_T HG19 1131T>S 0.22% 6977 15 No No 
CGPLLU9 EGFR chr7_55196682-55196682_G_A HG18 1499-4G>A 0.14% 6370 9 Not Assessed No 
CGCRC316 EGFR chr7_55266407-55266407_C_T HG19 2702-3C>T 0.11% 8499 9 No No 
CGPLLU144 EGFR chr7_55224336-55224336_C_T HG19 373P>S 0.16% 5066 8 Yes No 
CGPLOV15 EGFR chr7_55225445-55225445_C_G HG19 433H>D 0.19% 4815 9 No No 
CGCRC306 EGFR chr7_55233103-55233103_A_G HG19 618H>R 6.32% 4935 312 Yes No 
CGPLBR48 EGFR chr7_55240762-55240762_G_A HG19 669R>Q 0.18% 5013 9 No No 
CGPLBR87 EGFR chr7_55240762-55240762_G_A HG19 669R>Q 0.36% 3339 12 Not Assessed No 
CGPLLU14 EGFR chr7_55209201-55209201_G_A HG18 719G>S 0.90% 743 7 Not Assessed Yes 
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CGPLLU166 EGFR chr7_55242462-55242462_C_G HG19 744I>M 0.12% 5608 7 Yes No 
CGPLLU65 EGFR chr7_55209960-55209974_GAATTAAGAGAAGCA_ HG18 745KELREA>K 0.33% 3910 13 Yes Yes 
CGPLLU214 EGFR chr7_55242466-55242480_GAATTAAGAGAAGCA_ HG19 745KELREA>K 0.68% 2950 20 
Not 
Assessed Yes 
CGPLLU135 EGFR chr7_55209959-55209973_GGAATTAAGAGAAGC_ HG18 745KELREA>T 0.19% 3699 7 Yes Yes 
CGPLLU136 EGFR chr7_55209959-55209973_GGAATTAAGAGAAGC_ HG18 745KELREA>T 0.21% 4343 9 Yes Yes 
CGPLLU19 EGFR chr7_55209959-55209973_GGAATTAAGAGAAGC_ HG18 745KELREA>T 1.76% 2890 51 Yes Yes 
CGPLLU207 EGFR chr7_55242465-55242479_GGAATTAAGAGAAGC_ HG19 745KELREA>T 0.28% 4703 13 Yes Yes 
CGPLLU20 EGFR chr7_55209959-55209973_GGAATTAAGAGAAGC_ HG18 745KELREA>T 0.29% 1712 5 Yes Yes 
CGPLLU202 EGFR chr7.fa:55249071-55249071_C_T HG19 790T>M 0.05% 13342 4 Yes Yes 
CGPLLU207 EGFR chr7.fa:55249071-55249071_C_T HG19 790T>M 0.09% 12421 6 No Yes 
CGPLLU14 EGFR chr7_55216565-55216565_C_T HG18 790T>M 0.40% 718 3 Not Assessed Yes 
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CGPLLU14 EGFR chr7_55216565-55216565_C_T HG18 790T>M 0.33% 1208 4 Not Assessed Yes 
CGPLLU162 EGFR chr7_55259515-55259515_T_G HG19 858L>R 0.22% 6346 14 Yes Yes 
CGPLLU166 EGFR chr7_55259515-55259515_T_G HG19 858L>R 0.44% 7451 33 Yes Yes 
CGPLLU168 EGFR chr7.fa:55259515-55259515_T_G HG19 858L>R 0.07% 11196 4 Yes Yes 
CGPLLU198 EGFR chr7_55259515-55259515_T_G HG19 858L>R 0.52% 5176 27 Yes Yes 
CGPLLU208 EGFR chr7_55259515-55259515_T_G HG19 858L>R 0.86% 5686 49 Yes Yes 
CGPLLU14 EGFR chr7_55227018-55227018_T_A HG18 861L>Q 0.40% 737 3 Not Assessed Yes 
CGPLLU202 EGFR chr7_55259544-55259544_G_T HG19 868E>X 0.13% 5463 7 No No 
CGPLLU118 EGFR chr7_55235571-55235571_C_T HG18 973R>X 2.68% 3243 87 Yes No 
CGPLLU1 ERBB2 chr17_35121734-35121734_C_T HG18 310S>F 0.30% 4342 13 Yes No 
CGPLLU146 ERBB2 chr17_37880982-37880982__GCATACGTGATG HG19 771->AYVM 1.18% 6200 73 Yes No 
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CGPLBR67 ERBB4 chr2_212285302-212285302_T_G HG19 1000D>A 0.28% 3864 11 No No 
CGPLBR42 ERBB4 chr2_212248464-212248464_T_C HG19 1268Y>C 0.21% 3817 8 Not Assessed No 
CGPLLU164 ERBB4 chr2_212248371-212248371_G_A HG19 1299P>L 0.96% 3008 29 Yes No 
CGCRC307 ERBB4 chr2_213403205-213403205_G_A HG19 17A>V 0.15% 5893 9 No No 
CGPLLU164 ERBB4 chr2_212587243-212587243_T_C HG19 253N>S 0.22% 3234 7 No No 
CGPLLU170 ERBB4 chr2_212576859-212576859_G_A HG19 347T>I 0.27% 5234 14 Not Assessed No 
CGPLLU144 ERBB4 chr2_212568841-212568841_C_T HG19 426R>K 0.18% 4498 8 No No 
CGPLOV21 ERBB4 chr2_212530114-212530114_C_G HG19 602S>T 14.36% 9659 1387 No No 
CGCRC333 ERBB4 chr2_212495194-212495194_T_G HG19 691E>A 1.00% 3613 36 No No 
CGCRC320 ERBB4 chr2_212989479-212989479_G_A HG19 78R>W 0.12% 5654 7 No No 
CGPLLU175 ERBB4 chr2_212288925-212288925_G_A HG19 941Q>X 3.64% 4502 164 Yes No 
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CGCRC332 ESR1 chr6_152129111-152129111_G_T HG19 22E>X 0.38% 1847 7 Not Assessed No 
CGPLLU145 ESR1 chr6_152332868-152332868_G_A HG19 392V>I 0.37% 5112 19 Not Assessed No 
CGPLBR102 ESR1 chr6_152415658-152415658_G_A HG19 503R>Q 0.17% 6547 11 Not Assessed No 
CGCRC307 FBXW7 chr4_153249385-153249385_G_A HG19 465R>C 0.31% 6399 20 Yes Yes 
CGCRC315 FBXW7 chr4_153247289-153247289_G_A HG19 505R>C 0.25% 5691 14 Yes Yes 
CGCRC295 FBXW7 chr4_153259012-153259013_AT_ HG19 M268Dfs*18 0.50% 3377 17 No No 
CGCRC295 FBXW7 chr4_153251985-153251989_CTTTT_ HG19 R339Sfs*22 2.09% 4249 89 Yes No 
CGPLLU68 FGFR2 chr10_123269525-123269525_A_T HG18 299S>R 0.12% 5905 7 Not Assessed No 
CGCRC305 GNA11 chr19_3118954-3118954_G_A HG19 213R>Q 0.11% 7025 8 Yes No 
CGPLLU164 GNA11 chr19_3118919-3118919_C_T HG19 606-3C>T 0.20% 4070 8 No No 
CGCRC307 GNAS chr20_57484420-57484420_C_T HG19 201R>C 0.24% 3271 8 Yes# Yes 
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CGPLBR104 GNAS chr20_57484420-57484420_C_T HG19 201R>C 0.13% 3200 4 Not Assessed Yes 
CGPLBR55 GNAS chr20_57484421-57484421_G_A HG19 201R>H 0.68% 3247 22 Yes Yes 
CGPLBR97 GNAS chr20_57484421-57484421_G_A HG19 201R>H 0.13% 2995 4 Yes Yes 
CGPLLU165 GNAS chr20_57484421-57484421_G_A HG19 201R>H 0.16% 3676 6 Yes Yes 
CGPLLU169 HNF1A chr12_121426820-121426820_C_T HG19 171R>X 0.13% 7587 10 Yes No 
CGPLOV14 HNF1A chr12_121431484-121431484_G_A HG19 230E>K 0.14% 6643 9 No No 
CGPLLU174 JAK2 chr9_5050695-5050695_G_T HG19 160D>Y 0.40% 2271 9 Yes No 
CGPLBR87 JAK2 chr9_5054591-5054591_C_T HG19 215R>X 0.35% 2270 8 No No 
CGCRC307 JAK2 chr9_5080662-5080662_C_G HG19 805L>V 0.56% 3419 19 No No 
CGPLOV6 JAK3 chr19_17808961-17808961_T_G HG18 588H>P 2.55% 510 13 Not Assessed No 
CGPLOV13 KIT chr4_55564516-55564516_G_A HG19 135R>H 0.35% 4886 17 Yes No 
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CGPLOV27 KIT chr4_55594262-55594262_T_A HG19 655N>K 0.18% 4360 8 Not Assessed No 
CGPLOV4 KIT chr4_55292273-55292273_A_G HG18 722M>V 1.39% 2945 41 Not Assessed No 
CGPLLU47 KIT chr4_55292809-55292809_G_C HG18 750R>T 0.70% 6376 42 Not Assessed No 
CGPLLU47 KIT chr4_55292809-55292809_G_C HG18 750R>T 0.56% 5187 29 Not Assessed No 
CGPLOV27 KIT chr4_55599332-55599332_G_T HG19 820D>Y 5.58% 4499 251 Not Assessed No 
CGPLLU204 KIT chr4_55604659-55604659_G_A HG19 956R>Q 0.26% 4533 12 No No 
CGCRC291 KRAS chr12_25398284-25398284_C_G HG19 12G>A 14.65% 4800 703 Yes Yes 
CGPLLU144 KRAS chr12_25398285-25398285_C_A HG19 12G>C 5.10% 4587 234 Yes Yes 
CGPLLU174 KRAS chr12_25398285-25398285_C_A HG19 12G>C 0.16% 3065 5 Yes Yes 
CGPLLU26 KRAS chr12_25289552-25289552_C_A HG18 12G>C 2.67% 675 18 Yes Yes 
CGCRC314 KRAS chr12_25398284-25398284_C_T HG19 12G>D 0.30% 2960 9 Yes Yes 
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CGCRC319 KRAS chr12_25398284-25398284_C_T HG19 12G>D 0.11% 3731 4 Yes Yes 
CGCRC338 KRAS chr12_25398284-25398284_C_T HG19 12G>D 27.03% 2379 643 Yes Yes 
CGPLLU4 KRAS chr12_25289551-25289551_C_T HG18 12G>D 0.22% 2267 5 Not Assessed Yes 
CGCRC313 KRAS chr12_25398285-25398285_C_T HG19 12G>S 0.17% 2950 5 Yes Yes 
CGCRC310 KRAS chr12_25398284-25398284_C_A HG19 12G>V 0.13% 4448 6 Yes Yes 
CGCRC336 KRAS chr12_25398284-25398284_C_A HG19 12G>V 42.87% 2442 1047 Yes Yes 
CGPLLU177 KRAS chr12_25398284-25398284_C_A HG19 12G>V 2.49% 3941 98 Yes Yes 
CGPLOV2 KRAS chr12_25289551-25289551_C_A HG18 12G>V 0.34% 2940 10 Yes Yes 
CGPLLU44 KRAS chr12_25289551-25289551_C_A HG18 12G>V 9.09% 3532 321 Not Assessed Yes 
CGPLLU44 KRAS chr12_25289551-25289551_C_A HG18 12G>V 15.00% 2027 300 Not Assessed Yes 
CGCRC339 KRAS chr12_25398281-25398281_C_T HG19 13G>D 1.94% 1908 37 Yes Yes 
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CGPLLU57 KRAS chr12_25289548-25289548_C_T HG18 13G>D 7.58% 1254 95 Not Assessed Yes 
CGPLLU57 KRAS chr12_25289548-25289548_C_T HG18 13G>D 8.67% 1903 165 Not Assessed Yes 
CGCRC292 KRAS chr12_25378561-25378561_G_A HG19 146A>V 1.41% 2757 39 No Yes 
CGCRC306 KRAS chr12_25380277-25380277_G_T HG19 61Q>K 7.30% 4232 309 Yes Yes 
CGCRC295 MAP2K1 chr15_66727455-66727455_G_T HG19 57K>N 2.26% 5529 125 Not Assessed No 
CGCRC309 MLH1 chr3_37089132-37089132__GGC HG19 618K>KA 0.89% 6423 57 No No 
CGCRC320 MLH1 chr3_37089132-37089132__GGC HG19 618K>KA 0.64% 5640 36 No No 
CGPLBR82 MYC chr8_128750755-128750755_C_T HG19 98R>W 0.12% 7262 9 Yes No 
CGPLLU208 MYC chr8_128750755-128750755_C_T HG19 98R>W 0.17% 5293 9 No No 
CGCRC315 NRAS chr1_115258747-115258747_C_T HG19 12G>D 0.27% 5246 14 Yes Yes 
CGCRC312 NRAS chr1_115256530-115256530_G_T HG19 61Q>K 0.47% 2354 11 Yes Yes 
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CGCRC295 PDGFRA chr4_55124988-55124988_C_T HG19 49+4C>T 0.45% 3805 17 No No 
CGPLLU170 PDGFRA chr4_55124988-55124988_C_T HG19 49+4C>T 0.31% 4769 15 Not Assessed No 
CGPLLU44 PDGFRA chr4_54835769-54835769_C_T HG18 553P>L 1.28% 4600 59 Not Assessed No 
CGPLLU44 PDGFRA chr4_54835769-54835769_C_T HG18 553P>L 1.00% 2934 31 Not Assessed No 
CGCRC342 PDGFRA chr4_55144601-55144601_G_T HG19 692S>I 0.25% 5704 14 Not Assessed No 
CGPLBR44 PDGFRA chr4_55153609-55153609_G_A HG19 859V>M 0.13% 6745 9 Yes No 
CGPLLU209 PDGFRA chr4_55155052-55155052_G_A HG19 921A>T 9.82% 5806 570 Yes No 
CGCRC339 PIK3CA chr3_178952085-178952085_A_T HG19 1047H>L 1.71% 2926 50 Yes Yes 
CGPLBR102 PIK3CA chr3_178952085-178952085_A_G HG19 1047H>R 0.25% 5274 13 Not Assessed Yes 
CGPLBR75 PIK3CA chr3_178952085-178952085_A_G HG19 1047H>R 0.14% 4869 7 Yes Yes 
CGPLBR76 PIK3CA chr3_178952085-178952085_A_G HG19 1047H>R 0.12% 7334 9 Yes Yes 
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CGCRC334 PIK3CA chr3_178916924-178916924_C_G HG19 104P>R 3.85% 2934 113 No No 
CGPLBR55 PIK3CA chr3_178921553-178921553_T_A HG19 345N>K 0.42% 2157 9 Yes Yes 
CGPLLU44 PIK3CA chr3_180399419-180399419_C_T HG18 38R>C 0.18% 5470 10 Not Assessed No 
CGPLLU44 PIK3CA chr3_180399419-180399419_C_T HG18 38R>C 0.26% 3412 9 Not Assessed No 
CGCRC339 PIK3CA chr3_178927457-178927457_G_T HG19 407C>F 3.14% 1813 57 Yes No 
CGCRC298 PIK3CA chr3_178927478-178927478_G_T HG19 414G>V 0.55% 3657 20 No No 
CGPLLU9 PIK3CA chr3_180399318-180399318_G_T HG18 4R>L 1.70% 2500 43 Not Assessed No 
CGPLLU9 PIK3CA chr3_180399318-180399318_G_T HG18 4R>L 0.48% 2904 14 Not Assessed No 
CGCRC291 PIK3CA chr3_178936082-178936082_G_A HG19 542E>K 18.11% 3938 713 Yes Yes 
CGPLBR41 PIK3CA chr3_178936082-178936082_G_A HG19 542E>K 0.32% 3143 10 Not Assessed Yes 
CGCRC306 PIK3CA chr3_178936092-178936092_A_C HG19 545E>A 0.96% 3122 30 No Yes 
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CGPLBR67 PIK3CA chr3_178936091-178936091_G_A HG19 545E>K 0.68% 3076 21 Yes Yes 
CGPLLU144 PIK3CA chr3_178936091-178936091_G_A HG19 545E>K 2.94% 3940 116 Yes Yes 
CGPLLU178 PIK3CA chr3_178947145-178947145_C_T HG19 861Q>X 0.17% 4012 7 No No 
CGCRC334 PIK3R1 chr5_67589576-67589593_AAAAAATTACATGAATAT_ HG19 446GKKLHEY>G 0.56% 1432 8 Yes No 
CGPLBR77 PTEN chr10_89711891-89711891_G_T HG19 170S>I 2.29% 3319 76 Yes No 
CGPLBR99 PTEN chr10_89653785-89653785__TT HG19 Y29Ffs*26 0.57% 2291 13 Not Assessed No 
CGPLLU47 RB1 chr13_47853511-47853511_G_C HG18 542L>F 2.50% 2752 68 Not Assessed No 
CGPLLU47 RB1 chr13_47853511-47853511_G_C HG18 542L>F 2.61% 2377 62 Not Assessed No 
CGPLLU180 RB1 chr13_48955578-48955578_C_G HG19 565S>X 1.01% 3163 32 Yes No 
CGPLLU146 RB1 chr13_48937095-48937095_T_C HG19 861+2T>C 0.87% 2868 25 Yes No 
CGPLOV3 SMAD4 chr18_46857030-46857030_C_T HG18 445R>X 9.88% 1528 151 Yes No 
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CGPLBR87 SMAD4 chr18_48604664-48604664_C_T HG19 496R>C 0.40% 4551 18 No No 
CGCRC291 SMAD4 chr18_48591806-48591807_GT_ HG19 C324Ffs*6 22.69% 7307 1658 Yes No 
CGCRC307 SMARCB1 chr22_24145480-24145480_A_G HG19 501-2A>G 0.34% 4728 16 Yes No 
CGPLLU180 SMARCB1 chr22_24159061-24159062_AT_ HG19 I245Rfs*35 2.39% 5697 136 Yes No 
CGPLLU164 STK11 chr19_1220629-1220629_C_A HG19 216S>Y 1.23% 3416 42 Yes No 
CGPLLU180 STK11 chr19_1220691-1220691_G_T HG19 237D>Y 2.43% 3377 82 Yes No 
CGPLLU26 STK11 chr19_1172998-1172998_C_T HG18 305Q>X 1.05% 569 6 Yes No 
CGCRC291 STK11 chr19_1207027-1207027_C_T HG19 39R>C 0.14% 5165 7 No No 
CGPLLU174 STK11 chr19_1220505-1220505_G_T HG19 597+1G>T 0.33% 3050 10 Yes No 
CGCRC337 STK11 chr19_1220718-1220718_T_A HG19 734+2T>A 0.12% 8482 10 No No 
CGPLLU177 STK11 chr19_1221266-1221266_G_ HG19 L263Ffs*24 3.22% 4414 142 Yes No 
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CGPLLU209 TP53 chr17_7579389-7579389_G_A HG19 100Q>X 9.97% 5258 524 Yes No 
CGCRC332 TP53 chr17_7579313-7579313_G_C HG19 125T>R 19.98% 936 187 Yes No 
CGPLLU206 TP53 chr17_7578538-7578538_T_C HG19 131N>S 0.21% 6283 13 No No 
CGPLBR99 TP53 chr17_7578535-7578537_TTG_ HG19 131NK>K 0.90% 4242 38 Yes No 
CGPLLU168 TP53 chr17.fa:7578524-7578524_G_A HG19 136Q>X 0.06% 15310 5 Yes Yes 
CGCRC302 TP53 chr17_7578508-7578508_C_T HG19 141C>Y 0.05% 11449 6 Yes Yes 
CGPLLU44 TP53 chr17.fa:7519233-7519233_C_T HG18 141C>Y 0.09% 4511 4 Not Assessed Yes 
CGPLLU19 TP53 chr17_7519228-7519228_C_T HG18 143V>M 0.12% 3288 4 No Yes 
CGPLLU14 TP53 chr17_7519186-7519186_C_A HG18 157V>F 1.50% 750 11 Not Assessed Yes 
CGPLLU14 TP53 chr17_7519186-7519186_C_A HG18 157V>F 0.51% 1366 7 Not Assessed Yes 
CGPLLU57 TP53 chr17_7519186-7519186_C_A HG18 157V>F 6.51% 1459 95 Not Assessed Yes 
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CGPLLU57 TP53 chr17_7519186-7519186_C_A HG18 157V>F 6.32% 2628 166 Not Assessed Yes 
CGPLLU9 TP53 chr17_7519186-7519186_C_A HG18 157V>F 1.70% 3932 68 Not Assessed Yes 
CGPLLU9 TP53 chr17_7519186-7519186_C_A HG18 157V>F 0.77% 6528 50 Not Assessed Yes 
CGPLLU67 TP53 chr17_7519182-7519182_C_A HG18 158R>L 0.19% 6943 13 Yes Yes 
CGPLLU164 TP53 chr17_7578450-7578450_C_A HG19 160M>I 1.86% 5638 105 Yes No 
CGPLLU164 TP53 chr17_7578449-7578449_C_A HG19 161A>S 1.78% 5734 102 Yes No 
CGPLLU44 TP53 chr17_7519174-7519174_C_T HG18 161A>T 3.65% 7556 276 Not Assessed Yes 
CGPLLU44 TP53 chr17_7519174-7519174_C_T HG18 161A>T 5.00% 4627 229 Not Assessed Yes 
CGPLLU198 TP53 chr17_7578445-7578445_A_T HG19 162I>N 0.87% 5268 46 Yes No 
CGCRC291 TP53 chr17_7578431-7578431_G_A HG19 167Q>X 22.85% 9599 2193 Yes Yes 
CGCRC303 TP53 chr17_7578413-7578413_C_A HG19 173V>L 0.08% 6324 5 Yes Yes 
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CGCRC336 TP53 chr17_7578406-7578406_C_T HG19 175R>H 75.26% 7220 5434 Yes Yes 
CGPLLU166 TP53 chr17_7578406-7578406_C_T HG19 175R>H 0.42% 10271 43 Yes Yes 
CGCRC293 TP53 chr17_7578404-7578404_A_T HG19 176C>S 0.35% 4244 15 No No 
CGPLLU180 TP53 chr17.fa:7578400-7578400_G_A HG19 177P>L 0.08% 8874 4 No Yes 
CGPLLU175 TP53 chr17_7578394-7578394_T_C HG19 179H>R 8.03% 6349 510 Yes Yes 
CGPLBR102 TP53 chr17_7578395-7578395_G_A HG19 179H>Y 0.16% 5606 9 Not Assessed Yes 
CGPLOV22 TP53 chr17_7578271-7578271_T_G HG19 193H>P 0.49% 5675 28 Yes No 
CGPLOV20 TP53 chr17_7578265-7578265_A_G HG19 195I>T 0.21% 3352 7 Yes Yes 
CGCRC306 TP53 chr17_7578263-7578263_G_A HG19 196R>X 0.12% 4933 6 No Yes 
CGCRC340 TP53 chr17_7578263-7578263_G_A HG19 196R>X 18.26% 1813 331 Yes Yes 
CGPLLU147 TP53 chr17_7578247-7578247_A_T HG19 201L>X 0.55% 2930 16 Yes No 
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CGPLBR96 TP53 chr17.fa:7578212-7578212_G_A HG19 213R>X 0.10% 9808 4 No Yes 
CGPLLU1 TP53 chr17_7518937-7518937_G_A HG18 213R>X 0.29% 4145 12 Yes Yes 
CGPLOV3 TP53 chr17_7518937-7518937_G_A HG18 213R>X 4.18% 1961 82 Yes Yes 
CGPLLU29 TP53 chr17_7518928-7518928_C_T HG18 216V>M 0.30% 3039 9 Not Assessed Yes 
CGPLLU9 TP53 chr17_7518900-7518920_ACCTCAGGCGGCTCATAGGGC_ HG18 219PYEPPE>- 0.90% 3842 34 
Not 
Assessed No 
CGPLLU9 TP53 chr17_7518900-7518920_ACCTCAGGCGGCTCATAGGGC_ HG18 219PYEPPE>- 0.18% 5669 10 
Not 
Assessed No 
CGCRC317 TP53 chr17_7578190-7578190_T_C HG19 220Y>C 0.36% 6753 24 Yes Yes 
CGPLLU144 TP53 chr17_7577559-7577559_G_A HG19 241S>F 1.95% 5590 109 Yes Yes 
CGPLBR38 TP53 chr17_7577560-7577560_A_G HG19 241S>P 0.53% 4505 24 Yes No 
CGPLLU19 TP53 chr17_7518282-7518282_A_G HG18 242C>R 0.53% 2656 14 Yes No 
CGPLLU44 TP53 chr17_7518282-7518282_A_G HG18 242C>R 0.14% 5584 8 Not Assessed No 
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CGPLLU26 TP53 chr17_7518276-7518276_C_A HG18 244G>C 0.59% 847 5 Yes Yes 
CGCRC316 TP53 chr17_7577548-7577548_C_T HG19 245G>S 6.52% 7665 500 Yes Yes 
CGCRC334 TP53 chr17_7577548-7577548_C_T HG19 245G>S 13.44% 3006 404 Yes Yes 
CGPLLU14 TP53 chr17_7518264-7518264_G_C HG18 248R>G 1.60% 683 11 Not Assessed No 
CGPLLU14 TP53 chr17_7518264-7518264_G_C HG18 248R>G 0.56% 1070 6 Not Assessed No 
CGPLLU147 TP53 chr17_7577538-7577538_C_T HG19 248R>Q 0.15% 2644 4 No Yes 
CGPLOV11 TP53 chr17_7577538-7577538_C_T HG19 248R>Q 0.87% 4580 40 Yes Yes 
CGPLOV17 TP53 chr17_7577538-7577538_C_T HG19 248R>Q 0.32% 2772 9 Yes Yes 
CGPLLU44 TP53 chr17_7518261-7518261_T_C HG18 249R>G 0.12% 6072 7 Not Assessed Yes 
CGPLLU208 TP53 chr17_7577532-7577532_G_A HG19 250P>L 1.33% 4668 62 Yes Yes 
CGCRC294 TP53 chr17_7577525-7577527_GAG_ HG19 252L>- 0.17% 5973 10 Yes No 
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CGPLBR92 TP53 chr17_7577511-7577511_A_G HG19 257L>P 0.20% 5486 11 Yes No 
CGPLBR61 TP53 chr17_7577129-7577129_A_C HG19 270F>C 0.44% 4573 20 Not Assessed No 
CGCRC291 TP53 chr17_7577124-7577124_C_T HG19 272V>M 0.10% 5985 6 No Yes 
CGCRC319 TP53 chr17_7577124-7577124_C_T HG19 272V>M 0.07% 7496 5 No Yes 
CGPLOV2 TP53 chr17_7517846-7517846_G_A HG18 273R>C 0.14% 4371 6 Yes Yes 
CGCRC305 TP53 chr17_7577120-7577120_C_T HG19 273R>H 0.19% 6265 12 No Yes 
CGPLBR71 TP53 chr17_7577120-7577120_C_T HG19 273R>H 0.10% 4834 5 Yes Yes 
CGPLOV19 TP53 chr17_7577120-7577120_C_T HG19 273R>H 36.83% 5430 2000 Yes Yes 
CGPLLU135 TP53 chr17_7517845-7517845_C_A HG18 273R>L 0.23% 3976 9 Yes Yes 
CGPLOV21 TP53 chr17_7577114-7577114_C_T HG19 275C>Y 2.04% 9798 200 Yes No 
CGPLLU164 TP53 chr17_7577106-7577106_G_A HG19 278P>S 0.10% 4788 5 No Yes 
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CGPLOV15 TP53 chr17_7577106-7577106_G_A HG19 278P>S 3.54% 4629 164 Yes Yes 
CGPLLU146 TP53 chr17_7577093-7577093_C_G HG19 282R>P 1.30% 5379 70 Yes No 
CGPLLU180 TP53 chr17_7577093-7577093_C_G HG19 282R>P 1.94% 4546 88 Yes No 
CGPLLU180 TP53 chr17_7577060-7577060_C_A HG19 293G>V 2.07% 4981 103 Yes No 
CGPLOV10 TP53 chr17_7574003-7574003_G_A HG19 342R>X 3.14% 2962 93 Yes Yes 
CGPLLU47 TP53 chr17.fa:7514728-7514728_G_A HG18 342R>X 0.08% 5246 4 Not Assessed Yes 
CGPLLU207 TP53 chr17_7578555-7578555_C_T HG19 376-1G>A 0.32% 5858 19 Yes Yes 
CGPLLU47 TP53 chr17_7519011-7519019_AGACCTAAG_ HG18 560-5_563delCTTAGGTCT 16.10% 4690 755 
Not 
Assessed No 
CGPLLU47 TP53 chr17_7519011-7519019_AGACCTAAG_ HG18 560-5_563delCTTAGGTCT 18.87% 3392 640 
Not 
Assessed No 
CGPLLU206 TP53 chr17_7578176-7578176_C_T HG19 672+1G>A 26.13% 6457 1687 Yes Yes 
CGCRC333 TP53 chr17_7577610-7577610_T_C HG19 673-2A>G 43.03% 2805 1207 Yes No 
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CGPLOV23 TP53 chr17_7577498-7577498_C_A HG19 782+1G>T 1.39% 4523 63 Not Assessed No 
CGPLOV16 TP53 chr17_7579316-7579317_CA_ HG19 C124Hfs*24 1.12% 2668 30 Yes No 
CGCRC337 TP53 chr17_7578376-7578379_CTAT_ HG19 D184Afs*62 57.84% 8975 5191 Yes No 
CGPLOV37 TP53 chr17_7578394-7578394_T_C HG19 179H>R 0.29% 7173 21 Not Assessed Yes 
CGPLOV38 PTEN chr10_89624261-89624261_A_T HG19 12N>I 3.78% 3093 117 Not Assessed No 
CGPLOV38 TP53 chr17_7577539-7577539_G_A HG19 248R>W 4.89% 4434 217 Not Assessed Yes 
CGPLOV40 APC chr5_112179623-112179623_G_T HG19 2778A>S 6.73% 8066 543 Not Assessed No 
CGPLOV40 NRAS chr1_115256536-115256536_C_T HG19 59A>T 0.29% 3798 11 Not Assessed No 
CGPLOV40 TP53 chr17_7578406-7578406_C_T HG19 175R>H 0.63% 9964 63 Not Assessed Yes 
CGPLOV41 TP53 chr17_7578406-7578406_C_T HG19 175R>H 0.60% 4364 26 Not Assessed Yes 
CGPLOV42 TP53 chr17_7578263-7578263_G_A HG19 196R>X 1.24% 6793 84 Not Assessed Yes 
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CGPLOV44 TP53 chr17_7577022-7577022_G_A HG19 306R>X 0.37% 4646 17 Not Assessed Yes 
CGPLOV47 ERBB4 chr2_212251595-212251595_C_T HG19 1155R>Q 3.20% 4467 143 Not Assessed No 
CGPLOV48 RB1 chr13_48951174-48951174_A_G HG19 1332+4A>G 10.70% 1934 207 Not Assessed No 
CGPLOV48 TP53 chr17_7577120-7577120_C_T HG19 273R>H 0.13% 3089 4 Not Assessed Yes 
CGPLOV49 TP53 chr17_7577120-7577120_C_T HG19 273R>H 0.17% 4146 7 Not Assessed Yes 
CGPLOV49 TP53 chr17_7577547-7577547_C_A HG19 245G>V 2.03% 4184 85 Not Assessed Yes 
CGPLOV40 PTPN11 chr12.fa:112888199-112888199_C_T HG19 72A>V 0.06% 7095 4 Not Assessed Yes 
 
*"Hotspot" indicates an alteration occurring at the same nucleotide position in at least 20 other cancer cases in COSMIC.  The matching COSMIC cases are indicated in the column 
labelled "Reported samples with the identical somatic mutation" (for HG19) and "Reported somatic mutations in the same amino acid residue" (for HG18). 
#"Alteration Detected in Tumor" indicates mutations that were confirmed in the matching tumor sample of each case.  For sample CGCRC307 the corresponding GNAS mutation was not 






Table 3.12. Summary of colorectal cancer patient outcomes. 












Overall Survival  
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(ng/ml) Smoking status 
CGCRC291 IV 22.85% 1 21.10 1 25.87 2.10 Non-smoker 
CGCRC292 IV 1.41% 0 32.07 0 32.07 8.90 Non-smoker 
CGCRC293 IV 0.35% 0 2.67 0 2.67 23.00 Non-smoker 
CGCRC294 II 0.17% 0 31.37 0 31.37 2.90 Non-smoker 
CGCRC295 IV 2.26% 1 7.43 1 19.00 No Data Non-smoker 
CGCRC296 II 0.00% 0 31.00 0 31.00 3.50 Former-smoker 
CGCRC297 III 0.00% 0 30.83 0 30.83 2.70 Former-smoker 
CGCRC298 II 0.55% 0 30.80 0 30.80 3.40 Non-smoker 
CGCRC299 I 0.00% 0 30.43 0 30.43 4.80 Non-smoker 
CGCRC300 I 0.00% 0 30.40 0 30.40 3.50 Non-smoker 
CGCRC301 I 0.21% 0 30.37 0 30.37 No Data Current-smoker 
CGCRC302 II 0.12% 0 9.53 0 9.53 2.50 Former-smoker 
CGCRC303 III 0.08% 0 30.13 0 30.13 19.00 Non-smoker 
CGCRC304 II 0.27% 1 22.73 1 28.90 2.40 Former-smoker 
CGCRC305 II 0.19% 0 29.20 0 29.20 1.80 Non-smoker 
CGCRC306 II 8.02% 1 11.43 1 11.57 39.00 Non-smoker 
CGCRC307 II 0.56% 1 24.17 0 24.17 37.00 Non-smoker 
CGCRC308 III 0.11% 0 28.80 0 28.80 116.00 Current-smoker 
CGCRC309 III 3.00% 1 7.03 1 7.67 1.90 Non-smoker 
CGCRC310 II 0.15% 0 28.57 0 28.57 3.80 Former-smoker 
CGCRC311 I 0.00% 0 28.43 0 28.43 1.00 Non-smoker 
CGCRC312 III 0.59% 0 28.27 0 28.27 2.60 Current-smoker 
CGCRC313 III 0.17% 0 28.00 0 28.00 18.00 Former-smoker 
CGCRC314 I 0.38% 0 27.63 0 27.63 4.00 Former-smoker 
CGCRC315 III 0.27% 0 27.63 0 27.63 1.50 Non-smoker 
CGCRC316 III 6.52% 0 27.17 0 27.17 8.40 Non-smoker 
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CGCRC317 III 0.36% 0 27.17 0 27.17 6.40 Non-smoker 
CGCRC318 I 0.00% 0 26.93 0 26.93 1.90 Non-smoker 
CGCRC319 III 0.11% 0 26.83 0 26.83 5.30 Non-smoker 
CGCRC320 I 0.64% 0 26.90 0 26.90 3.10 Former-smoker 










EARLY NONINVASIVE PREDICTION OF RESPONSE TO TARGETED THERAPY 






Patient and sample characteristics 
 
Sixteen patients with metastatic non-small cell lung cancer undergoing treatment with a TKI at 
UCSD or Johns Hopkins Hospital were included in our study.  Clinical and pathological 
characteristics for all patients are summarized in Tables 4.1, 4.2, 4.3, and 4.4, study design is 
shown in Figure 4.1 and tumor load dynamics are shown in Figures 4.2, 4.3 and 4.4.  Patient 
enrollment and genomic studies were conducted in accordance with the Declaration of Helsinki, 
were approved by the Institutional Review Board (IRB) and patients provided written informed 
consent for sample acquisition for research purposes. 
Four patients were initially diagnosed with stage II or III disease and treated with chemotherapy 
followed by EGFR inhibition upon disease progression.  Two patients were diagnosed at stage IV 
and treated with chemotherapy prior to EGFR inhibition. Six patients were diagnosed at stage IV 
and treated directly with first-line EGFR inhibition.  These 12 patients progressed on first or 
second line EGFR inhibition and were subsequently treated with osimertinib dosed at 80mg PO 
daily (Tables 4.1, 4.2 and 4.3).  The remaining four patients were diagnosed at stage IV and 
treated with afatinib. 
The response evaluation criteria in solid tumors (RECIST) version 1.1 were used for assessment 
of response. Of the sixteen patients analyzed, ten achieved a partial response to osimertinib or 
afatinib while one patient exhibited stable disease after treatment with osimertinib and one patient 
had unmeasurable disease after treatment with afatinib.  Out of these twelve patients, seven 
eventually experienced disease progression while three continue to derive clinical benefit from 
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targeted inhibition, one has stable disease and one had unmeasureable disease as of last follow-
up.  Four patients were considered non-responders and did not exhibit radiographic response by 
RECIST 1.1 (Tables 4.1, 4.2 and 4.3).   
For all patients, serial blood draws were collected over the course of treatment with targeted 
inhibition for isolation of plasma and extraction of cfDNA for genomic analyses.  Time-points 
were analyzed prior to treatment as well as post treatment and are reported in Supplementary 
Table 4.4.   
 
Sample preparation and next-generation sequencing of cfDNA 
 
Whole blood was collected in K2 EDTA tubes or Streck tubes and processed immediately or 
within 2 hours after storage at 4°C to separate plasma and cellular components by centrifugation 
at 3000 g for 10 minutes at 4°C.  Plasma was centrifuged a second time at 18,000 g at room 
temperature to remove any remaining cellular debris and stored at -80°C until the time of DNA 
extraction.  DNA was isolated from plasma using the Qiagen Circulating Nucleic Acids Kit 
(Qiagen GmbH, Hilden DE) and eluted in LoBind tubes (Eppendorf AG, Hamburg, DE).  
Concentration and quality of cfDNA was assessed using the Bioanalyzer 2100 (Agilent 
Technologies, Santa Clara, CA).   
TEC-Seq next-generation sequencing cell-free DNA libraries were prepared from 11 to 350 ng of 
cfDNA.  Genomic libraries were prepared as previously described (26).  Briefly, the NEBNext 
DNA Library Prep Kit for Illumina (New England Biolabs, Ipswich, MA) was used with four 
main modifications to the manufacturer’s guidelines: 1) The library purification steps utilized the 
on-bead Ampure XP approach, 2) reagent volumes were adjusted accordingly to accommodate 
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the on-bead strategy, 3) a pool of 8 unique Illumina dual index adapters with 8 bp barcodes were 
used in the ligation reaction, and 4) cfDNA libraries were amplified with Hotstart Phusion 
Polymerase.  Details of genomic library preparation conditions are provided here6.  
Concentration and quality of cfDNA genomic libraries were assessed using the Bioanalyzer 2100 
(Agilent Technologies, Santa Clara, CA).   
Targeted capture was performed using the Agilent SureSelect reagents and a custom set of 
hybridization probes targeting 58 genes (Table 4.5) per the manufacturer’s guidelines. The 
captured library was amplified with HotStart Phusion Polymerase (New England Biolabs). The 
concentration and quality of captured cfDNA libraries was assessed on the Bioanalyzer 2100 
using the DNA 1000 Kit (Agilent Technologies, Santa Clara, CA).  TEC-seq libraries were 
sequenced using 100 bp paired end runs on the Illumina HiSeq 2000/2500 (Illumina, San Diego, 
CA). 
 
Primary processing of next-generation sequencing data and identification of putative 
somatic mutations 
 
Primary processing of next-generation sequence data for cfDNA samples was performed as 
previously described (26) using Illumina CASAVA software (v1.8), including demultiplexing and 
masking of dual index adapter sequences. Sequence reads were aligned against the human 
reference genome (hg19) using Novoalign with additional realignment of select regions using the 
Needleman-Wunsch method (37).   
Next, candidate somatic mutations, consisting of point mutations, small insertions, and deletions 
were identified using VariantDx23 across the targeted regions of interest. VariantDx examined 
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sequence alignments of cfDNA plasma samples while applying filters to exclude alignment and 
sequencing artifacts as previously described (26). Specifically, an alignment filter was applied to 
exclude quality failed reads, unpaired reads, and poorly mapped reads in the plasma. A base 
quality filter was applied to limit inclusion of bases with reported phred quality score > 30. 
Criteria for calling alterations in cfDNA have been previously described (26).  Briefly, an 
alteration was considered a candidate somatic mutation only when: (i) Three distinct paired reads 
contained the mutation in the plasma and the number of distinct paired reads containing a 
particular mutation in the plasma was at least 0.1% of the total distinct read pairs; or (ii) Four 
distinct paired reads contained the mutation in the plasma and the number of distinct paired reads 
containing a particular mutation in the plasma was at least 0.05% and less than 0.1% of the total 
distinct read pairs; (iii) the mismatched base was not present in >1% of the reads in a panel of 
unmatched normal samples as well as not present in a custom database of common germline 
variants derived from dbSNP; (iv) the altered base did not arise from misplaced genome 
alignments including paralogous sequences; and (v) the mutation fell within a protein coding 
region and was classified as a missense, nonsense, frameshift, or splice site alteration. 
As previously described (26), candidate alterations were defined as somatic hotspots if the 
nucleotide change and amino acid change were identical to an alteration observed in ≥ 20 cancer 
cases reported in the COSMIC database.  Alterations that were not hotspots were retained only if 
either (i) seven or more distinct paired reads contained the mutation in the plasma and the number 
of distinct paired reads containing a particular mutation in the plasma was at least 0.1% and less 
than 0.2%, of the total distinct read pairs, or (ii) six or more distinct paired reads contained the 
mutation in the plasma and the number of distinct paired reads containing a particular mutation in 
the plasma was at least 0.2% of the total distinct read pairs.  In order to track clonal changes over 
time, any alteration identified in at least one blood draw was followed in the remaining serial 
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timepoints regardless of whether mutant allele fractions fit the criteria defined to call a single 
hotspot or non-hotspot mutation.   
Candidate mutations were further limited as previously described (26).  Briefly, common 
germline variants were identified and removed if present in ≥ 25% of reads or < 25% of reads if 
the variant was recurrent and the majority of alterations at that position had a mutant allele 
fraction ≥ 25%.  Variants known to be at a somatic hotspot position, or producing a truncating 
mutation in a tumor suppressor gene were not excluded as germline changes.  Because of the high 
frequency of mutations in specific genes and the possible confounding between somatic and 
germline changes, we limited analyses in the APC gene to frameshift or nonsense mutations, and 
in KRAS, HRAS and NRAS to positions to 12, 13, 61, and 146.  Finally, we excluded 
hematopoietic expansion related variants that have been previously described (39, 41, 50-52), 
including those in DNMT3A, IDH1, and IDH2 and specific alterations within ATM, GNAS, 
JAK2, or TP53 (Tables 4.5 and 4.6). 
Sequence alterations identified at each timepoint for each patient are reported in Supplementary 
Table 4.7.  At each timepoint, cfTL was assessed as the mutant allele fraction of the most 









As a proof of concept, we evaluated cell-free DNA (cfDNA) from sixteen patients with late-stage 
non-small cell lung cancer, treated with either afatinib or osimertinib.  For each patient, ~5 ml of 
plasma were collected prior to therapy, at 6-22 days after therapy initiation, and at additional 
timepoints until disease progression was confirmed by radiographic assessment (Tables 4.1, 4.2 
and 4.3). Target lesions were evaluated before therapy with CT/MRI scans and approximately 
every six weeks until disease progression. Based on response assessment by RECIST 1.1 of the 
initial scans, eight of sixteen patients experienced partial response, one stable disease, four 
progressive disease, and one who had unmeasurable disease due to bone-only metastases (Tables 
4.1, 4.2 and 4.3). The patient with stable disease achieved a partial response on later scans.   
To analyze changes in cfDNA in these patients and capture the clonal heterogeneity of metastatic 
disease, we used an ultrasensitive approach called targeted error correction sequencing (TEC-
Seq) to evaluate 58 well-known cancer driver genes (Figure 4.1 and Tables 4.5, 4.7, and 4.8) (26).  
This method is based on targeted capture of multiple regions of the genome and deep sequencing 
(>30,000x) of DNA fragments to provide a high degree of specificity across 80,930 bp of coding 
gene regions and enable identification of tumor-specific alterations while distinguishing these 
from amplification and sequencing artifacts, germline changes, or alterations related to blood cell 
proliferation that may be present in cfDNA (26).   
We evaluated ctDNA in all patients at baseline and 6-22 days after the initiation of therapy.  In 
the blood draws that were analyzed, we detected alterations in 14 of 16 cases.  At the baseline 
timepoint, patients had an average of 3.6 tumor-specific somatic mutations, affecting 14 driver 
genes, ranging from one to 14 alterations per case (Table 4.7). At least one targetable mutation in 
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either EGFR or ERBB2 was detected in each case analyzed, with levels of ctDNA ranging from 
mutant allele fractions of 0.10% to 53.71% (Table 4.7). Eight out of fourteen patients had EGFR 
T790M resistance mutations in the circulation at baseline with ctDNA amounts ranging from 
mutant allele fractions of 0.17% to 10.09% (Table 4.7).  Previously described alterations in genes 
involved in blood cell proliferation (39, 41, 50-52) were observed in ten patients across all 
timepoints analyzed, and were removed from further analyses (Table 4.6).   
Based on the alterations observed in cfDNA, we developed a new metric, termed cell-free tumor 
load (cfTL), defined as the mutant allele fraction in ctDNA of the most abundant alteration 
identified among the 80,930 bp analyzed at any particular timepoint (Figure 4.1 and Table 4.7).   
This approach has the benefit of providing a comprehensive assessment of tumor-derived 
alterations that would represent overall tumor burden during the course of disease and selective 
pressure of therapeutic interventions.  All patients with a radiographic response to targeted 
therapy displayed a rapid suppression of cfTL at 6-22 days after initiation of therapy.  Figure 4.2 
A depicts a representative patient with metastatic disease (CGPLLU12) who had a rapid decline 
of cfTL from baseline to day 10. This patient exhibited a progression-free survival of 7.0 months 
on osimertinib therapy, then subsequently developed resistance in the primary lung lesion.  All 
ten patients with a radiographic response or stable disease had a dramatic reduction in ctDNA 
levels (Figures 4.2 and 4.4).  In these patients, cfTL levels ranged from an average mutant allele 
fraction of 10.80% at baseline to 0.20%, or >95% reduction in cfTL levels at 6-22 days after 
treatment (Table 4.7) (P = 0.016, Wilcoxon test).  In contrast, all four patients that were 
radiographic non-responders to targeted therapy experienced limited reduction or increases in 
cfTL ranging from an average of 6.38% at baseline to 5.70% at 6-22 days after treatment, 
resulting in a range of 72% reduction to 101% increase in cfTL levels (Figures 4.3 and 4.4) (P = 
0.25, Wilcoxon test).   
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In addition to changes in cfTL, the number of observed alterations also decreased in responders 
from 4.0 to 1.2 mutations per patient (P = 0.010, paired t test), while non-responders had no 
change in the number of mutations observed during therapy (2.5 mutations per patient both before 
and after therapy).  We also observed that all non-responders had at least one mutation with a 
lower mutant allele fraction, presumably representing tumor subclones, that increased after 
therapy, while only two of the ten responding patients had such subclonal increases (Figure 4.4). 
These observations suggest that both ctDNA levels and clonal heterogeneity are dramatically 
reduced at early timepoints in responding patients due to therapeutic selective pressure, and in 
non-responding patients the emergence of tumor subclones can be detected earlier than clinical 
progression. 
For a subset of patients, we evaluated multiple follow-up blood draws at extremely early 
timepoints in therapy.  An immediate timepoint at 4-12 hours after the initiation of treatment was 
available for four patients who experienced a partial radiographic response on the first or second 
scan (CGPLLU12, CGPLLU14, CGPLLU86, CGPLLU99), one clinical responder with non-
measurable disease (CGLU315), and one patient with progressive disease (CGLU294).  In these 
early timepoints after drug administration, we detected a rapid increase in the levels of ctDNA in 
eight mutations in three patients compared to baseline (cfTL increase of 86%) (Figure 4.1 and 
Table 4.7).  In five of the six patients for whom immediate timepoints were evaluated, increasing 
ctDNA levels allowed for the identification of seven tumor-derived alterations not previously 
detected at baseline including the targetable EGFR 746ELREATS>D clone in patient 
CGPLLU86 detected at a mutant allele fraction of 0.19%.  Mutant allele fractions of the newly 
detected clones ranged from 0.16% to 1.70% with an average of 0.63% indicating that these 
alterations were likely below the technical limit of detection at baseline and rose above the 
threshold of sensitivity only due to the increase in ctDNA levels.  This dramatic increase is 
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consistent with studies showing BIM-mediated apoptosis in responsive tumors within 48 hours 
after exposure to EGFR inhibitors (53, 54).  Interestingly, non-responder CGLU294 exhibited an 
increase in ctDNA levels from baseline to four hours post treatment indicating that the patient 
may have had some early response to treatment, however ctDNA clones remained high at 7 days 
post treatment indicating lack of response over time.  Patient CGPLLU99 experienced a sustained 
partial response to osimertinib yet a blood draw taken 8 hours after treatment did not reveal an 
increase in ctDNA levels compared to any clones identified at baseline.  Based on the durability 
of this patient’s response, the half-life of cfDNA in the blood, and the kinetics of osimertinib drug 
activity we hypothesize that this patient may have exhibited a rapid efflux of ctDNA in response 
to treatment much earlier than 8 hours post therapy, perhaps on the order of 2-4 hours. 
For responders CGPLLU86, CGPLLU89, and CGPLLU99 analyses after 6-22 days showed 
reduction of ctDNA levels for several weeks after initiation of therapy (Figure 4.4).  Patients 
CGPLLU12 and CGPLLU88, who were treated with osimertinib and experienced partial response 
at first radiographic assessment, exhibited a rise in the 745KELREA>T EGFR activating clone in 
subsequent timepoints, while the T790M clone remained controlled and was either undetectable 
or at low levels (Figure 4.1 A and Figure 4.4).  In contrast, non-responders continued to show a 
rise in ctDNA levels at later timepoints after initiation of therapy, and in all cases these levels 
were above those observed at baseline (Figure 4.1 B and Figure 4.4). 
We evaluated whether the dynamic cfTL changes observed at early timepoints after treatment 
initiation were associated with differences in clinical outcome.  cfTL levels at day 6-22 were 
bimodal (Figures 4.5 and 4.6), with the lower group clustering at an average percent reduction in 
cfTL of 99.44% and the higher group having an average percent increase in cfTL of 25.16% 
(Figure 4.5).  We defined molecular responders as those with reduction in cfTL levels within 
three standard deviations of the lower group average reduction (greater than 96.3%) while non-
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responders were above this threshold.  Four of  seven patients who developed a complete ctDNA 
response (cfTL reduction of 100%) at day 6-22 experienced a progression-free survival longer 
than one year while the remaining three patients continue to respond, but have not yet reached 
one year of follow-up (Figures 4.5 and 4.6).  One of the complete molecular responders assessed 
for cfTL reduction at day 7 and 17 post treatment (CGPLLU86) was classified as having 
radiographic stable disease with tumor reduction of 15.4% at 38 days post-treatment, but had 
incremental serial responses with a maximal reduction of 46% by the ninth CT scan, and a 
progression-free survival of 12.4 months (Figures 4.5 and 4.6).  Similarly, another complete 
molecular responder assessed at day 20 post treatment was classified as radiographically non-
measurable yet has a favorable clinical response and remains on treatment as of last follow-up.  
Overall, we observed a significantly longer median progression-free survival for molecular 
responders at day 6-22 compared to molecular non-responders (12.0 months vs. 1.5 months, P = 
0.0001, Figure 4.7).  Importantly, cfTL reduction at day 6-22 was a more accurate predictor of 














Figure 4.1. Schematic of cfTL determination and prediction of therapeutic response. 
Patients were analyzed using TEC-Seq liquid biopsy approach at baseline and at day 6-10 after 
treatment initiation. Cell-free DNA is extracted from blood, captured using probes covering 
80,930 bases, and sequenced to ~30,000x coverage.  Sequences are analyzed to identify tumor-
derived alterations and to distinguish these from hematopoietic and germline changes.  cfTL is 
determined as the highest concentration of ctDNA alterations at any time point.  cfTL levels  
distinguish molecular responders from non-responders and predict clinical response and outcome 
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Figure 4.5. Dynamic changes in ctDNA and progression-free survival.  cfTL levels at day 6-10 after osimertinib initiation (blue bars) along 
with corresponding progression-free survival based on imaging (orange bars).  RECIST 1.1 responses at initial image assessment (5-7 weeks) are 
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Figure 4.6.  Dynamic changes in ctDNA and molecular classification of patients.  cfTL levels at baseline and at day 6-10 indicate a bimodal 































Figure 4.7.  ctDNA and prediction of patient outcome.  Time to detection of response for CT scans based on RECIST 1.1 responses at week 5-7 
(P = 0.0054, Log-rank test, top left panel) and ctDNA (P = 0.0006, Log-rank test, top right panel).  Median time to detection of response using CT 
scans and ctDNA is indicated in the bottom panel (P < 0.0001, Wilcoxon test). 







 95% cfTL reduction
< 95% cfTL reduction








































































 Table 4.1.  Clinical characteristics of lung cancer patients analyzed at diagnosis. 
Patient 
Demographics  Data at Diagnosis 















CGPLLU12 67 F Never NA  Adenocarcinoma IV NA LUL NA NA Brain, spine, adrenal 
CGPLLU14 55 F Never NA  Adenocarcinoma IIA T1N1M0 RLL RLL Moderate NA 
CGPLLU18 50 F Never NA  Adenocarcinoma IIA T2N1M0 LLL LLL Moderate NA 
CGPLLU82 54 M Never NA  Adenocarcinoma IV NA RLL NA NA Brain 
CGPLLU86 55 M Never NA  Adenocarcinoma IV NA LUL NA NA Lung 
CGPLLU88 59 M Former NA  Adenocarcinoma IIA NA RML RML NA NA 
CGPLLU89 54 F Former NA  Adenocarcinoma IV NA RUL NA NA Brain, bone, lung 
CGPLLU97 57 F Never NA  Adenocarcinoma IV T3N0M1A RLL NA Poor Pleura 
CGPLLU99 53 M Never NA  Adenocarcinoma IIIA NA LUL LUL,RLL NA Lung, bone 
CGPLLU244 66 F Never NA  Adenocarcinoma IV NA RUL Liver 
Moderate to 
poor 




CGPLLU245 49 M Never NA  Adenocarcinoma IV T2aN2M1B LUL LUL NA Brain 
CGPLLU246 65 F Never NA  Adenocarcinoma IV NA RLL NA Poor Pleura 
CGLU294 51 M Never NA  Adenocarcinoma IV T1N2M1 LLL NA NA 
Lung, lymph node, 
bone 
CGLU315 54 M Never NA  Adenocarcinoma IV TXN0M1 
RLL, 
extensive NA Poor Lung, bone, adrenal 
CGLU319 74 F Never NA  Adenocarcinoma IV T2N1M1a RLL NA Well 
Lung, Hilar Lymph 
Node, Pleural Effusion 
CGLU324 60 F Former 23  Adenocarcinoma IV T4N3M1b RUL NA NA 
Lung, Brain, Bone, 
Thoracic Lymph 












   Table 4.2.  Clinical characteristics of lung cancer patients analyzed during prior treatment. 
Patient 
Prior Treatment 
Chemotherapy Radiation Targeted Inhibitor 
CGPLLU12 None Radiation Erlotinib 
CGPLLU14 Chemotherapy Radiation (brain) Erlotinib 
CGPLLU18 Chemotherapy Radiation (brain) Erlotinib 
CGPLLU82 None Radiation Erlotinib 
CGPLLU86 None None Erlotinib 
CGPLLU88 Chemotherapy None Erlotinib 
CGPLLU89 None Radiation (brain) Afatinib 
CGPLLU97 Chemotherapy Radiation Erlotinib 
CGPLLU99 Chemotherapy None Erlotinib 
CGPLLU244 None Radiation PF-06747775 
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CGPLLU245 Chemotherapy Radiation PF-06747775 
CGPLLU246 None Radiation (brain) PF-06747775 
CGLU294 None None None 
CGLU315 None None None 
CGLU319 None None None 






































CGPLLU12 Osimertinib 55 -40.0 Partial Response 167 431 Progressive disease Deceased 
Adrenal, liver, renal, 
spine 
CGPLLU14 Osimertinib 35 -33.3 Partial Response 459 713 Progressive disease Deceased Brain, sacrum 
CGPLLU18 Osimertinib 37 -57.5 Partial Response NA 104 Continued response Deceased 
Brain, liver, kidney, 
adrenal, bone 
CGPLLU82 Osimertinib 39 -65.2 Partial Response 934 993 Progressive disease  Liver 
CGPLLU86 Osimertinib 38 -15.4 Stable Disease 372 986 Progressive disease Alive 
Clivus, liver, other 
bone 
CGPLLU88 Osimertinib 35 -40.7 Partial Response 421 548 Progressive disease Deceased 
Lung, adrenal, bone, 
pleura 
CGPLLU89 Osimertinib 37 -41.2 Partial Response 206 427 Progressive disease Deceased 
Brain, lung, liver, 
bone 
CGPLLU97 Osimertinib 91 -35.2 Partial Response 192 413 Progressive disease  
Brain, lung, liver, 
bone 
CGPLLU99 Osimertinib 49 -53.3 Partial Response NA Ongoing Continued response Alive Lung, bone 
CGPLLU244 Osimertinib 37 39.3 Progressive Disease 37 90 
Progressive 
disease Deceased 




CGPLLU245 Osimertinib 52 20.8 Progressive Disease 52 134 
Progressive 
disease Alive Bone, liver,  pleura 
CGPLLU246 Osimertinib 38 33.3 Progressive Disease 38 59 
Progressive 
disease Deceased Bone, lung, brain 
CGLU294 Afatinib 56 57.0 Progressive Disease 56 57 
Progressive 
disease Alive 
PD in lung, LN and 
new bone 
CGLU315 Afatinib 18* NA Non-measurable* NA Ongoing 
Non-
measurable Alive 
Lung improving, bone 
stable, no remaining 
adrenal mass 
CGLU319 Afatinib  -28.0 Partial response NA Ongoing 
Continued 
response Alive Same as baseline 











   Table 4.4.  Serial timepoints analyzed. 











CGPLLU12 CGPLLU12P_6 Pre Osimertinib -150.0 5.00 350.30 350.30 
CGPLLU12 CGPLLU12P_22 Pre Osimertinib 0.0 7.00 1254.20 250.00 
CGPLLU12 CGPLLU12P_18 Post Osimertinib 0.2 6.80 559.60 250.00 
CGPLLU12 CGPLLU12P_20 Post Osimertinib 10.0 6.00 324.30 250.00 
CGPLLU12 CGPLLU12P_34 Post Osimertinib 227.0 5.00 191.00 191.00 
CGPLLU14 CGPLLU14P_8 Pre Osimertinib -38.0 4.20 59.50 59.50 
CGPLLU14 CGPLLU14P_12 Pre Osimertinib -16.0 4.20 47.00 47.00 
CGPLLU14 CGPLLU14P_15 Pre Osimertinib -3.0 5.00 72.00 72.00 
CGPLLU14 CGPLLU14P_21 Pre Osimertinib 0.0 5.00 16.82 16.82 
CGPLLU14 CGPLLU14P_19 Post Osimertinib 0.3 4.60 121.60 121.60 
CGPLLU14 CGPLLU14P_23 Post Osimertinib 7.0 3.20 19.26 19.26 
CGPLLU18 CGPLLU18P_4 Pre Osimertinib -1.0 5.00 2196.70 250.00 
CGPLLU18 CGPLLU18P_15 Post Osimertinib 6.0 6.00 446.30 250.00 
CGPLLU18 CGPLLU18P_11 Post Osimertinib 20.0 3.00 24.00 24.00 
CGPLLU244 CGPLLU244P_1 Pre Osimertinib -7.0 4.50 80.26 80.26 
CGPLLU244 CGPLLU244P_2 Pre Osimertinib -1.0 4.10 132.44 125.00 
CGPLLU244 CGPLLU244P_3 Post Osimertinib 6.0 4.70 255.79 125.00 
CGPLLU244 CGPLLU244P_4 Post Osimertinib 62.0 2.90 74.95 74.95 
CGPLLU245 CGPLLU245P_1 Pre Osimertinib -32.0 4.70 91.28 91.28 
CGPLLU245 CGPLLU245P_2 Pre Osimertinib 0.0 4.30 468.58 125.00 
CGPLLU245 CGPLLU245P_3 Post Osimertinib 7.0 3.00 314.40 125.00 
CGPLLU245 CGPLLU245P_4 Post Osimertinib 21.0 3.30 161.49 125.00 
CGPLLU246 CGPLLU246P_1 Pre Osimertinib -21.0 5.50 101.78 101.78 
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CGPLLU246 CGPLLU246P_2 Pre Osimertinib 0.0 5.00 118.00 118.00 
CGPLLU246 CGPLLU246P_4 Post Osimertinib 9.0 3.30 43.48 43.48 
CGPLLU246 CGPLLU246P_5 Post Osimertinib 42.0 3.40 46.51 46.51 
CGPLLU82 CGPLLU82P Post Osimertinib 0.1 4.70 18.05 18.05 
CGPLLU82 CGPLLU82P_1 Post Osimertinib 0.3 4.50 24.69 24.69 
CGPLLU82 CGPLLU82P_7 Post Osimertinib 251.0 4.70 41.17 41.17 
CGPLLU86 CGPLLU86P_6 Pre Osimertinib 0.0 4.00 31.60 31.60 
CGPLLU86 CGPLLU86P_1 Post Osimertinib 0.5 4.00 14.50 14.50 
CGPLLU86 CGPLLU86P_8 Post Osimertinib 7.0 4.60 14.50 14.50 
CGPLLU86 CGPLLU86P_9 Post Osimertinib 17.0 5.00 19.90 19.90 
CGPLLU88 CGPLLU88P_2 Pre Osimertinib 0.0 5.00 138.31 138.31 
CGPLLU88 CGPLLU88P Post Osimertinib 7.0 5.00 32.43 32.43 
CGPLLU88 CGPLLU88P_5 Post Osimertinib 297.0 4.00 12.16 12.16 
CGPLLU89 CGPLLU89P Pre Osimertinib 0.0 8.00 67.40 67.40 
CGPLLU89 CGPLLU89P_2 Post Osimertinib 7.0 6.50 40.60 40.60 
CGPLLU89 CGPLLU89P_5 Post Osimertinib 22.0 6.00 17.90 17.90 
CGPLLU97 CGPLLU97P_11 Pre Osimertinib 0.0 6.50 26.10 26.10 
CGPLLU97 CGPLLU97P_4 Post Osimertinib 7.0 6.40 22.23 22.23 
CGPLLU97 CGPLLU97P_20 Post Osimertinib 273.0 6.00 27.54 27.54 
CGPLLU99 CGPLLU99P_8 Pre Osimertinib 0.0 6.00 50.60 50.60 
CGPLLU99 CGPLLU99P_10 Post Osimertinib 0.3 5.00 45.99 45.99 
CGPLLU99 CGPLLU99P_12 Post Osimertinib 9.0 5.00 24.99 24.99 
CGPLLU99 CGPLLU99P_11 Post Osimertinib 21.0 4.00 18.76 18.76 
CGLU294 CGLU294P_1 Pre Afatinib 0.0 5.00 17.36 17.36 
CGLU294 CGLU294P1_1 Post Afatinib 0.2 5.00 15.52 15.52 
CGLU294 CGLU294P2_1 Post Afatinib 3.0 5.00 16.59 16.59 
CGLU294 CGLU294P3_2 Post Afatinib 7.0 5.00 10.73 10.73 
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CGLU294 CGLU294P4_1 Post Afatinib 29.0 5.00 12.22 12.22 
CGLU315 CGLU315P_1 Pre Afatinib 0.0 5.00 25.96 25.96 
CGLU315 CGLU315P1_1 Post Afatinib 0.2 5.00 22.48 22.48 
CGLU315 CGLU315P2_1 Post Afatinib 20.0 5.00 22.62 22.62 
CGLU319 CGLU319P_1 Pre Afatinib 0.0 5.00 53.14 53.14 
CGLU319 CGLU319P1_1 Post Afatinib 14.0 5.00 48.26 48.26 
CGLU324 CGLU324P_1 Post Afatinib 1.0 5.00 32.96 32.96 















  Table 4.5.  Genes analyzed. 
 
Gene Region Analyzed Gene Category* 
ABL1 Specific Exons Cancer Driver Gene 
AKT1 Specific Exons Cancer Driver Gene 
ALK Full Coding Region Cancer Driver Gene 
APC Specific Exons Cancer Driver Gene 
AR Full Coding Region Cancer Driver Gene 
ATM Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
BRAF Full Coding Region Cancer Driver Gene 
CDH1 Specific Exons Cancer Driver Gene 
CDK4 Full Coding Region Cancer Driver Gene 
CDK6 Full Coding Region Cancer Driver Gene 
CDKN2A Specific Exons Cancer Driver Gene 
CSF1R Specific Exons Cancer Driver Gene 
CTNNB1 Specific Exons Cancer Driver Gene 
DNMT3A Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
EGFR Full Coding Region Cancer Driver Gene 
ERBB2 Specific Exons Cancer Driver Gene 
ERBB4 Full Coding Region Cancer Driver Gene 
ESR1 Full Coding Region Cancer Driver Gene 
EZH2 Specific Exons Cancer Driver Gene 
FBXW7 Specific Exons Cancer Driver Gene 
FGFR1 Specific Exons Cancer Driver Gene 
FGFR2 Specific Exons Cancer Driver Gene 
FGFR3 Specific Exons Cancer Driver Gene 
FLT3 Specific Exons Cancer Driver Gene 
GNA11 Specific Exons Cancer Driver Gene 
GNAQ Specific Exons Cancer Driver Gene 
GNAS Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
HNF1A Specific Exons Cancer Driver Gene 
HRAS Full Coding Region Cancer Driver Gene 
IDH1 Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
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IDH2 Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
JAK2 Full Coding Region Cancer Driver and Clonal Hematopoiesis Gene 
JAK3 Specific Exons Cancer Driver Gene 
KDR Specific Exons Cancer Driver Gene 
KIT Full Coding Region Cancer Driver Gene 
KRAS Full Coding Region Cancer Driver Gene 
MAP2K1 Specific Exons Cancer Driver Gene 
MET Specific Exons Cancer Driver Gene 
MLH1 Specific Exons Cancer Driver Gene 
MPL Specific Exons Cancer Driver Gene 
MYC Specific Exons Cancer Driver Gene 
NPM1 Specific Exons Cancer Driver Gene 
NRAS Full Coding Region Cancer Driver Gene 
PDGFRA Full Coding Region Cancer Driver Gene 
PIK3CA Full Coding Region Cancer Driver Gene 
PIK3R1 Specific Exons Cancer Driver Gene 
PTEN Full Coding Region Cancer Driver Gene 
PTPN11 Specific Exons Cancer Driver Gene 
RB1 Specific Exons Cancer Driver Gene 
RET Specific Exons Cancer Driver Gene 
SMAD4 Specific Exons Cancer Driver Gene 
SMARCB1 Specific Exons Cancer Driver Gene 
SMO Specific Exons Cancer Driver Gene 
SRC Specific Exons Cancer Driver Gene 
STK11 Full Coding Region Cancer Driver Gene 
TERT Specific Exons Cancer Driver Gene 
TP53 Full Coding Region Cancer Driver Gene 
VHL Specific Exons Cancer Driver Gene 
* Analyzed genes inlcuded those that have been commonly implicated in cancer.  Specific genes (DNMT3A, IDH1, and IDH2) or certain 





Table 4.6.  Blood cell proliferation alterations detected in cfDNA. 




















CGPLLU12 CGPLLU12P_18 DNMT3A chr2_25467464-25467464_T_C 538T>A 0.17% 1.47 5740 10 No 
CGPLLU12 CGPLLU12P_34 DNMT3A chr2_25463508-25463508_C_T 2173+1G>A 0.23% 2.00 4329 10 No 
CGPLLU12 CGPLLU12P_6 DNMT3A chr2_25467464-25467464_T_C 538T>A 0.23% 1.20 2573 6 No 
CGPLLU12 CGPLLU12P_20 DNMT3A chr2_25467464-25467464_T_C 538T>A 0.25% 1.83 4323 11 No 
CGPLLU12 CGPLLU12P_34 DNMT3A chr2_25467464-25467464_T_C 538T>A 0.25% 2.40 4828 12 No 
CGPLLU12 CGPLLU12P_22 DNMT3A chr2_25467464-25467464_T_C 538T>A 0.28% 2.14 5282 15 No 
CGPLLU14 CGPLLU14P_19 DNMT3A chr2_25457173-25457173_A_C 905L>R 0.20% 1.74 4085 8 No 
CGPLLU14 CGPLLU14P_15 DNMT3A chr2_25457173-25457173_A_C 905L>R 0.22% 2.00 4454 10 No 
CGPLLU14 CGPLLU14P_12 DNMT3A chr2_25457173-25457173_A_C 905L>R 0.28% 1.90 2896 8 No 
CGPLLU18 CGPLLU18P_4 DNMT3A chr2_25463168-25463168_T_C 2322+3A>G 0.49% 3.60 3650 18 No 
CGPLLU18 CGPLLU18P_15 DNMT3A chr2_25463168-25463168_T_C 2322+3A>G 0.97% 6.33 3913 38 No 
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CGPLLU18 CGPLLU18P_11 DNMT3A chr2_25463168-25463168_T_C 2322+3A>G 1.70% 18.67 3295 56 No 
CGPLLU246 CGPLLU246P_4 DNMT3A chr2_25457243-25457243_G_A 882R>C 0.17% 2.73 5422 9 Yes 
CGPLLU246 CGPLLU246P_2 DNMT3A chr2_25463289-25463289_T_G 735Y>S 0.20% 1.60 3964 8 No 
CGPLLU246 CGPLLU246P_2 DNMT3A chr2_25457243-25457243_G_A 882R>C 0.23% 2.80 5984 14 Yes 
CGPLLU246 CGPLLU246P_1 DNMT3A chr2_25457243-25457243_G_A 882R>C 0.24% 2.91 6640 16 Yes 
CGPLLU246 CGPLLU246P_5 DNMT3A chr2_25463289-25463289_T_G 735Y>S 0.24% 3.24 4666 11 No 
CGPLLU246 CGPLLU246P_4 DNMT3A chr2_25463289-25463289_T_G 735Y>S 0.28% 3.64 4264 12 No 
CGPLLU246 CGPLLU246P_5 DNMT3A chr2_25457243-25457243_G_A 882R>C 0.32% 5.88 6282 20 Yes 
CGPLLU246 CGPLLU246P_1 DNMT3A chr2_25463289-25463289_T_G 735Y>S 0.34% 3.09 4939 17 No 
CGPLLU246 CGPLLU246P_1 DNMT3A chr2_25467468-25467468_G_C 536Y>X 1.25% 15.82 6946 87 No 
CGPLLU246 CGPLLU246P_2 DNMT3A chr2_25467468-25467468_G_C 536Y>X 1.37% 18.60 6783 93 No 
CGPLLU246 CGPLLU246P_4 DNMT3A chr2_25467468-25467468_G_C 536Y>X 1.46% 25.45 5749 84 No 
CGPLLU246 CGPLLU246P_5 DNMT3A chr2_25467468-25467468_G_C 536Y>X 1.65% 29.41 6068 100 No 
CGPLLU82 CGPLLU82P_7 DNMT3A chr2_25463288-25463288_G_C 735Y>X 0.21% 1.70 3897 8 No 
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CGPLLU86 CGPLLU86P_6 DNMT3A chr2_25463524-25463524_G_A 720R>C 0.32% 4.50 5575 18 No 
CGPLLU86 CGPLLU86P_9 DNMT3A chr2_25463524-25463524_G_A 720R>C 0.35% 2.00 2857 10 No 
CGPLLU86 CGPLLU86P_8 DNMT3A chr2_25463524-25463524_G_A 720R>C 0.42% 2.61 2888 12 No 
CGPLLU86 CGPLLU86P_1 DNMT3A chr2_25463524-25463524_G_A 720R>C 0.54% 4.00 2962 16 No 
CGPLLU88 CGPLLU88P_2 DNMT3A chr2_25457252-25457252_T_C 879N>D 0.19% 2.60 6691 13 No 
CGPLLU88 CGPLLU88P_2 DNMT3A chr2_25467408-25467408_C_T 1667+1G>A 1.31% 11.60 4440 58 No 
CGPLLU88 CGPLLU88P DNMT3A chr2_25467408-25467408_C_T 1667+1G>A 1.98% 10.60 2678 53 No 
CGPLLU88 CGPLLU88P_5 DNMT3A chr2_25467408-25467408_C_T 1667+1G>A 2.23% 10.50 1886 42 No 
CGPLLU14 CGPLLU14P_8 TP53 chr17_7578461-7578461_C_A 157V>F 1.06% 5.24 2080 22 Yes 
CGPLLU14 CGPLLU14P_8 EGFR chr7_55241707-55241707_G_A 719G>S 0.75% 3.81 2141 16 Yes 
CGPLLU14 CGPLLU14P_8 EGFR chr7_55249071-55249071_C_T 790T>M 0.45% 2.62 2456 11 Yes 
CGPLLU14 CGPLLU14P_8 EGFR chr7_55259524-55259524_T_A 861L>Q 0.89% 5.00 2357 21 Yes 
CGPLLU14 CGPLLU14P_12 TP53 chr17_7578461-7578461_C_A 157V>F 0.26% 1.90 3106 8 Yes 
CGPLLU14 CGPLLU14P_15 TP53 chr17_7578461-7578461_C_A 157V>F 0.46% 4.80 5178 24 Yes 
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CGPLLU14 CGPLLU14P_12 EGFR chr7_55241707-55241707_G_A 719G>S 0.15% 0.95 2722 4 Yes 
CGPLLU14 CGPLLU14P_12 EGFR chr7_55249071-55249071_C_T 790T>M 0.16% 1.19 3196 5 Yes 
CGPLLU14 CGPLLU14P_12 EGFR chr7_55259524-55259524_T_A 861L>Q 0.18% 1.19 2823 5 Yes 
CGPLLU14 CGPLLU14P_21 TP53 chr17_7578461-7578461_C_A 157V>F 0.77% 5.00 3254 25 Yes 
CGPLLU14 CGPLLU14P_19 TP53 chr17_7578461-7578461_C_A 157V>F 0.86% 9.13 4877 42 Yes 
CGPLLU14 CGPLLU14P_15 EGFR chr7_55241707-55241707_G_A 719G>S 0.49% 3.80 3888 19 Yes 
CGPLLU14 CGPLLU14P_15 EGFR chr7_55249071-55249071_C_T 790T>M 0.48% 4.80 5004 24 Yes 
CGPLLU14 CGPLLU14P_15 EGFR chr7_55259524-55259524_T_A 861L>Q 0.45% 3.80 4233 19 Yes 
CGPLLU14 CGPLLU14P_23 TP53 chr17_7578461-7578461_C_A 157V>F 0.77% 7.81 3254 25 Yes 
CGPLLU245 CGPLLU245P_2 TP53 chr17_7578191-7578191_A_T 220Y>N 0.10% 1.86 7725 8 No 
CGPLLU14 CGPLLU14P_21 EGFR chr7_55241707-55241707_G_A 719G>S 0.79% 4.40 2801 22 Yes 
CGPLLU14 CGPLLU14P_21 EGFR chr7_55249071-55249071_C_T 790T>M 0.98% 6.40 3281 32 Yes 
CGPLLU14 CGPLLU14P_21 EGFR chr7_55259524-55259524_T_A 861L>Q 1.39% 8.00 2876 40 Yes 
CGPLLU14 CGPLLU14P_8 TP53 chr17_7577539-7577539_G_C 248R>G 1.64% 7.38 1890 31 No 
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CGPLLU14 CGPLLU14P_12 TP53 chr17_7577539-7577539_G_C 248R>G 0.85% 5.24 2576 22 No 
CGPLLU14 CGPLLU14P_19 EGFR chr7_55241707-55241707_G_A 719G>S 1.05% 8.48 3697 39 Yes 
CGPLLU14 CGPLLU14P_19 EGFR chr7_55249071-55249071_C_T 790T>M 0.90% 9.35 4760 43 Yes 
CGPLLU14 CGPLLU14P_19 EGFR chr7_55259524-55259524_T_A 861L>Q 0.96% 9.13 4383 42 Yes 
CGPLLU14 CGPLLU14P_19 MYC chr8_128750755-128750755_C_T 98R>W 0.28% 2.39 3894 11 No 
CGPLLU14 CGPLLU14P_15 TP53 chr17_7577539-7577539_G_C 248R>G 0.60% 4.60 3834 23 No 
CGPLLU14 CGPLLU14P_21 TP53 chr17_7577539-7577539_G_C 248R>G 1.26% 6.40 2545 32 No 
CGPLLU14 CGPLLU14P_19 TP53 chr17_7577539-7577539_G_C 248R>G 0.65% 5.22 3679 24 No 
CGPLLU14 CGPLLU14P_23 TP53 chr17_7577539-7577539_G_C 248R>G 1.26% 10.00 2545 32 No 
CGPLLU14 CGPLLU14P_23 TP53 chr17_7577539-7577539_G_C 248R>G 0.68% 5.00 2349 16 No 
CGPLLU18 CGPLLU18P_4 TP53 chr17_7579376-7579376_T_ Q104Rfs*19 47.18% 279.40 2961 1397 No 
CGPLLU99 CGPLLU99P_8 EGFR chr7_55242466-55242466__GCATCTCC E746Afs*5 0.62% 6.33 6095 38 No 
CGPLLU99 CGPLLU99P_8 EGFR chr7_55242467-55242481_AATTAAGAGAAGCAA_ 746ELREA>- 19.65% 214.00 6533 1284 Yes 
CGPLLU99 CGPLLU99P_8 EGFR chr7_55249071-55249071_C_T 790T>M 7.24% 116.17 9626 697 Yes 
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CGPLLU18 CGPLLU18P_15 TP53 chr17_7579376-7579376_T_ Q104Rfs*19 0.24% 1.33 3270 8 No 
CGPLLU99 CGPLLU99P_10 EGFR chr7_55242466-55242466__GCATCTCC E746Afs*5 0.51% 6.40 6246 32 No 
CGPLLU99 CGPLLU99P_10 EGFR chr7_55242467-55242481_AATTAAGAGAAGCAA_ 746ELREA>- 15.67% 207.60 6626 1038 Yes 
CGPLLU99 CGPLLU99P_10 EGFR chr7_55249071-55249071_C_T 790T>M 5.76% 100.40 8714 502 Yes 
CGPLLU18 CGPLLU18P_11 TP53 chr17_7579376-7579376_T_ Q104Rfs*19 0.43% 4.33 3022 13 No 













Table 4.7.  Somatic alterations detected in cfDNA. 
Patient Patient Timepoint 
Days since 

















E770_A771insAYVM 0.02 4098 98 No 
CGLU294 CGLU294P_1 0 TP53 chr17_7578433-7578433_G_C S166* 0.01 3864 34 No 




E770_A771insAYVM 0.07 2410 169 No 
CGLU294 CGLU294P1_1 0.167 ERBB2 chr17_37880996-37880996__ATACG G776Yfs*17 0.00 2480 9 No 
CGLU294 CGLU294P1_1 0.167 TP53 chr17_7578433-7578433_G_C S166* 0.02 1909 46 No 




E770_A771insAYVM 0.04 1891 83 No 
CGLU294 CGLU294P2_1 3 TP53 chr17_7578433-7578433_G_C S166* 0.02 1543 26 No 
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E770_A771insAYVM 0.05 2227 107 No 
CGLU294 CGLU294P3_2 7 TP53 chr17_7578433-7578433_G_C S166* 0.02 1782 38 No 




E770_A771insAYVM 0.02 490 8 No 
CGLU315 CGLU315P_1 0 EGFR chr7_55259524-55259524_T_A L861Q 0.03 413 12 Yes 
CGLU315 CGLU315P1_1 0.167 CTNNB1 chr3_41266136-41266136_T_C S45P 0.01 1417 19 Yes 
CGLU315 CGLU315P1_1 0.167 EGFR chr7_55259524-55259524_T_A L861Q 0.02 1592 31 Yes 
CGLU315 CGLU315P1_1 0.167 TP53 chr17_7577120-7577120_C_T R273H 0.02 1232 21 Yes 




E746_A750del 0.00  3 Yes 
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E746_A750del 0.00 1325 5 Yes 
CGLU324 CGLU324P_1 1 STK11 chr19_1223121-1223121_T_A L353H 0.01 1137 6 No 




745KELREA>T 0.10 2705 276 Yes 
CGPLLU12 CGPLLU12P_6 -150 EGFR chr7_55249071-55249071_C_T 790T>M 0.05 3182 160 Yes 
CGPLLU12 CGPLLU12P_6 -150 TP53 chr17_7577509-7577509_C_T 258E>K 0.04 1928 73 No 




745KELREA>T 0.20 5141 1038 Yes 
CGPLLU12 CGPLLU12P_22 0 EGFR chr7_55249071-55249071_C_T 790T>M 0.08 7649 619 Yes 
CGPLLU12 CGPLLU12P_22 0 RB1 chr13_49033896-49033896__ATAT I680Yfs*13 0.00 4183 10 No 
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CGPLLU12 CGPLLU12P_22 0 STK11 chr19_1219357-1219357_C_T 137Q>X 0.01 1326 13 No 
CGPLLU12 CGPLLU12P_22 0 TP53 chr17_7577509-7577509_C_T 258E>K 0.10 3356 348 No 




745->KTSP 0.00 5498 9 No 




745KELREA>T 0.22 5712 1231 Yes 
CGPLLU12 CGPLLU12P_18 0.17 EGFR chr7_55249071-55249071_C_T 790T>M 0.09 8897 834 Yes 
CGPLLU12 CGPLLU12P_18 0.17 ERBB4 chr2_212488652-212488652_A_T 733Y>N 0.00 3438 13 No 
CGPLLU12 CGPLLU12P_18 0.17 RB1 chr13_49033896-49033896__ATAT I680Yfs*13 0.01 4480 33 No 
CGPLLU12 CGPLLU12P_18 0.17 STK11 chr19_1219357-1219357_C_T 137Q>X 0.01 1410 21 No 
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CGPLLU12 CGPLLU12P_18 0.17 TP53 chr17_7577509-7577509_C_T 258E>K 0.11 3768 412 No 




745KELREA>T 0.00 4095 7 Yes 
CGPLLU12 CGPLLU12P_20 10 TP53 chr17_7577509-7577509_C_T 258E>K 0.00 3688 6 No 




745KELREA>T 0.07 4189 297 Yes 
CGPLLU12 CGPLLU12P_34 227 TP53 chr17_7577509-7577509_C_T 258E>K 0.03 3802 132 No 
CGPLLU14 CGPLLU14P_8 -38 EGFR chr7_55241707-55241707_G_A 719G>S 0.01 2141 16 Yes 
CGPLLU14 CGPLLU14P_8 -38 EGFR chr7_55249071-55249071_C_T 790T>M 0.00 2456 11 Yes 
CGPLLU14 CGPLLU14P_8 -38 EGFR chr7_55259524-55259524_T_A 861L>Q 0.01 2357 21 Yes 
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CGPLLU14 CGPLLU14P_12 -16 EGFR chr7_55241707-55241707_G_A 719G>S 0.00 2722 4 Yes 
CGPLLU14 CGPLLU14P_12 -16 EGFR chr7_55249071-55249071_C_T 790T>M 0.00 3196 5 Yes 
CGPLLU14 CGPLLU14P_12 -16 EGFR chr7_55259524-55259524_T_A 861L>Q 0.00 2823 5 Yes 
CGPLLU14 CGPLLU14P_15 -3 EGFR chr7_55241707-55241707_G_A 719G>S 0.00 3888 19 Yes 
CGPLLU14 CGPLLU14P_15 -3 EGFR chr7_55249071-55249071_C_T 790T>M 0.00 5004 24 Yes 
CGPLLU14 CGPLLU14P_15 -3 EGFR chr7_55259524-55259524_T_A 861L>Q 0.00 4233 19 Yes 
CGPLLU14 CGPLLU14P_21 0 EGFR chr7_55241707-55241707_G_A 719G>S 0.01 2801 22 Yes 
CGPLLU14 CGPLLU14P_21 0 EGFR chr7_55249071-55249071_C_T 790T>M 0.01 3281 32 Yes 
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CGPLLU14 CGPLLU14P_21 0 EGFR chr7_55259524-55259524_T_A 861L>Q 0.01 2876 40 Yes 
CGPLLU14 CGPLLU14P_19 0.33 EGFR chr7_55241707-55241707_G_A 719G>S 0.01 3697 39 Yes 
CGPLLU14 CGPLLU14P_19 0.33 EGFR chr7_55249071-55249071_C_T 790T>M 0.01 4760 43 Yes 
CGPLLU14 CGPLLU14P_19 0.33 EGFR chr7_55259524-55259524_T_A 861L>Q 0.01 4383 42 Yes 
CGPLLU14 CGPLLU14P_19 0.33 MYC chr8_128750755-128750755_C_T 98R>W 0.00 3894 11 No 
CGPLLU18 CGPLLU18P_4 -1 ABL1 chr9_133750433-133750433_G_A 422V>I 0.00 4028 7 No 
CGPLLU18 CGPLLU18P_4 -1 BRAF chr7_140534480-140534480_C_A 145A>S 0.00 3949 8 No 
CGPLLU18 CGPLLU18P_4 -1 CDKN2A chr9_21974792-21974792_G_A 12S>L 0.01 2478 13 No 
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CGPLLU18 CGPLLU18P_4 -1 CTNNB1 chr3_41266181-41266181_T_A 60S>T 0.00 3251 12 No 
CGPLLU18 CGPLLU18P_4 -1 EGFR chr7_55249071-55249071_C_T 790T>M 0.10 17897 1806 Yes 
CGPLLU18 CGPLLU18P_4 -1 EGFR chr7_55259515-55259515_T_G 858L>R 0.54 14755 7925 Yes 
CGPLLU18 CGPLLU18P_4 -1 ERBB2 chr17_37881150-37881150_A_G 827M>V 0.00 5137 14 No 
CGPLLU18 CGPLLU18P_4 -1 ERBB4 chr2_212537909-212537909_G_T 566L>I 0.00 3892 10 No 
CGPLLU18 CGPLLU18P_4 -1 ESR1 chr6_152129177-152129177_C_A 44L>M 0.01 4528 34 No 
CGPLLU18 CGPLLU18P_4 -1 ESR1 chr6_152129230-152129230_G_C 61E>D 0.00 3624 13 No 
CGPLLU18 CGPLLU18P_4 -1 MYC chr8_128750983-128750983_A_G 174S>G 0.00 4935 7 No 
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CGPLLU18 CGPLLU18P_4 -1 MYC chr8_128750607-128750607_G_C 48Q>H 0.00 3939 14 No 
CGPLLU18 CGPLLU18P_4 -1 MYC chr8_128750755-128750755_C_T 98R>W 0.00 4728 7 No 
CGPLLU18 CGPLLU18P_4 -1 PDGFRA chr4_55127322-55127322_A_G 37K>R 0.00 4030 8 No 
CGPLLU18 CGPLLU18P_15 6 AR chrX_66765080-66765080_G_T 31R>L 0.00 3995 7 No 
CGPLLU18 CGPLLU18P_15 6 EGFR chr7_55249071-55249071_C_T 790T>M 0.00 6660 17 Yes 
CGPLLU18 CGPLLU18P_15 6 EGFR chr7_55259515-55259515_T_G 858L>R 0.01 5625 73 Yes 
CGPLLU18 CGPLLU18P_11 20 AR chrX_66765080-66765080_G_T 31R>L 0.00 3554 6 No 
CGPLLU18 CGPLLU18P_11 20 CDKN2A chr9_21974792-21974792_G_A 12S>L 0.00 2592 4 No 
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CGPLLU18 CGPLLU18P_11 20 EGFR chr7_55249071-55249071_C_T 790T>M 0.01 4423 28 Yes 
CGPLLU18 CGPLLU18P_11 20 EGFR chr7_55259515-55259515_T_G 858L>R 0.0168 4101 69 Yes 
CGPLLU244 CGPLLU244P_1 -7 EGFR chr7_55210075-55210075_T_G 62L>R 0.0448 5898 264 No 
CGPLLU244 CGPLLU244P_1 -7 EGFR chr7_55259515-55259515_T_G 858L>R 0.0413 6681 276 Yes 
CGPLLU244 CGPLLU244P_1 -7 TP53 chr17_7578530-7578530_A_G 134F>L 0.0498 7524 375 No 
CGPLLU244 CGPLLU244P_2 -1 EGFR chr7_55210075-55210075_T_G 62L>R 0.0341 5746 196 No 
CGPLLU244 CGPLLU244P_2 -1 EGFR chr7_55259515-55259515_T_G 858L>R 0.0284 7348 209 Yes 
CGPLLU244 CGPLLU244P_2 -1 TP53 chr17_7578530-7578530_A_G 134F>L 0.0283 8797 249 No 
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CGPLLU244 CGPLLU244P_3 6 EGFR chr7_55210075-55210075_T_G 62L>R 0.0514 6240 321 No 
CGPLLU244 CGPLLU244P_3 6 EGFR chr7_55259515-55259515_T_G 858L>R 0.0557 7526 419 Yes 
CGPLLU244 CGPLLU244P_3 6 TP53 chr17_7578530-7578530_A_G 134F>L 0.0476 8721 415 No 
CGPLLU244 CGPLLU244P_4 62 EGFR chr7_55210075-55210075_T_G 62L>R 0.1098 6602 725 No 
CGPLLU244 CGPLLU244P_4 62 EGFR chr7_55259515-55259515_T_G 858L>R 0.118 7043 831 Yes 
CGPLLU244 CGPLLU244P_4 62 TP53 chr17_7578530-7578530_A_G 134F>L 0.1123 8098 909 No 




745KELREA>K 0.106 5869 622 Yes 
CGPLLU245 CGPLLU245P_1 -32 EGFR chr7_55249071-55249071_C_T 790T>M 0.0556 9722 541 Yes 
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CGPLLU245 CGPLLU245P_1 -32 PDGFRA chr4_55133574-55133574_G_A 293R>H 0.0044 6374 28 No 




745KELREA>K 0.141 8086 1140 Yes 
CGPLLU245 CGPLLU245P_2 0 EGFR chr7_55249071-55249071_C_T 790T>M 0.0676 14582 986 Yes 
CGPLLU245 CGPLLU245P_2 0 PDGFRA chr4_55133574-55133574_G_A 293R>H 0.0092 8550 79 No 




745KELREA>K 0.0856 6892 590 Yes 
CGPLLU245 CGPLLU245P_3 7 EGFR chr7_55249071-55249071_C_T 790T>M 0.0407 11765 479 Yes 
CGPLLU245 CGPLLU245P_3 7 PDGFRA chr4_55133574-55133574_G_A 293R>H 0.006 7673 46 No 




745KELREA>K 0.1069 7287 779 Yes 
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CGPLLU245 CGPLLU245P_4 21 EGFR chr7_55249071-55249071_C_T 790T>M 0.0459 13165 604 Yes 
CGPLLU245 CGPLLU245P_4 21 PDGFRA chr4_55133574-55133574_G_A 293R>H 0.01 8020 80 No 
CGPLLU246 CGPLLU246P_1 -21 EGFR chr7_55249071-55249071_C_T 790T>M 0.0049 7780 38 Yes 
CGPLLU246 CGPLLU246P_1 -21 EGFR chr7_55259515-55259515_T_G 858L>R 0.0048 5826 28 Yes 
CGPLLU246 CGPLLU246P_1 -21 MAP2K1 chr15_66727483-66727483_G_A 67D>N 0.0018 7080 13 No 
CGPLLU246 CGPLLU246P_2 0 EGFR chr7_55249071-55249071_C_T 790T>M 0.0606 8612 522 Yes 
CGPLLU246 CGPLLU246P_2 0 EGFR chr7_55259515-55259515_T_G 858L>R 0.0617 5933 366 Yes 




P34Sfs*4 0.0248 2181 54 No 
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CGPLLU246 CGPLLU246P_4 9 EGFR chr7_55249071-55249071_C_T 790T>M 0.0131 6170 81 Yes 
CGPLLU246 CGPLLU246P_4 9 EGFR chr7_55259515-55259515_T_G 858L>R 0.0172 5051 87 Yes 




P34Sfs*4 0.002 2461 5 No 
CGPLLU246 CGPLLU246P_5 42 EGFR chr7_55249071-55249071_C_T 790T>M 0.043 7229 311 Yes 
CGPLLU246 CGPLLU246P_5 42 EGFR chr7_55259515-55259515_T_G 858L>R 0.0529 5932 314 Yes 
CGPLLU246 CGPLLU246P_5 42 MAP2K1 chr15_66727483-66727483_G_A 67D>N 0.0011 6149 7 No 




P34Sfs*4 0.0187 2669 50 No 




746ELREATS>D 0.0019 2626 5 Yes 
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CGPLLU88 CGPLLU88P_2 0 CTNNB1 chr3_41266098-41266098_A_T 32D>V 0.1217 5474 666 Yes 




745KELREA>T 0.0906 6447 584 Yes 
CGPLLU88 CGPLLU88P_2 0 EGFR chr7_55249071-55249071_C_T 790T>M 0.0865 10829 937 Yes 
CGPLLU88 CGPLLU88P_2 0 MYC chr8_128750603-128750603_A_T 47Y>F 0.0011 6119 7 No 
CGPLLU88 CGPLLU88P_2 0 PIK3CA chr3_178937483-178937483_C_G 624T>R 0.0257 3188 82 No 
CGPLLU88 CGPLLU88P 7 CTNNB1 chr3_41266098-41266098_A_T 32D>V 0.0022 3623 8 Yes 




745KELREA>T 0.0011 3568 4 Yes 
CGPLLU88 CGPLLU88P 7 EGFR chr7_55249071-55249071_C_T 790T>M 0.0015 4095 6 Yes 
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CGPLLU88 CGPLLU88P 7 FGFR2 chr10_123279522-123279522_C_T 304D>N 0.0024 3746 9 No 
CGPLLU88 CGPLLU88P_5 297 CTNNB1 chr3_41266098-41266098_A_T 32D>V 0.0242 2229 54 Yes 




745KELREA>T 0.0093 2155 20 Yes 
CGPLLU88 CGPLLU88P_5 297 EGFR chr7_55249071-55249071_C_T 790T>M 0.0013 2394 3 Yes 
CGPLLU89 CGPLLU89P 0 CTNNB1 chr3_41266098-41266098_A_G 32D>G 0.0027 5556 15 Yes 




747LREATS>- 0.0042 5434 23 Yes 
CGPLLU89 CGPLLU89P 0 EGFR chr7_55249071-55249071_C_T 790T>M 0.0017 6320 11 Yes 







0.0036 5598 20 No 
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CGPLLU89 CGPLLU89P_2 7 CTNNB1 chr3_41266098-41266098_A_G 32D>G 0.0028 3595 10 Yes 




747LREATS>- 0.002 3540 7 Yes 
CGPLLU89 CGPLLU89P_2 7 EGFR chr7_55249071-55249071_C_T 790T>M 0.0019 3715 7 Yes 
CGPLLU89 CGPLLU89P_5 22 CTNNB1 chr3_41266098-41266098_A_G 32D>G 0.0021 1870 4 Yes 







0.0026 1929 5 No 




746ELREA>- 0.1965 6533 1284 No 
CGPLLU99 CGPLLU99P_8 0 EGFR chr7_55249071-55249071_C_T 790T>M 0.0724 9626 697 Yes 




E746Afs*5 0.0062 6095 38 No 
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CGPLLU99 CGPLLU99P_8 0 TP53 chr17_7577022-7577022_G_A 306R>X 0.1969 5003 985 Yes 




746ELREA>- 0.1567 6626 1038 No 
CGPLLU99 CGPLLU99P_10 0.33 EGFR chr7_55249071-55249071_C_T 790T>M 0.0576 8714 502 Yes 




E746Afs*5 0.0051 6246 32 No 










 Table 4.8.  Summary of lung cancer dynamics genomic analyses. 



















CGPLLU12 CGPLLU12P_18 TEC-Seq 100 80,930 7,900,133,500 3,863,298,051 49% 45,929 8,508 
CGPLLU12 CGPLLU12P_20 TEC-Seq 100 80,930 7,756,705,100 3,517,430,064 45% 40,943 5,816 
CGPLLU12 CGPLLU12P_22 TEC-Seq 100 80,930 8,057,252,300 3,802,086,289 47% 45,136 7,805 
CGPLLU12 CGPLLU12P_34 TEC-Seq 100 80,930 8,777,269,900 4,524,962,642 52% 52,841 5,766 
CGPLLU12 CGPLLU12P_6 TEC-Seq 100 80,930 7,201,712,800 3,608,246,175 50% 44,081 2,867 
CGPLLU14 CGPLLU14P_12 TEC-Seq 100 80,930 8,668,655,700 3,980,731,089 46% 48,628 3,148 
CGPLLU14 CGPLLU14P_15 TEC-Seq 100 80,930 8,271,043,600 4,105,092,738 50% 50,152 4,497 
CGPLLU14 CGPLLU14P_19 TEC-Seq 100 80,930 7,149,809,200 3,405,754,720 48% 40,382 6,170 
CGPLLU14 CGPLLU14P_21 TEC-Seq 100 80,930 6,556,332,200 3,289,504,484 50% 39,004 4,081 
CGPLLU14 CGPLLU14P_23 TEC-Seq 100 80,930 7,410,378,300 3,464,236,558 47% 41,108 4,259 
CGPLLU14 CGPLLU14P_8 TEC-Seq 100 80,930 7,530,190,700 3,752,054,349 50% 45,839 2,469 
CGPLLU18 CGPLLU18P_11 TEC-Seq 100 80,930 8,873,158,100 4,118,821,432 46% 48,136 5,160 
CGPLLU18 CGPLLU18P_15 TEC-Seq 100 80,930 6,258,355,400 3,199,373,401 51% 37,270 7,926 
CGPLLU18 CGPLLU18P_4 TEC-Seq 100 80,930 9,997,401,400 4,940,336,941 49% 57,994 6,805 
CGPLLU244 CGPLLU244P_1 TEC-Seq 100 80,930 8,305,560,600 4,182,616,104 50% 50,851 7,569 
CGPLLU244 CGPLLU244P_2 TEC-Seq 100 80,930 7,739,951,100 3,788,487,116 49% 45,925 8,552 
CGPLLU244 CGPLLU244P_3 TEC-Seq 100 80,930 8,061,928,000 4,225,322,272 52% 51,279 8,646 
CGPLLU244 CGPLLU244P_4 TEC-Seq 100 80,930 8,894,936,700 4,437,962,639 50% 53,862 7,361 
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CGPLLU245 CGPLLU245P_1 TEC-Seq 100 80,930 7,679,235,200 3,935,822,054 51% 47,768 7,266 
CGPLLU245 CGPLLU245P_2 TEC-Seq 100 80,930 8,985,252,500 4,824,268,339 54% 58,338 10,394 
CGPLLU245 CGPLLU245P_3 TEC-Seq 100 80,930 8,518,229,300 4,480,236,927 53% 54,083 10,125 
CGPLLU245 CGPLLU245P_4 TEC-Seq 100 80,930 9,031,131,000 4,824,738,475 53% 58,313 10,598 
CGPLLU246 CGPLLU246P_1 TEC-Seq 100 80,930 8,520,360,800 3,509,660,305 41% 42,349 8,086 
CGPLLU246 CGPLLU246P_2 TEC-Seq 100 80,930 5,451,467,800 2,828,351,657 52% 34,243 8,256 
CGPLLU246 CGPLLU246P_4 TEC-Seq 100 80,930 8,137,616,600 4,135,036,174 51% 50,121 6,466 
CGPLLU246 CGPLLU246P_5 TEC-Seq 100 80,930 8,385,724,600 4,413,323,333 53% 53,495 7,303 
CGPLLU82 CGPLLU82P TEC-Seq 100 80,930 7,528,379,600 3,680,247,626 49% 43,812 3,374 
CGPLLU82 CGPLLU82P_1 TEC-Seq 100 80,930 6,815,879,400 3,371,577,171 49% 40,210 3,643 
CGPLLU82 CGPLLU82P_7 TEC-Seq 100 80,930 8,296,401,700 4,074,081,704 49% 48,653 7,026 
CGPLLU86 CGPLLU86P_1 TEC-Seq 100 80,930 8,222,093,400 3,523,035,056 43% 41,165 3,614 
CGPLLU86 CGPLLU86P_6 TEC-Seq 100 80,930 8,305,719,500 4,271,264,008 51% 49,508 6,681 
CGPLLU86 CGPLLU86P_8 TEC-Seq 100 80,930 6,787,785,300 3,443,658,418 51% 40,192 3,643 
CGPLLU86 CGPLLU86P_9 TEC-Seq 100 80,930 6,213,229,400 3,120,325,926 50% 36,413 3,560 
CGPLLU88 CGPLLU88P TEC-Seq 100 80,930 7,679,995,800 4,004,738,253 52% 46,951 6,387 
CGPLLU88 CGPLLU88P_2 TEC-Seq 100 80,930 7,252,433,900 3,621,678,746 50% 42,719 8,599 
CGPLLU88 CGPLLU88P_5 TEC-Seq 100 80,930 6,509,178,000 3,316,053,733 51% 39,274 2,661 
CGPLLU89 CGPLLU89P TEC-Seq 100 80,930 7,662,496,600 3,781,536,306 49% 44,097 7,909 
CGPLLU89 CGPLLU89P_2 TEC-Seq 100 80,930 7,005,599,500 3,339,612,564 48% 38,977 5,034 
CGPLLU89 CGPLLU89P_5 TEC-Seq 100 80,930 8,325,998,600 3,094,796,789 37% 36,061 2,822 
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CGPLLU97 CGPLLU97P_11 TEC-Seq 100 80,930 9,607,549,400 4,714,483,715 49% 55,065 3,275 
CGPLLU97 CGPLLU97P_20 TEC-Seq 100 80,930 7,977,402,200 3,981,840,609 50% 46,594 4,592 
CGPLLU97 CGPLLU97P_4 TEC-Seq 100 80,930 7,975,580,500 3,458,563,174 43% 40,224 4,228 
CGPLLU99 CGPLLU99P_10 TEC-Seq 100 80,930 8,350,456,400 4,112,640,680 49% 48,035 7,434 
CGPLLU99 CGPLLU99P_11 TEC-Seq 100 80,930 8,455,525,300 4,248,480,856 50% 49,401 3,388 
CGPLLU99 CGPLLU99P_12 TEC-Seq 100 80,930 8,172,750,100 3,937,309,188 48% 46,100 3,983 
CGPLLU99 CGPLLU99P_8 TEC-Seq 100 80,930 6,563,589,000 3,167,459,274 48% 36,917 7,020 
CGLU294 CGLU294P_1 TEC-Seq 100 80,930 13,391,053,400 6,557,523,556 49% 78,449 4,975 
CGLU294 CGLU294P1_1 TEC-Seq 100 80,930 6,123,688,700 2,559,160,575 42% 30,475 2,658 
CGLU294 CGLU294P2_1 TEC-Seq 100 80,930 6,826,939,100 2,696,933,517 40% 32,177 2,227 
CGLU294 CGLU294P3_2 TEC-Seq 100 80,930 6,537,975,900 2,964,372,304 45% 35,429 2,504 
CGLU294 CGLU294P4_1 TEC-Seq 100 80,930 4,382,617,500 2,052,259,803 47% 24,503 764 
CGLU315 CGLU315P_1 TEC-Seq 100 80,930 1,511,727,500 772,328,073 51% 9,226 498 
CGLU315 CGLU315P1_1 TEC-Seq 100 80,930 3,516,057,800 1,651,476,480 47% 19,709 1,923 
CGLU315 CGLU315P2_1 TEC-Seq 100 80,930 2,406,092,800 1,154,037,968 48% 13,766 956 
CGLU319 CGLU319P_1 TEC-Seq 100 80,930 6,167,692,000 3,135,436,369 51% 37,285 3,583 
CGLU319 CGLU319P1_1 TEC-Seq 100 80,930 5,458,775,500 2,458,429,678 45% 29,096 2,715 
CGLU324 CGLU324P_1 TEC-Seq 100 80,930 6,404,352,500 3,124,992,053 49% 37,062 2,071 














These studies together show the utility of ctDNA as a biomarker for cancer and the feasibility of 
clinical translation of liquid biopsies at multiple points during cancer initiation and progression 
such as early detection and detection of residual or progressive disease.   
Analyses of ctDNA in pancreatic cancer highlight the possibility of early detection using digital 
PCR approaches specific for tumor-derived alterations and detection of residual disease earlier 
than CT imaging.  Although careful measures were taken to increase the sensitivity of detecting 
genetic changes in the tumors and in the circulation of these patients, some alterations may not 
have been detected due to low tumor purity, limited plasma amounts and low mutant allele 
frequency.  Despite these limitations, these data add to our growing understanding of pancreatic 
cancer. We have shown that ctDNA in the circulation of pancreatic cancer patients may provide a 
marker of early detection of subclinical, residual or recurrent disease.  These analyses suggest 
future efforts to evaluate more intensive therapies for patients with detectable ctDNA after 
surgical resection. 
Intrigued by the potential for early detection of cancer through detection of ctDNA we developed 
an approach for noninvasive direct detection of patients with early-stage disease across common 
cancer types. A conceptual benefit of this approach is that detectable alterations in cfDNA are, by 
definition, clonal and therefore indicate an underlying population of cells with identical somatic 
mutations. This high degree of specificity is one of the potential benefits of ctDNA detection 
com- pared to other blood-based biomarkers, which may be increased in other normal tissues in 
patients without cancer. 
Although ctDNA analyses have raised the possibility of direct detection of patients with early-
stage disease (4, 55), the de novo identification of somatic alterations has remained a major 
challenge for the development of early detection approaches. The analytical performance 
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characteristics of the TEC-Seq method suggest that it may be suitable for such analyses. Other 
methods have been used for analyses of cf DNA in late-stage cancer patients (4-13), but the 
specificity and sensitivity of these methods may limit their applicability for detection of early- 
stage disease. A variety of experimental and bioinformatic aspects may contribute to the high 
specificity of the TEC-Seq method compared to previous approaches, including deep sequencing 
(>30,000-fold coverage), use of a small number of adaptors with long prespecified barcodes, and 
multiple bioinformatic filtering steps comprising error correction, removal of repetitive sequences 
and mapping artifacts, and identification and removal of germline and hematopoietic sequences. 
Using the TEC-Seq approach, no tumor-derived alterations were identified in the plasma of the 
healthy individuals in our study. Although the average age of the healthy cohort was younger than 
the cancer patients analyzed, this corresponds to an age at which cancer screening may be 
initiated. Likewise, the concordance between liquid and tumor biopsies was high and suggested 
that liquid biopsies may have advantages for detection of heterogeneous tumor-specific 
alterations that may be missed by tissue biopsies. In the colorectal cancer case analyzed through 
multiple tissue biopsies, we showed that heterogeneous alterations appeared to have lower 
amounts of ctDNA and may explain the wide range of mutant allele fractions in ctDNA in the 
same individuals. One concern is that clonal hematopoietic changes may be confounded with 
heterogeneous tumor-specific mutations (39, 41) and lead to over-diagnoses. Large-scale studies 
of cell-free alterations in healthy individuals will be important to catalog the frequency and 
spectrum of these changes in the circulation. The higher fraction of healthy individuals in whom 
we detected mutations in blood cell proliferation genes compared to previous studies (39-41) will 
require further investigation to see whether these alterations become clinically relevant over time. 
Given the different tumors that could potentially be detected, imaging and other diagnostic 
studies will be needed to complement any positive ctDNA analysis to appropriately identify the 
tumor of origin. In the future, ctDNA mutations combined with other molecular characteristics 
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(56) may be helpful to identify the source of occult lesions. 
Achieving effective sensitivity in ctDNA analyses has similarly presented a major technical 
hurdle. The high rate of conversion of cf DNA molecules in TEC-Seq libraries, combined with 
the use of endogenous as well as a limited number of exogenous barcodes, has increased the 
number of molecules that can be evaluated through NGS approaches. The parallel analysis of 55 
cancer driver genes in this approach has the advantage of detecting a high fraction of tumors 
without previous knowledge of the genetic makeup of these cancers. The ability to detect multiple 
alterations in each case can increase sensitivity even when an individual mutation may not be 
detected. The inclusion of additional genes in larger panels could increase sensitivity, although 
this would be associated with higher sequencing costs. In some cancer types, we have surpassed 
the theoretical estimate of cases that could be detected, potentially because of the limited number 
of cases analyzed or under-estimates of mutation prevalence in existing databases. Overall, 
sensitivity may be further improved by deeper sequencing, improved error correction methods, 
larger blood volumes, and repeated testing at regular intervals, but it is likely that biologic 
characteristics of ctDNA will ultimately determine the ability to detect very small tumors or pre- 
neoplastic lesions. 
Despite these limitations, the ability to detect half to three quarters of patients with early-stage 
colorectal, ovarian, lung, or breast cancer provides opportunities for early detection and 
intervention. The survival difference between late- and early-stage disease in these cancers 
accounts for more than a million lives worldwide each year (17). ctDNA-based cancer detection 
followed by appropriate intervention at earlier stages in even a fraction of individuals would 
likely dwarf the current health impact of most late-stage cancer therapies. Additionally, as we 
observed in colorectal cancer, the amount and type of ctDNA at the time of diagnosis may 
provide additional insight related to patient prognosis that could inform further clinical 
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intervention. Although screening for ctDNA will require larger validation studies, the success of 
cancer screening efforts based on other molecular tests (57) suggests that these approaches could, 
in principle, be implemented on a broad scale. 
To follow-up on our study of direct detection of early stage cancer using ctDNA, we applied the 
TEC-Seq approach towards charting out ctDNA dynamics after treatment with targeted therapies.  
Despite the success of targeted therapy for lung cancer, durable responses typically give way to 
progressive disease due to the evolution of resistant clones. However, the standard method for 
treatment efficacy assessment is primarily based on tumor dimensions (58), which does not 
reflect the current knowledge of clonal changes over the treatment. More recently, several studies 
have addressed the role of ctDNA for disease monitoring, mainly based on technologies that do 
not allow inferences on the dynamics of multiple clones simultaneously.  To our knowledge, this 
is the first study that addresses the value of measurements of ctDNA across multiple genes within 
days after treatment initiation.       
Here, we demonstrate that dynamic changes in plasma ctDNA immediately after drug exposure 
may provide insights into clinical efficacy of targeted therapy.  Given the heterogeneity of 
metastatic disease, an ultrasensitive cfTL approach comprehensively assessing a large number of 
driver genes has the advantage of accurately measuring overall tumor burden of clonal 
populations during selective pressure of targeted therapies.  Faster and predictive determinants of 
patient response can aid in navigating adaptive therapeutic strategies to reduce toxicity, identify 
early resistance to targeted therapy, and enable the consideration of combinatorial approaches 
early in a patient’s therapy.   
These results suggest a new paradigm in cancer therapeutics and drug development in which cfTL 
molecular response criteria may be used to provide insight into clinical endpoints including 
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overall survival and progression-free survival.  For patients without molecular response, liquid or 
tissue biopsies can provide additional information related to mechanisms of resistance and 
provide a context to consider other therapeutic strategies.  cfTL monitoring may provide an early 
biomarker for proof-of-concept studies of targeted therapies.  Combining cfTL response 
information with early pharmacokinetic data may ultimately provide the biologically effective 
dose needed for an individual’s cancer rather than a maximally tolerated dose.  Novel clinical 
trials could include rapid response assessments using cfTL in basket designs to expedite drug 
development.   
It is clear that the implementation of liquid biopsies in the clinic will be feasible and beneficial.  
We have observed real-time detection of ctDNA as an indication of the presence of cancer at 
early stage, residual disease post resection, and progressive disease post treatment.  Together 
these studies highlight noninvasive, sensitive, and specific detection of ctDNA as a biomarker for 
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